Unnamed: 0,GENE,MUTATION_REMARK,GENOMIC_MUTATION_ID,FUSION_ID,MUTATION_AA_SYNTAX,DISEASE,ACTIONABILITY_RANK,DEVELOPMENT_STATUS,DRUG_COMBINATION,TESTING_REQUIRED,TRIAL_STATUS,TRIAL_ID,TRIAL_NAME,COMPLETION_STATUS,TRIAL_PRIMARY_COMPLETION_DATE,PATIENT_PRESCREENING,RESULTS_AVAILABILITY,PROGRESSION_REMARK,SOURCE_TYPE,SOURCE,TREATMENT_HISTORY,PATIENT_AGE,PRIMARY_OUTCOME_MEASURE,NUMBER_OF_PATIENTS,TREATED_NUMBER,CONTROL_NUMBER,CONTROL_TREATMENT,ORR_TREAT,ORR_CON,ORR_CI,ORR_PVAL,DOR_TREAT,DOR_CON,DOR_CI,DOR_PVAL,PFS_TREAT,PFS_CON,PFS_HR,PFS_CI,PFS_PVAL,TTP_TREAT,TTP_CON,TTP_HR,TTP_CI,TTP_PVAL,DCR_TREAT,DCR_CON,DCR_PVAL,OS_TREAT,OS_CON,OS_HR,OS_CI,OS_PVAL,OBJ_RR_TREAT,CR_COUNT,PR_COUNT,SD_COUNT,RFS_TREAT,RFS_CON,RFS_HR,RFS_CI,RFS_PVAL,BLOOD_RESPONSE,RESPONSE_VALUE,TIMEPOINT,CLASSIFICATION_ID,LAST_UPDATED,COSMIC_PHENOTYPE_ID,SITE_PRIMARY_COSMIC,SITE_SUBTYPE1_COSMIC,SITE_SUBTYPE2_COSMIC,SITE_SUBTYPE3_COSMIC,HISTOLOGY_COSMIC,HIST_SUBTYPE1_COSMIC,HIST_SUBTYPE2_COSMIC,HIST_SUBTYPE3_COSMIC
5700.0,EGFR,EGFR_E709K/A,51767260 + 51772956,,p.E709A + p.E709K,lung / carcinoma / non small cell carcinoma,4.0,Case study,Afatinib,,Unknown,,,,,Yes,Yes,,1.0,26354527,Previously-treated,,Unknown,4.0,,,,,,,,,,,,,,,,,12.2,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5701.0,EGFR,EGFR_E709K/A,51767260 + 51772956,,p.E709A + p.E709K,lung / carcinoma / non small cell carcinoma,4.0,Case study,Afatinib,,Unknown,,,,,Yes,Yes,,1.0,26354527,Previously-treated,,Unknown,4.0,,,,,,,,,,,,,,,,,12.2,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5702.0,EGFR,EGFR_E709K/A,51767260 + 51772956,,p.E709A + p.E709K,lung / carcinoma / non small cell carcinoma,4.0,Case study,Afatinib,,Unknown,,,,,Yes,Yes,,1.0,26354527,Previously-treated,,Unknown,4.0,,,,,,,,,,,,,,,,,12.2,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5703.0,EGFR,EGFR_E709K/A,51767260 + 51772956,,p.E709A + p.E709K,lung / carcinoma / non small cell carcinoma,4.0,Case study,Afatinib,,Unknown,,,,,Yes,Yes,,1.0,26354527,Previously-treated,,Unknown,4.0,,,,,,,,,,,,,,,,,12.2,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5704.0,EGFR,EGFR_E709K/A,51767260 + 51772956,,p.E709A + p.E709K,lung / carcinoma / non small cell carcinoma,4.0,Case study,Afatinib,,Unknown,,,,,Yes,Yes,,1.0,26354527,Previously-treated,,Unknown,4.0,,,,,,,,,,,,,,,,,12.2,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5705.0,EGFR,EGFR_E709K/A,51767260 + 51772956,,p.E709A + p.E709K,lung / carcinoma / non small cell carcinoma,4.0,Case study,Afatinib,,Unknown,,,,,Yes,Yes,,1.0,26354527,Previously-treated,,Unknown,4.0,,,,,,,,,,,,,,,,,12.2,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5706.0,EGFR,EGFR_E709K/A,51767260 + 51772956,,p.E709A + p.E709K,lung / carcinoma / non small cell carcinoma,4.0,Case study,Afatinib,,Unknown,,,,,Yes,Yes,,1.0,26354527,Previously-treated,,Unknown,4.0,,,,,,,,,,,,,,,,,12.2,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5707.0,EGFR,EGFR_E709K/A,51767260 + 51772956,,p.E709A + p.E709K,lung / carcinoma / non small cell carcinoma,4.0,Case study,Afatinib,,Unknown,,,,,Yes,Yes,,1.0,26354527,Previously-treated,,Unknown,4.0,,,,,,,,,,,,,,,,,12.2,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5708.0,EGFR,EGFR_E709K/A,51767260 + 51772956,,p.E709A + p.E709K,lung / carcinoma / non small cell carcinoma,4.0,Case study,Afatinib,,Unknown,,,,,Yes,Yes,,1.0,26354527,Previously-treated,,Unknown,4.0,,,,,,,,,,,,,,,,,12.2,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5709.0,EGFR,EGFR_E709_T710delinsD,51779132,,p.E709_T710delinsD,lung / carcinoma / non small cell carcinoma,4.0,Case study,Afatinib,,Unknown,,,,,Yes,Yes,,1.0,28625646,,,Unknown,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5710.0,EGFR,EGFR_E709_T710delinsD,51779132,,p.E709_T710delinsD,lung / carcinoma / non small cell carcinoma,4.0,Case study,Afatinib,,Unknown,,,,,Yes,Yes,,1.0,28625646,,,Unknown,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5711.0,EGFR,EGFR_E709_T710delinsD,51779132,,p.E709_T710delinsD,lung / carcinoma / non small cell carcinoma,4.0,Case study,Afatinib,,Unknown,,,,,Yes,Yes,,1.0,28625646,,,Unknown,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5712.0,EGFR,EGFR_E709_T710delinsD,51779132,,p.E709_T710delinsD,lung / carcinoma / non small cell carcinoma,4.0,Case study,Afatinib,,Unknown,,,,,Yes,Yes,,1.0,28625646,,,Unknown,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5713.0,EGFR,EGFR_E709_T710delinsD,51779132,,p.E709_T710delinsD,lung / carcinoma / non small cell carcinoma,4.0,Case study,Afatinib,,Unknown,,,,,Yes,Yes,,1.0,28625646,,,Unknown,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5714.0,EGFR,EGFR_E709_T710delinsD,51779132,,p.E709_T710delinsD,lung / carcinoma / non small cell carcinoma,4.0,Case study,Afatinib,,Unknown,,,,,Yes,Yes,,1.0,28625646,,,Unknown,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5715.0,EGFR,EGFR_E709_T710delinsD,51779132,,p.E709_T710delinsD,lung / carcinoma / non small cell carcinoma,4.0,Case study,Afatinib,,Unknown,,,,,Yes,Yes,,1.0,28625646,,,Unknown,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5716.0,EGFR,EGFR_E709_T710delinsD,51779132,,p.E709_T710delinsD,lung / carcinoma / non small cell carcinoma,4.0,Case study,Afatinib,,Unknown,,,,,Yes,Yes,,1.0,28625646,,,Unknown,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5717.0,EGFR,EGFR_E709_T710delinsD,51779132,,p.E709_T710delinsD,lung / carcinoma / non small cell carcinoma,4.0,Case study,Afatinib,,Unknown,,,,,Yes,Yes,,1.0,28625646,,,Unknown,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6033.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Completed,NCT00949650,LUX-Lung 3,PCD,2012Feb09,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,Untreated,,Progression free survival,345.0,230.0,115.0,Chemotherapy,50.4,19.11,,,,,,,11.1,6.9,0.58,0.43-0.78,p<0.001,,,,,,,,,28.2,28.2,0.88,0.66-1.17,0.39,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6034.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Completed,NCT00949650,LUX-Lung 3,PCD,2012Feb09,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,Untreated,,Progression free survival,345.0,230.0,115.0,Chemotherapy,50.4,19.11,,,,,,,11.1,6.9,0.58,0.43-0.78,p<0.001,,,,,,,,,28.2,28.2,0.88,0.66-1.17,0.39,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6035.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Completed,NCT00949650,LUX-Lung 3,PCD,2012Feb09,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,Untreated,,Progression free survival,345.0,230.0,115.0,Chemotherapy,50.4,19.11,,,,,,,11.1,6.9,0.58,0.43-0.78,p<0.001,,,,,,,,,28.2,28.2,0.88,0.66-1.17,0.39,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6036.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Completed,NCT00949650,LUX-Lung 3,PCD,2012Feb09,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,Untreated,,Progression free survival,345.0,230.0,115.0,Chemotherapy,50.4,19.11,,,,,,,11.1,6.9,0.58,0.43-0.78,p<0.001,,,,,,,,,28.2,28.2,0.88,0.66-1.17,0.39,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6037.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Completed,NCT00949650,LUX-Lung 3,PCD,2012Feb09,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,Untreated,,Progression free survival,345.0,230.0,115.0,Chemotherapy,50.4,19.11,,,,,,,11.1,6.9,0.58,0.43-0.78,p<0.001,,,,,,,,,28.2,28.2,0.88,0.66-1.17,0.39,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6038.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Completed,NCT00949650,LUX-Lung 3,PCD,2012Feb09,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,Untreated,,Progression free survival,345.0,230.0,115.0,Chemotherapy,50.4,19.11,,,,,,,11.1,6.9,0.58,0.43-0.78,p<0.001,,,,,,,,,28.2,28.2,0.88,0.66-1.17,0.39,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6039.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Completed,NCT00949650,LUX-Lung 3,PCD,2012Feb09,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,Untreated,,Progression free survival,345.0,230.0,115.0,Chemotherapy,50.4,19.11,,,,,,,11.1,6.9,0.58,0.43-0.78,p<0.001,,,,,,,,,28.2,28.2,0.88,0.66-1.17,0.39,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6040.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Completed,NCT00949650,LUX-Lung 3,PCD,2012Feb09,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,Untreated,,Progression free survival,345.0,230.0,115.0,Chemotherapy,50.4,19.11,,,,,,,11.1,6.9,0.58,0.43-0.78,p<0.001,,,,,,,,,28.2,28.2,0.88,0.66-1.17,0.39,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6041.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Completed,NCT00949650,LUX-Lung 3,PCD,2012Feb09,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,Untreated,,Progression free survival,345.0,230.0,115.0,Chemotherapy,50.4,19.11,,,,,,,11.1,6.9,0.58,0.43-0.78,p<0.001,,,,,,,,,28.2,28.2,0.88,0.66-1.17,0.39,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6375.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,NCT01466660,LUX-Lung 7,PCD,2016Apr08,Yes,Yes,,1.0,27083334,Untreated,,"PFS, TTP, OS",319.0,160.0,159.0,Gefitinib,72.5,56.0,1.32-3.40,0.0018,,,,,11.0,10.9,0.74,0.57-0.95,p=0.0178,13.7,5.5,0.75,0.60-0.94,p=0.0136,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6376.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,NCT01466660,LUX-Lung 7,PCD,2016Apr08,Yes,Yes,,1.0,27083334,Untreated,,"PFS, TTP, OS",319.0,160.0,159.0,Gefitinib,72.5,56.0,1.32-3.40,0.0018,,,,,11.0,10.9,0.74,0.57-0.95,p=0.0178,13.7,5.5,0.75,0.60-0.94,p=0.0136,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6377.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,NCT01466660,LUX-Lung 7,PCD,2016Apr08,Yes,Yes,,1.0,27083334,Untreated,,"PFS, TTP, OS",319.0,160.0,159.0,Gefitinib,72.5,56.0,1.32-3.40,0.0018,,,,,11.0,10.9,0.74,0.57-0.95,p=0.0178,13.7,5.5,0.75,0.60-0.94,p=0.0136,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6378.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,NCT01466660,LUX-Lung 7,PCD,2016Apr08,Yes,Yes,,1.0,27083334,Untreated,,"PFS, TTP, OS",319.0,160.0,159.0,Gefitinib,72.5,56.0,1.32-3.40,0.0018,,,,,11.0,10.9,0.74,0.57-0.95,p=0.0178,13.7,5.5,0.75,0.60-0.94,p=0.0136,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6379.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,NCT01466660,LUX-Lung 7,PCD,2016Apr08,Yes,Yes,,1.0,27083334,Untreated,,"PFS, TTP, OS",319.0,160.0,159.0,Gefitinib,72.5,56.0,1.32-3.40,0.0018,,,,,11.0,10.9,0.74,0.57-0.95,p=0.0178,13.7,5.5,0.75,0.60-0.94,p=0.0136,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6380.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,NCT01466660,LUX-Lung 7,PCD,2016Apr08,Yes,Yes,,1.0,27083334,Untreated,,"PFS, TTP, OS",319.0,160.0,159.0,Gefitinib,72.5,56.0,1.32-3.40,0.0018,,,,,11.0,10.9,0.74,0.57-0.95,p=0.0178,13.7,5.5,0.75,0.60-0.94,p=0.0136,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6381.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,NCT01466660,LUX-Lung 7,PCD,2016Apr08,Yes,Yes,,1.0,27083334,Untreated,,"PFS, TTP, OS",319.0,160.0,159.0,Gefitinib,72.5,56.0,1.32-3.40,0.0018,,,,,11.0,10.9,0.74,0.57-0.95,p=0.0178,13.7,5.5,0.75,0.60-0.94,p=0.0136,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6382.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,NCT01466660,LUX-Lung 7,PCD,2016Apr08,Yes,Yes,,1.0,27083334,Untreated,,"PFS, TTP, OS",319.0,160.0,159.0,Gefitinib,72.5,56.0,1.32-3.40,0.0018,,,,,11.0,10.9,0.74,0.57-0.95,p=0.0178,13.7,5.5,0.75,0.60-0.94,p=0.0136,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6383.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,NCT01466660,LUX-Lung 7,PCD,2016Apr08,Yes,Yes,,1.0,27083334,Untreated,,"PFS, TTP, OS",319.0,160.0,159.0,Gefitinib,72.5,56.0,1.32-3.40,0.0018,,,,,11.0,10.9,0.74,0.57-0.95,p=0.0178,13.7,5.5,0.75,0.60-0.94,p=0.0136,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7203.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,JRCT031180136,NEJ027,PCD,2019Dec23,Yes,Yes,,2.0,10.1186/s12885-021-07861-1,Untreated,Geriatric,Overall Response Rate,37.0,37.0,,,75.7,,58.8-88.2,,,,,,14.2,,,9.5-19.0,,,,,,,,,,35.2,,,35.2-,,,,,,,,,,,,,,COSO29915674,2022Feb15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7204.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,JRCT031180136,NEJ027,PCD,2019Dec23,Yes,Yes,,2.0,10.1186/s12885-021-07861-1,Untreated,Geriatric,Overall Response Rate,37.0,37.0,,,75.7,,58.8-88.2,,,,,,14.2,,,9.5-19.0,,,,,,,,,,35.2,,,35.2-,,,,,,,,,,,,,,COSO29915674,2022Feb15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7205.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,JRCT031180136,NEJ027,PCD,2019Dec23,Yes,Yes,,2.0,10.1186/s12885-021-07861-1,Untreated,Geriatric,Overall Response Rate,37.0,37.0,,,75.7,,58.8-88.2,,,,,,14.2,,,9.5-19.0,,,,,,,,,,35.2,,,35.2-,,,,,,,,,,,,,,COSO29915674,2022Feb15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7206.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,JRCT031180136,NEJ027,PCD,2019Dec23,Yes,Yes,,2.0,10.1186/s12885-021-07861-1,Untreated,Geriatric,Overall Response Rate,37.0,37.0,,,75.7,,58.8-88.2,,,,,,14.2,,,9.5-19.0,,,,,,,,,,35.2,,,35.2-,,,,,,,,,,,,,,COSO29915674,2022Feb15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7207.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,JRCT031180136,NEJ027,PCD,2019Dec23,Yes,Yes,,2.0,10.1186/s12885-021-07861-1,Untreated,Geriatric,Overall Response Rate,37.0,37.0,,,75.7,,58.8-88.2,,,,,,14.2,,,9.5-19.0,,,,,,,,,,35.2,,,35.2-,,,,,,,,,,,,,,COSO29915674,2022Feb15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7208.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,JRCT031180136,NEJ027,PCD,2019Dec23,Yes,Yes,,2.0,10.1186/s12885-021-07861-1,Untreated,Geriatric,Overall Response Rate,37.0,37.0,,,75.7,,58.8-88.2,,,,,,14.2,,,9.5-19.0,,,,,,,,,,35.2,,,35.2-,,,,,,,,,,,,,,COSO29915674,2022Feb15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7209.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,JRCT031180136,NEJ027,PCD,2019Dec23,Yes,Yes,,2.0,10.1186/s12885-021-07861-1,Untreated,Geriatric,Overall Response Rate,37.0,37.0,,,75.7,,58.8-88.2,,,,,,14.2,,,9.5-19.0,,,,,,,,,,35.2,,,35.2-,,,,,,,,,,,,,,COSO29915674,2022Feb15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7210.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,JRCT031180136,NEJ027,PCD,2019Dec23,Yes,Yes,,2.0,10.1186/s12885-021-07861-1,Untreated,Geriatric,Overall Response Rate,37.0,37.0,,,75.7,,58.8-88.2,,,,,,14.2,,,9.5-19.0,,,,,,,,,,35.2,,,35.2-,,,,,,,,,,,,,,COSO29915674,2022Feb15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7211.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,JRCT031180136,NEJ027,PCD,2019Dec23,Yes,Yes,,2.0,10.1186/s12885-021-07861-1,Untreated,Geriatric,Overall Response Rate,37.0,37.0,,,75.7,,58.8-88.2,,,,,,14.2,,,9.5-19.0,,,,,,,,,,35.2,,,35.2-,,,,,,,,,,,,,,COSO29915674,2022Feb15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7788.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,NCT02369484,NICHE,PCD,2017Sep15,Yes,Yes,,4.0,NCT02369484,,,"Disease control rate, Clinical benefit rate",13.0,13.0,,,7.7,,,,,,,,3.67,,,1.38-8.17,,,,,,,53.8,,,12.93,,,,,,,,,,,,,,,,,COSO29915674,2021Dec14,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7789.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,NCT02369484,NICHE,PCD,2017Sep15,Yes,Yes,,4.0,NCT02369484,,,"Disease control rate, Clinical benefit rate",13.0,13.0,,,7.7,,,,,,,,3.67,,,1.38-8.17,,,,,,,53.8,,,12.93,,,,,,,,,,,,,,,,,COSO29915674,2021Dec14,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7790.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,NCT02369484,NICHE,PCD,2017Sep15,Yes,Yes,,4.0,NCT02369484,,,"Disease control rate, Clinical benefit rate",13.0,13.0,,,7.7,,,,,,,,3.67,,,1.38-8.17,,,,,,,53.8,,,12.93,,,,,,,,,,,,,,,,,COSO29915674,2021Dec14,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7791.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,NCT02369484,NICHE,PCD,2017Sep15,Yes,Yes,,4.0,NCT02369484,,,"Disease control rate, Clinical benefit rate",13.0,13.0,,,7.7,,,,,,,,3.67,,,1.38-8.17,,,,,,,53.8,,,12.93,,,,,,,,,,,,,,,,,COSO29915674,2021Dec14,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7792.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,NCT02369484,NICHE,PCD,2017Sep15,Yes,Yes,,4.0,NCT02369484,,,"Disease control rate, Clinical benefit rate",13.0,13.0,,,7.7,,,,,,,,3.67,,,1.38-8.17,,,,,,,53.8,,,12.93,,,,,,,,,,,,,,,,,COSO29915674,2021Dec14,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7793.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,NCT02369484,NICHE,PCD,2017Sep15,Yes,Yes,,4.0,NCT02369484,,,"Disease control rate, Clinical benefit rate",13.0,13.0,,,7.7,,,,,,,,3.67,,,1.38-8.17,,,,,,,53.8,,,12.93,,,,,,,,,,,,,,,,,COSO29915674,2021Dec14,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7794.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,NCT02369484,NICHE,PCD,2017Sep15,Yes,Yes,,4.0,NCT02369484,,,"Disease control rate, Clinical benefit rate",13.0,13.0,,,7.7,,,,,,,,3.67,,,1.38-8.17,,,,,,,53.8,,,12.93,,,,,,,,,,,,,,,,,COSO29915674,2021Dec14,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7795.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,NCT02369484,NICHE,PCD,2017Sep15,Yes,Yes,,4.0,NCT02369484,,,"Disease control rate, Clinical benefit rate",13.0,13.0,,,7.7,,,,,,,,3.67,,,1.38-8.17,,,,,,,53.8,,,12.93,,,,,,,,,,,,,,,,,COSO29915674,2021Dec14,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7796.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,NCT02369484,NICHE,PCD,2017Sep15,Yes,Yes,,4.0,NCT02369484,,,"Disease control rate, Clinical benefit rate",13.0,13.0,,,7.7,,,,,,,,3.67,,,1.38-8.17,,,,,,,53.8,,,12.93,,,,,,,,,,,,,,,,,COSO29915674,2021Dec14,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8103.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Unknown,,Afatinib FDA,,,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,,,Not defined,8.0,8.0,,,75.0,,,,17.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8104.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Unknown,,Afatinib FDA,,,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,,,Not defined,8.0,8.0,,,75.0,,,,17.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8105.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Unknown,,Afatinib FDA,,,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,,,Not defined,8.0,8.0,,,75.0,,,,17.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8106.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Unknown,,Afatinib FDA,,,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,,,Not defined,8.0,8.0,,,75.0,,,,17.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8107.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Unknown,,Afatinib FDA,,,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,,,Not defined,8.0,8.0,,,75.0,,,,17.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8108.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Unknown,,Afatinib FDA,,,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,,,Not defined,8.0,8.0,,,75.0,,,,17.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8109.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Unknown,,Afatinib FDA,,,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,,,Not defined,8.0,8.0,,,75.0,,,,17.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8110.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Unknown,,Afatinib FDA,,,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,,,Not defined,8.0,8.0,,,75.0,,,,17.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8111.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Unknown,,Afatinib FDA,,,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,,,Not defined,8.0,8.0,,,75.0,,,,17.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8139.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Afatinib,,Completed,,,,,Yes,Yes,,1.0,26051236,,,Unknown,18.0,18.0,,,77.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8140.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Afatinib,,Completed,,,,,Yes,Yes,,1.0,26051236,,,Unknown,18.0,18.0,,,77.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8141.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Afatinib,,Completed,,,,,Yes,Yes,,1.0,26051236,,,Unknown,18.0,18.0,,,77.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8142.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Afatinib,,Completed,,,,,Yes,Yes,,1.0,26051236,,,Unknown,18.0,18.0,,,77.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8143.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Afatinib,,Completed,,,,,Yes,Yes,,1.0,26051236,,,Unknown,18.0,18.0,,,77.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8144.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Afatinib,,Completed,,,,,Yes,Yes,,1.0,26051236,,,Unknown,18.0,18.0,,,77.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8145.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Afatinib,,Completed,,,,,Yes,Yes,,1.0,26051236,,,Unknown,18.0,18.0,,,77.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8146.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Afatinib,,Completed,,,,,Yes,Yes,,1.0,26051236,,,Unknown,18.0,18.0,,,77.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8147.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Afatinib,,Completed,,,,,Yes,Yes,,1.0,26051236,,,Unknown,18.0,18.0,,,77.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8148.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Retrospective/Meta-analysis,Afatinib,,Unknown,,,,,Yes,Yes,,1.0,34540680,,,,82.0,82.0,,,52.4,,,,,,,,11.3,,,5.6-17.0,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8149.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Retrospective/Meta-analysis,Afatinib,,Unknown,,,,,Yes,Yes,,1.0,34540680,,,,82.0,82.0,,,52.4,,,,,,,,11.3,,,5.6-17.0,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8150.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Retrospective/Meta-analysis,Afatinib,,Unknown,,,,,Yes,Yes,,1.0,34540680,,,,82.0,82.0,,,52.4,,,,,,,,11.3,,,5.6-17.0,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8151.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Retrospective/Meta-analysis,Afatinib,,Unknown,,,,,Yes,Yes,,1.0,34540680,,,,82.0,82.0,,,52.4,,,,,,,,11.3,,,5.6-17.0,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8152.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Retrospective/Meta-analysis,Afatinib,,Unknown,,,,,Yes,Yes,,1.0,34540680,,,,82.0,82.0,,,52.4,,,,,,,,11.3,,,5.6-17.0,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8153.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Retrospective/Meta-analysis,Afatinib,,Unknown,,,,,Yes,Yes,,1.0,34540680,,,,82.0,82.0,,,52.4,,,,,,,,11.3,,,5.6-17.0,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8154.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Retrospective/Meta-analysis,Afatinib,,Unknown,,,,,Yes,Yes,,1.0,34540680,,,,82.0,82.0,,,52.4,,,,,,,,11.3,,,5.6-17.0,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8155.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Retrospective/Meta-analysis,Afatinib,,Unknown,,,,,Yes,Yes,,1.0,34540680,,,,82.0,82.0,,,52.4,,,,,,,,11.3,,,5.6-17.0,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8156.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Retrospective/Meta-analysis,Afatinib,,Unknown,,,,,Yes,Yes,,1.0,34540680,,,,82.0,82.0,,,52.4,,,,,,,,11.3,,,5.6-17.0,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8292.0,EGFR,EGFR_L861Q,51766344,,p.L861Q,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Unknown,,Afatinib FDA,,,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,,,Not defined,12.0,12.0,,,58.3,,,,9.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8293.0,EGFR,EGFR_L861Q,51766344,,p.L861Q,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Unknown,,Afatinib FDA,,,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,,,Not defined,12.0,12.0,,,58.3,,,,9.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8294.0,EGFR,EGFR_L861Q,51766344,,p.L861Q,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Unknown,,Afatinib FDA,,,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,,,Not defined,12.0,12.0,,,58.3,,,,9.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8295.0,EGFR,EGFR_L861Q,51766344,,p.L861Q,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Unknown,,Afatinib FDA,,,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,,,Not defined,12.0,12.0,,,58.3,,,,9.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8296.0,EGFR,EGFR_L861Q,51766344,,p.L861Q,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Unknown,,Afatinib FDA,,,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,,,Not defined,12.0,12.0,,,58.3,,,,9.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8297.0,EGFR,EGFR_L861Q,51766344,,p.L861Q,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Unknown,,Afatinib FDA,,,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,,,Not defined,12.0,12.0,,,58.3,,,,9.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8298.0,EGFR,EGFR_L861Q,51766344,,p.L861Q,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Unknown,,Afatinib FDA,,,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,,,Not defined,12.0,12.0,,,58.3,,,,9.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8299.0,EGFR,EGFR_L861Q,51766344,,p.L861Q,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Unknown,,Afatinib FDA,,,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,,,Not defined,12.0,12.0,,,58.3,,,,9.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8300.0,EGFR,EGFR_L861Q,51766344,,p.L861Q,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Unknown,,Afatinib FDA,,,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,,,Not defined,12.0,12.0,,,58.3,,,,9.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8310.0,EGFR,EGFR_L861Q,51766344,,p.L861Q,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Afatinib,,Completed,,,,,Yes,Yes,,1.0,26051236,,,Unknown,16.0,16.0,,,56.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8311.0,EGFR,EGFR_L861Q,51766344,,p.L861Q,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Afatinib,,Completed,,,,,Yes,Yes,,1.0,26051236,,,Unknown,16.0,16.0,,,56.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8312.0,EGFR,EGFR_L861Q,51766344,,p.L861Q,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Afatinib,,Completed,,,,,Yes,Yes,,1.0,26051236,,,Unknown,16.0,16.0,,,56.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8313.0,EGFR,EGFR_L861Q,51766344,,p.L861Q,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Afatinib,,Completed,,,,,Yes,Yes,,1.0,26051236,,,Unknown,16.0,16.0,,,56.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8314.0,EGFR,EGFR_L861Q,51766344,,p.L861Q,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Afatinib,,Completed,,,,,Yes,Yes,,1.0,26051236,,,Unknown,16.0,16.0,,,56.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8315.0,EGFR,EGFR_L861Q,51766344,,p.L861Q,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Afatinib,,Completed,,,,,Yes,Yes,,1.0,26051236,,,Unknown,16.0,16.0,,,56.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8316.0,EGFR,EGFR_L861Q,51766344,,p.L861Q,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Afatinib,,Completed,,,,,Yes,Yes,,1.0,26051236,,,Unknown,16.0,16.0,,,56.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8317.0,EGFR,EGFR_L861Q,51766344,,p.L861Q,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Afatinib,,Completed,,,,,Yes,Yes,,1.0,26051236,,,Unknown,16.0,16.0,,,56.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8318.0,EGFR,EGFR_L861Q,51766344,,p.L861Q,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Afatinib,,Completed,,,,,Yes,Yes,,1.0,26051236,,,Unknown,16.0,16.0,,,56.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8319.0,EGFR,EGFR_S768I,51768106,,p.S768I,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Unknown,,Afatinib FDA,,,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,,,Not defined,1.0,1.0,,,100.0,,,,37.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8320.0,EGFR,EGFR_S768I,51768106,,p.S768I,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Unknown,,Afatinib FDA,,,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,,,Not defined,1.0,1.0,,,100.0,,,,37.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8321.0,EGFR,EGFR_S768I,51768106,,p.S768I,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Unknown,,Afatinib FDA,,,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,,,Not defined,1.0,1.0,,,100.0,,,,37.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8322.0,EGFR,EGFR_S768I,51768106,,p.S768I,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Unknown,,Afatinib FDA,,,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,,,Not defined,1.0,1.0,,,100.0,,,,37.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8323.0,EGFR,EGFR_S768I,51768106,,p.S768I,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Unknown,,Afatinib FDA,,,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,,,Not defined,1.0,1.0,,,100.0,,,,37.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8324.0,EGFR,EGFR_S768I,51768106,,p.S768I,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Unknown,,Afatinib FDA,,,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,,,Not defined,1.0,1.0,,,100.0,,,,37.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8325.0,EGFR,EGFR_S768I,51768106,,p.S768I,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Unknown,,Afatinib FDA,,,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,,,Not defined,1.0,1.0,,,100.0,,,,37.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8326.0,EGFR,EGFR_S768I,51768106,,p.S768I,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Unknown,,Afatinib FDA,,,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,,,Not defined,1.0,1.0,,,100.0,,,,37.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8327.0,EGFR,EGFR_S768I,51768106,,p.S768I,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Afatinib,Required,Unknown,,Afatinib FDA,,,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,,,Not defined,1.0,1.0,,,100.0,,,,37.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan23,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8337.0,EGFR,EGFR_S768I,51768106,,p.S768I,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Afatinib,,Completed,,,,,Yes,Yes,,1.0,26051236,,,Unknown,8.0,8.0,,,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8338.0,EGFR,EGFR_S768I,51768106,,p.S768I,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Afatinib,,Completed,,,,,Yes,Yes,,1.0,26051236,,,Unknown,8.0,8.0,,,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8339.0,EGFR,EGFR_S768I,51768106,,p.S768I,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Afatinib,,Completed,,,,,Yes,Yes,,1.0,26051236,,,Unknown,8.0,8.0,,,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8340.0,EGFR,EGFR_S768I,51768106,,p.S768I,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Afatinib,,Completed,,,,,Yes,Yes,,1.0,26051236,,,Unknown,8.0,8.0,,,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8341.0,EGFR,EGFR_S768I,51768106,,p.S768I,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Afatinib,,Completed,,,,,Yes,Yes,,1.0,26051236,,,Unknown,8.0,8.0,,,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8342.0,EGFR,EGFR_S768I,51768106,,p.S768I,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Afatinib,,Completed,,,,,Yes,Yes,,1.0,26051236,,,Unknown,8.0,8.0,,,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8343.0,EGFR,EGFR_S768I,51768106,,p.S768I,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Afatinib,,Completed,,,,,Yes,Yes,,1.0,26051236,,,Unknown,8.0,8.0,,,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8344.0,EGFR,EGFR_S768I,51768106,,p.S768I,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Afatinib,,Completed,,,,,Yes,Yes,,1.0,26051236,,,Unknown,8.0,8.0,,,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8345.0,EGFR,EGFR_S768I,51768106,,p.S768I,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Afatinib,,Completed,,,,,Yes,Yes,,1.0,26051236,,,Unknown,8.0,8.0,,,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8364.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Case study,Afatinib,,Completed,NCT00711594,LUX-Lung 4,PCD,2013Nov01,Yes,Yes,,1.0,22071596,Previously-treated,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8365.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Case study,Afatinib,,Completed,NCT00711594,LUX-Lung 4,PCD,2013Nov01,Yes,Yes,,1.0,22071596,Previously-treated,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8366.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Case study,Afatinib,,Completed,NCT00711594,LUX-Lung 4,PCD,2013Nov01,Yes,Yes,,1.0,22071596,Previously-treated,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8367.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Case study,Afatinib,,Completed,NCT00711594,LUX-Lung 4,PCD,2013Nov01,Yes,Yes,,1.0,22071596,Previously-treated,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8368.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Case study,Afatinib,,Completed,NCT00711594,LUX-Lung 4,PCD,2013Nov01,Yes,Yes,,1.0,22071596,Previously-treated,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8369.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Case study,Afatinib,,Completed,NCT00711594,LUX-Lung 4,PCD,2013Nov01,Yes,Yes,,1.0,22071596,Previously-treated,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8370.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Case study,Afatinib,,Completed,NCT00711594,LUX-Lung 4,PCD,2013Nov01,Yes,Yes,,1.0,22071596,Previously-treated,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8371.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Case study,Afatinib,,Completed,NCT00711594,LUX-Lung 4,PCD,2013Nov01,Yes,Yes,,1.0,22071596,Previously-treated,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8372.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Case study,Afatinib,,Completed,NCT00711594,LUX-Lung 4,PCD,2013Nov01,Yes,Yes,,1.0,22071596,Previously-treated,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8373.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Out of trials human study,Afatinib,,Unknown,,,,,Comparison with wt,Yes,,1.0,24035188,,,Unknown,34.0,21.0,13.0,,5.0,38.0,,,,,,,3.2,4.6,,,0.33,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May11,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8374.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Out of trials human study,Afatinib,,Unknown,,,,,Comparison with wt,Yes,,1.0,24035188,,,Unknown,34.0,21.0,13.0,,5.0,38.0,,,,,,,3.2,4.6,,,0.33,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May11,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8375.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Out of trials human study,Afatinib,,Unknown,,,,,Comparison with wt,Yes,,1.0,24035188,,,Unknown,34.0,21.0,13.0,,5.0,38.0,,,,,,,3.2,4.6,,,0.33,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May11,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8376.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Out of trials human study,Afatinib,,Unknown,,,,,Comparison with wt,Yes,,1.0,24035188,,,Unknown,34.0,21.0,13.0,,5.0,38.0,,,,,,,3.2,4.6,,,0.33,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May11,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8377.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Out of trials human study,Afatinib,,Unknown,,,,,Comparison with wt,Yes,,1.0,24035188,,,Unknown,34.0,21.0,13.0,,5.0,38.0,,,,,,,3.2,4.6,,,0.33,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May11,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8378.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Out of trials human study,Afatinib,,Unknown,,,,,Comparison with wt,Yes,,1.0,24035188,,,Unknown,34.0,21.0,13.0,,5.0,38.0,,,,,,,3.2,4.6,,,0.33,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May11,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8379.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Out of trials human study,Afatinib,,Unknown,,,,,Comparison with wt,Yes,,1.0,24035188,,,Unknown,34.0,21.0,13.0,,5.0,38.0,,,,,,,3.2,4.6,,,0.33,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May11,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8380.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Out of trials human study,Afatinib,,Unknown,,,,,Comparison with wt,Yes,,1.0,24035188,,,Unknown,34.0,21.0,13.0,,5.0,38.0,,,,,,,3.2,4.6,,,0.33,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May11,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8381.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Out of trials human study,Afatinib,,Unknown,,,,,Comparison with wt,Yes,,1.0,24035188,,,Unknown,34.0,21.0,13.0,,5.0,38.0,,,,,,,3.2,4.6,,,0.33,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May11,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9255.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 1,Afatinib,,Terminated,NCT03711422,,PCD,2019Dec20,Yes,No,,4.0,NCT03711422,,,"OS, PFS",2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9256.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 1,Afatinib,,Terminated,NCT03711422,,PCD,2019Dec20,Yes,No,,4.0,NCT03711422,,,"OS, PFS",2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9257.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 1,Afatinib,,Terminated,NCT03711422,,PCD,2019Dec20,Yes,No,,4.0,NCT03711422,,,"OS, PFS",2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9258.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 1,Afatinib,,Terminated,NCT03711422,,PCD,2019Dec20,Yes,No,,4.0,NCT03711422,,,"OS, PFS",2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9259.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 1,Afatinib,,Terminated,NCT03711422,,PCD,2019Dec20,Yes,No,,4.0,NCT03711422,,,"OS, PFS",2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9260.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 1,Afatinib,,Terminated,NCT03711422,,PCD,2019Dec20,Yes,No,,4.0,NCT03711422,,,"OS, PFS",2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9261.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 1,Afatinib,,Terminated,NCT03711422,,PCD,2019Dec20,Yes,No,,4.0,NCT03711422,,,"OS, PFS",2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9262.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 1,Afatinib,,Terminated,NCT03711422,,PCD,2019Dec20,Yes,No,,4.0,NCT03711422,,,"OS, PFS",2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9263.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 1,Afatinib,,Terminated,NCT03711422,,PCD,2019Dec20,Yes,No,,4.0,NCT03711422,,,"OS, PFS",2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11190.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Afatinib,,"Active, not recruiting",NCT02183883,DARWIN1,ECD,2023Nov01,Yes,No,,4.0,NCT02183883,,,Progression free survival,48.0,48.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11191.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Afatinib,,"Active, not recruiting",NCT02183883,DARWIN1,ECD,2023Nov01,Yes,No,,4.0,NCT02183883,,,Progression free survival,48.0,48.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11192.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Afatinib,,"Active, not recruiting",NCT02183883,DARWIN1,ECD,2023Nov01,Yes,No,,4.0,NCT02183883,,,Progression free survival,48.0,48.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11193.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Afatinib,,"Active, not recruiting",NCT02183883,DARWIN1,ECD,2023Nov01,Yes,No,,4.0,NCT02183883,,,Progression free survival,48.0,48.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11194.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Afatinib,,"Active, not recruiting",NCT02183883,DARWIN1,ECD,2023Nov01,Yes,No,,4.0,NCT02183883,,,Progression free survival,48.0,48.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11195.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Afatinib,,"Active, not recruiting",NCT02183883,DARWIN1,ECD,2023Nov01,Yes,No,,4.0,NCT02183883,,,Progression free survival,48.0,48.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11196.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Afatinib,,"Active, not recruiting",NCT02183883,DARWIN1,ECD,2023Nov01,Yes,No,,4.0,NCT02183883,,,Progression free survival,48.0,48.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11197.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Afatinib,,"Active, not recruiting",NCT02183883,DARWIN1,ECD,2023Nov01,Yes,No,,4.0,NCT02183883,,,Progression free survival,48.0,48.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11198.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Afatinib,,"Active, not recruiting",NCT02183883,DARWIN1,ECD,2023Nov01,Yes,No,,4.0,NCT02183883,,,Progression free survival,48.0,48.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11199.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Afatinib,,Recruiting,NCT04201756,,ECD,2022Apr30,Yes,No,,4.0,NCT04201756,,,Overall Response Rate,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11200.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Afatinib,,Recruiting,NCT04201756,,ECD,2022Apr30,Yes,No,,4.0,NCT04201756,,,Overall Response Rate,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11201.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Afatinib,,Recruiting,NCT04201756,,ECD,2022Apr30,Yes,No,,4.0,NCT04201756,,,Overall Response Rate,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11202.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Afatinib,,Recruiting,NCT04201756,,ECD,2022Apr30,Yes,No,,4.0,NCT04201756,,,Overall Response Rate,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11203.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Afatinib,,Recruiting,NCT04201756,,ECD,2022Apr30,Yes,No,,4.0,NCT04201756,,,Overall Response Rate,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11204.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Afatinib,,Recruiting,NCT04201756,,ECD,2022Apr30,Yes,No,,4.0,NCT04201756,,,Overall Response Rate,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11205.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Afatinib,,Recruiting,NCT04201756,,ECD,2022Apr30,Yes,No,,4.0,NCT04201756,,,Overall Response Rate,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11206.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Afatinib,,Recruiting,NCT04201756,,ECD,2022Apr30,Yes,No,,4.0,NCT04201756,,,Overall Response Rate,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11207.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Afatinib,,Recruiting,NCT04201756,,ECD,2022Apr30,Yes,No,,4.0,NCT04201756,,,Overall Response Rate,47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12216.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,NCT02597946,,PCD,2018Jul22,Expression confirmed,Yes,,4.0,NCT02597946,Previously-treated,,Overall Response Rate,18.0,18.0,,,0.0,,,,,,,,2.76,,,1.87-4.60,,2.76,,,1.87-4.60,,61.1,,,10.02,,,8.47-10/08,,,,,,,,,,,,,,COSO29915674,2021Dec14,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12217.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,NCT02597946,,PCD,2018Jul22,Expression confirmed,Yes,,4.0,NCT02597946,Previously-treated,,Overall Response Rate,18.0,18.0,,,0.0,,,,,,,,2.76,,,1.87-4.60,,2.76,,,1.87-4.60,,61.1,,,10.02,,,8.47-10/08,,,,,,,,,,,,,,COSO29915674,2021Dec14,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12218.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,NCT02597946,,PCD,2018Jul22,Expression confirmed,Yes,,4.0,NCT02597946,Previously-treated,,Overall Response Rate,18.0,18.0,,,0.0,,,,,,,,2.76,,,1.87-4.60,,2.76,,,1.87-4.60,,61.1,,,10.02,,,8.47-10/08,,,,,,,,,,,,,,COSO29915674,2021Dec14,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12219.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,NCT02597946,,PCD,2018Jul22,Expression confirmed,Yes,,4.0,NCT02597946,Previously-treated,,Overall Response Rate,18.0,18.0,,,0.0,,,,,,,,2.76,,,1.87-4.60,,2.76,,,1.87-4.60,,61.1,,,10.02,,,8.47-10/08,,,,,,,,,,,,,,COSO29915674,2021Dec14,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12220.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,NCT02597946,,PCD,2018Jul22,Expression confirmed,Yes,,4.0,NCT02597946,Previously-treated,,Overall Response Rate,18.0,18.0,,,0.0,,,,,,,,2.76,,,1.87-4.60,,2.76,,,1.87-4.60,,61.1,,,10.02,,,8.47-10/08,,,,,,,,,,,,,,COSO29915674,2021Dec14,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12221.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,NCT02597946,,PCD,2018Jul22,Expression confirmed,Yes,,4.0,NCT02597946,Previously-treated,,Overall Response Rate,18.0,18.0,,,0.0,,,,,,,,2.76,,,1.87-4.60,,2.76,,,1.87-4.60,,61.1,,,10.02,,,8.47-10/08,,,,,,,,,,,,,,COSO29915674,2021Dec14,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12222.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,NCT02597946,,PCD,2018Jul22,Expression confirmed,Yes,,4.0,NCT02597946,Previously-treated,,Overall Response Rate,18.0,18.0,,,0.0,,,,,,,,2.76,,,1.87-4.60,,2.76,,,1.87-4.60,,61.1,,,10.02,,,8.47-10/08,,,,,,,,,,,,,,COSO29915674,2021Dec14,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12223.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,NCT02597946,,PCD,2018Jul22,Expression confirmed,Yes,,4.0,NCT02597946,Previously-treated,,Overall Response Rate,18.0,18.0,,,0.0,,,,,,,,2.76,,,1.87-4.60,,2.76,,,1.87-4.60,,61.1,,,10.02,,,8.47-10/08,,,,,,,,,,,,,,COSO29915674,2021Dec14,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12224.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Afatinib,,Completed,NCT02597946,,PCD,2018Jul22,Expression confirmed,Yes,,4.0,NCT02597946,Previously-treated,,Overall Response Rate,18.0,18.0,,,0.0,,,,,,,,2.76,,,1.87-4.60,,2.76,,,1.87-4.60,,61.1,,,10.02,,,8.47-10/08,,,,,,,,,,,,,,COSO29915674,2021Dec14,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
16359.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16360.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16361.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16362.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16363.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16364.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16365.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16366.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16367.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16368.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16369.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16370.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16371.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16372.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16373.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16374.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16375.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16376.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16377.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16378.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16379.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16380.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16381.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16382.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16383.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16384.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16385.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16386.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16387.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16388.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16389.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16390.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16391.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16392.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16393.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16394.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16395.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16396.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16397.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16398.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16399.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16400.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16401.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16402.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16403.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16404.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16405.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16406.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16407.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16408.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16409.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16410.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16411.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16412.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16413.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16414.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16415.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16416.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16417.0,ERBB2,EGFR_A859T and ERBB2_G776L,51833668,,p.A859T + p.G776L,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,14.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16713.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16714.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16715.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16716.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16717.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16718.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16719.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16720.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16721.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16722.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16723.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16724.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16725.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16726.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16727.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16728.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16729.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16730.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16731.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16732.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16733.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16734.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16735.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16736.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16737.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16738.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16739.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16740.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16741.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16742.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16743.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16744.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16745.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16746.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16747.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16748.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16749.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16750.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16751.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16752.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16753.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16754.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16755.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16756.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16757.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16758.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16759.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16760.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16761.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16762.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16763.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16764.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16765.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16766.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16767.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16768.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16769.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16770.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16771.0,ERBB2,ERBB2_G778_P780dup,54064411 + 54065275 + 54070170 + 54085695,,p.G778_P780dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,4.0,,,,,,,,32.0,,,,,,,,1.0,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16772.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16773.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16774.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16775.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16776.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16777.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16778.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16779.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16780.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16781.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16782.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16783.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16784.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16785.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16786.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16787.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16788.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16789.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16790.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16791.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16792.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16793.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16794.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16795.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16796.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16797.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16798.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16799.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16800.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16801.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16802.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16803.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16804.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16805.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16806.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16807.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16808.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16809.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16810.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16811.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16812.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16813.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16814.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16815.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16816.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16817.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16818.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16819.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16820.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16821.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16822.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16823.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16824.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16825.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16826.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16827.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16828.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16829.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
16830.0,ERBB2,ERBB2_Y772_A775dup,54062164 + 54062409,,p.Y772_A775dup,lung / carcinoma / adenocarcinoma,4.0,Case study,Afatinib,,Completed,NCT00730925,,PCD,2012Jan01,Yes,Yes,,1.0,22325357,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,3.0,,,,,,,,12.0,,,,,,,1.0,,,,,,,,,,COSO29914826,2022Nov28,COSO29914826,lung,NS,NS,NS,carcinoma,adenocarcinoma,NS,NS
17393.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / squamous cell carcinoma,3.0,Approved FDA,Afatinib,Required,Completed,NCT01523587,LUX-Lung 8,PCD,2013Oct21,No,Yes,,1.0,26156651,Previously-treated,,Progression free survival,795.0,398.0,397.0,Erlotinib,,,,,,,,,2.4,1.9,0.82,0.68-1.0,0.043,,,,,,,,,7.9,6.8,0.81,0.61-0.95,0.008,,,,,,,,,,,,,COSO29914830,2022May03,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17394.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / squamous cell carcinoma,3.0,Approved FDA,Afatinib,Required,Completed,NCT01523587,LUX-Lung 8,PCD,2013Oct21,No,Yes,,1.0,26156651,Previously-treated,,Progression free survival,795.0,398.0,397.0,Erlotinib,,,,,,,,,2.4,1.9,0.82,0.68-1.0,0.043,,,,,,,,,7.9,6.8,0.81,0.61-0.95,0.008,,,,,,,,,,,,,COSO29914830,2022May03,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17395.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / squamous cell carcinoma,3.0,Approved FDA,Afatinib,Required,Completed,NCT01523587,LUX-Lung 8,PCD,2013Oct21,No,Yes,,1.0,26156651,Previously-treated,,Progression free survival,795.0,398.0,397.0,Erlotinib,,,,,,,,,2.4,1.9,0.82,0.68-1.0,0.043,,,,,,,,,7.9,6.8,0.81,0.61-0.95,0.008,,,,,,,,,,,,,COSO29914830,2022May03,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17396.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / squamous cell carcinoma,3.0,Approved FDA,Afatinib,Required,Completed,NCT01523587,LUX-Lung 8,PCD,2013Oct21,No,Yes,,1.0,26156651,Previously-treated,,Progression free survival,795.0,398.0,397.0,Erlotinib,,,,,,,,,2.4,1.9,0.82,0.68-1.0,0.043,,,,,,,,,7.9,6.8,0.81,0.61-0.95,0.008,,,,,,,,,,,,,COSO29914830,2022May03,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17397.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / squamous cell carcinoma,3.0,Approved FDA,Afatinib,Required,Completed,NCT01523587,LUX-Lung 8,PCD,2013Oct21,No,Yes,,1.0,26156651,Previously-treated,,Progression free survival,795.0,398.0,397.0,Erlotinib,,,,,,,,,2.4,1.9,0.82,0.68-1.0,0.043,,,,,,,,,7.9,6.8,0.81,0.61-0.95,0.008,,,,,,,,,,,,,COSO29914830,2022May03,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17398.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / squamous cell carcinoma,3.0,Approved FDA,Afatinib,Required,Completed,NCT01523587,LUX-Lung 8,PCD,2013Oct21,No,Yes,,1.0,26156651,Previously-treated,,Progression free survival,795.0,398.0,397.0,Erlotinib,,,,,,,,,2.4,1.9,0.82,0.68-1.0,0.043,,,,,,,,,7.9,6.8,0.81,0.61-0.95,0.008,,,,,,,,,,,,,COSO29914830,2022May03,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17399.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / squamous cell carcinoma,3.0,Approved FDA,Afatinib,Required,Completed,NCT01523587,LUX-Lung 8,PCD,2013Oct21,No,Yes,,1.0,26156651,Previously-treated,,Progression free survival,795.0,398.0,397.0,Erlotinib,,,,,,,,,2.4,1.9,0.82,0.68-1.0,0.043,,,,,,,,,7.9,6.8,0.81,0.61-0.95,0.008,,,,,,,,,,,,,COSO29914830,2022May03,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17400.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / squamous cell carcinoma,3.0,Approved FDA,Afatinib,Required,Completed,NCT01523587,LUX-Lung 8,PCD,2013Oct21,No,Yes,,1.0,26156651,Previously-treated,,Progression free survival,795.0,398.0,397.0,Erlotinib,,,,,,,,,2.4,1.9,0.82,0.68-1.0,0.043,,,,,,,,,7.9,6.8,0.81,0.61-0.95,0.008,,,,,,,,,,,,,COSO29914830,2022May03,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17401.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / squamous cell carcinoma,3.0,Approved FDA,Afatinib,Required,Completed,NCT01523587,LUX-Lung 8,PCD,2013Oct21,No,Yes,,1.0,26156651,Previously-treated,,Progression free survival,795.0,398.0,397.0,Erlotinib,,,,,,,,,2.4,1.9,0.82,0.68-1.0,0.043,,,,,,,,,7.9,6.8,0.81,0.61-0.95,0.008,,,,,,,,,,,,,COSO29914830,2022May03,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17402.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / squamous cell carcinoma,3.0,Approved FDA,Afatinib,Required,Completed,NCT01523587,LUX-Lung 8,PCD,2013Oct21,No,Yes,,1.0,26156651,Previously-treated,,Progression free survival,795.0,398.0,397.0,Erlotinib,,,,,,,,,2.4,1.9,0.82,0.68-1.0,0.043,,,,,,,,,7.9,6.8,0.81,0.61-0.95,0.008,,,,,,,,,,,,,COSO29914830,2022May03,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17403.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / squamous cell carcinoma,3.0,Approved FDA,Afatinib,Required,Completed,NCT01523587,LUX-Lung 8,PCD,2013Oct21,No,Yes,,1.0,26156651,Previously-treated,,Progression free survival,795.0,398.0,397.0,Erlotinib,,,,,,,,,2.4,1.9,0.82,0.68-1.0,0.043,,,,,,,,,7.9,6.8,0.81,0.61-0.95,0.008,,,,,,,,,,,,,COSO29914830,2022May03,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17404.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / squamous cell carcinoma,3.0,Approved FDA,Afatinib,Required,Completed,NCT01523587,LUX-Lung 8,PCD,2013Oct21,No,Yes,,1.0,26156651,Previously-treated,,Progression free survival,795.0,398.0,397.0,Erlotinib,,,,,,,,,2.4,1.9,0.82,0.68-1.0,0.043,,,,,,,,,7.9,6.8,0.81,0.61-0.95,0.008,,,,,,,,,,,,,COSO29914830,2022May03,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17405.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / squamous cell carcinoma,3.0,Approved FDA,Afatinib,Required,Completed,NCT01523587,LUX-Lung 8,PCD,2013Oct21,No,Yes,,1.0,26156651,Previously-treated,,Progression free survival,795.0,398.0,397.0,Erlotinib,,,,,,,,,2.4,1.9,0.82,0.68-1.0,0.043,,,,,,,,,7.9,6.8,0.81,0.61-0.95,0.008,,,,,,,,,,,,,COSO29914830,2022May03,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17406.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / squamous cell carcinoma,3.0,Approved FDA,Afatinib,Required,Completed,NCT01523587,LUX-Lung 8,PCD,2013Oct21,No,Yes,,1.0,26156651,Previously-treated,,Progression free survival,795.0,398.0,397.0,Erlotinib,,,,,,,,,2.4,1.9,0.82,0.68-1.0,0.043,,,,,,,,,7.9,6.8,0.81,0.61-0.95,0.008,,,,,,,,,,,,,COSO29914830,2022May03,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17407.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / squamous cell carcinoma,3.0,Approved FDA,Afatinib,Required,Completed,NCT01523587,LUX-Lung 8,PCD,2013Oct21,No,Yes,,1.0,26156651,Previously-treated,,Progression free survival,795.0,398.0,397.0,Erlotinib,,,,,,,,,2.4,1.9,0.82,0.68-1.0,0.043,,,,,,,,,7.9,6.8,0.81,0.61-0.95,0.008,,,,,,,,,,,,,COSO29914830,2022May03,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17423.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 1,Afatinib,,Unknown,NCT04132102,,ECD,2021Apr30,Yes,No,,4.0,NCT04132102,,,Progression free survival,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2022May03,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17424.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 1,Afatinib,,Unknown,NCT04132102,,ECD,2021Apr30,Yes,No,,4.0,NCT04132102,,,Progression free survival,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2022May03,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17425.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 1,Afatinib,,Unknown,NCT04132102,,ECD,2021Apr30,Yes,No,,4.0,NCT04132102,,,Progression free survival,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2022May03,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17426.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 1,Afatinib,,Unknown,NCT04132102,,ECD,2021Apr30,Yes,No,,4.0,NCT04132102,,,Progression free survival,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2022May03,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17427.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 1,Afatinib,,Unknown,NCT04132102,,ECD,2021Apr30,Yes,No,,4.0,NCT04132102,,,Progression free survival,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2022May03,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17428.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 1,Afatinib,,Unknown,NCT04132102,,ECD,2021Apr30,Yes,No,,4.0,NCT04132102,,,Progression free survival,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2022May03,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17429.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 1,Afatinib,,Unknown,NCT04132102,,ECD,2021Apr30,Yes,No,,4.0,NCT04132102,,,Progression free survival,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2022May03,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17430.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 1,Afatinib,,Unknown,NCT04132102,,ECD,2021Apr30,Yes,No,,4.0,NCT04132102,,,Progression free survival,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2022May03,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17431.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 1,Afatinib,,Unknown,NCT04132102,,ECD,2021Apr30,Yes,No,,4.0,NCT04132102,,,Progression free survival,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2022May03,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17432.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 1,Afatinib,,Unknown,NCT04132102,,ECD,2021Apr30,Yes,No,,4.0,NCT04132102,,,Progression free survival,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2022May03,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17433.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 1,Afatinib,,Unknown,NCT04132102,,ECD,2021Apr30,Yes,No,,4.0,NCT04132102,,,Progression free survival,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2022May03,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17434.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 1,Afatinib,,Unknown,NCT04132102,,ECD,2021Apr30,Yes,No,,4.0,NCT04132102,,,Progression free survival,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2022May03,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17435.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 1,Afatinib,,Unknown,NCT04132102,,ECD,2021Apr30,Yes,No,,4.0,NCT04132102,,,Progression free survival,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2022May03,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17436.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 1,Afatinib,,Unknown,NCT04132102,,ECD,2021Apr30,Yes,No,,4.0,NCT04132102,,,Progression free survival,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2022May03,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17437.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 1,Afatinib,,Unknown,NCT04132102,,ECD,2021Apr30,Yes,No,,4.0,NCT04132102,,,Progression free survival,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2022May03,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17708.0,MET,MET_N375S,59260365,,p.N375S,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17709.0,MET,MET_N375S,59260365,,p.N375S,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17710.0,MET,MET_N375S,59260365,,p.N375S,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17711.0,MET,MET_N375S,59260365,,p.N375S,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17712.0,MET,MET_N375S,59260365,,p.N375S,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17713.0,MET,MET_N375S,59260365,,p.N375S,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17714.0,MET,MET_N375S,59260365,,p.N375S,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17715.0,MET,MET_N375S,59260365,,p.N375S,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17716.0,MET,MET_N375S,59260365,,p.N375S,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17717.0,MET,MET_N375S,59260365,,p.N375S,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17718.0,MET,MET_N375S,59260365,,p.N375S,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17719.0,MET,MET_N375S,59260365,,p.N375S,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17720.0,MET,MET_N375S,59260365,,p.N375S,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17721.0,MET,MET_N375S,59260365,,p.N375S,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17722.0,MET,MET_N375S,59260365,,p.N375S,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17723.0,MET,MET_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17724.0,MET,MET_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17725.0,MET,MET_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17726.0,MET,MET_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17727.0,MET,MET_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17728.0,MET,MET_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17729.0,MET,MET_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17730.0,MET,MET_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17731.0,MET,MET_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17732.0,MET,MET_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17733.0,MET,MET_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17734.0,MET,MET_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17735.0,MET,MET_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17736.0,MET,MET_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17737.0,MET,MET_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17843.0,TP53,TP53_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17844.0,TP53,TP53_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17845.0,TP53,TP53_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17846.0,TP53,TP53_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17847.0,TP53,TP53_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17848.0,TP53,TP53_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17849.0,TP53,TP53_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17850.0,TP53,TP53_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17851.0,TP53,TP53_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17852.0,TP53,TP53_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17853.0,TP53,TP53_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17854.0,TP53,TP53_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17855.0,TP53,TP53_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17856.0,TP53,TP53_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
17857.0,TP53,TP53_unspecified,,,,lung / carcinoma / squamous cell carcinoma,3.0,Phase 2,Afatinib,,Not yet recruiting,NCT04533321,,ECD,2023Sep01,Yes,No,,4.0,NCT04533321,Previously-treated,,Unknown,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29914830,2021May18,COSO29914830,lung,NS,NS,NS,carcinoma,squamous_cell_carcinoma,NS,NS
714.0,ALK,ALK_C1156Y,66562303,,p.C1156Y,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
715.0,ALK,ALK_C1156Y,66562303,,p.C1156Y,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
716.0,ALK,ALK_C1156Y,66562303,,p.C1156Y,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
717.0,ALK,ALK_C1156Y,66562303,,p.C1156Y,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
718.0,ALK,ALK_C1156Y,66562303,,p.C1156Y,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
719.0,ALK,ALK_C1156Y,66562303,,p.C1156Y,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
720.0,ALK,ALK_C1156Y,66562303,,p.C1156Y,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
721.0,ALK,ALK_C1156Y,66562303,,p.C1156Y,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
722.0,ALK,ALK_C1156Y,66562303,,p.C1156Y,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
741.0,ALK,ALK_F1174,,,p.F1174X,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
742.0,ALK,ALK_F1174,,,p.F1174X,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
743.0,ALK,ALK_F1174,,,p.F1174X,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
744.0,ALK,ALK_F1174,,,p.F1174X,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
745.0,ALK,ALK_F1174,,,p.F1174X,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
746.0,ALK,ALK_F1174,,,p.F1174X,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
747.0,ALK,ALK_F1174,,,p.F1174X,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
748.0,ALK,ALK_F1174,,,p.F1174X,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
749.0,ALK,ALK_F1174,,,p.F1174X,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
822.0,ALK,ALK_L1196,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
823.0,ALK,ALK_L1196,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
824.0,ALK,ALK_L1196,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
825.0,ALK,ALK_L1196,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
826.0,ALK,ALK_L1196,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
827.0,ALK,ALK_L1196,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
828.0,ALK,ALK_L1196,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
829.0,ALK,ALK_L1196,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
830.0,ALK,ALK_L1196,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1056.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Alectinib,Required,Completed,NCT01801111,NP28673,PCD,2014Oct24,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf,Previously-treated,,Overall Response Rate,138.0,138.0,,,44.0,,,,11.2,,,,,,,,,,,,,,,,,,,,,,,,61.0,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1057.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Alectinib,Required,Completed,NCT01801111,NP28673,PCD,2014Oct24,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf,Previously-treated,,Overall Response Rate,138.0,138.0,,,44.0,,,,11.2,,,,,,,,,,,,,,,,,,,,,,,,61.0,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1058.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Alectinib,Required,Completed,NCT01801111,NP28673,PCD,2014Oct24,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf,Previously-treated,,Overall Response Rate,138.0,138.0,,,44.0,,,,11.2,,,,,,,,,,,,,,,,,,,,,,,,61.0,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1059.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Alectinib,Required,Completed,NCT01801111,NP28673,PCD,2014Oct24,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf,Previously-treated,,Overall Response Rate,138.0,138.0,,,44.0,,,,11.2,,,,,,,,,,,,,,,,,,,,,,,,61.0,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1060.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Alectinib,Required,Completed,NCT01801111,NP28673,PCD,2014Oct24,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf,Previously-treated,,Overall Response Rate,138.0,138.0,,,44.0,,,,11.2,,,,,,,,,,,,,,,,,,,,,,,,61.0,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1061.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Alectinib,Required,Completed,NCT01801111,NP28673,PCD,2014Oct24,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf,Previously-treated,,Overall Response Rate,138.0,138.0,,,44.0,,,,11.2,,,,,,,,,,,,,,,,,,,,,,,,61.0,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1062.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Alectinib,Required,Completed,NCT01801111,NP28673,PCD,2014Oct24,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf,Previously-treated,,Overall Response Rate,138.0,138.0,,,44.0,,,,11.2,,,,,,,,,,,,,,,,,,,,,,,,61.0,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1063.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Alectinib,Required,Completed,NCT01801111,NP28673,PCD,2014Oct24,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf,Previously-treated,,Overall Response Rate,138.0,138.0,,,44.0,,,,11.2,,,,,,,,,,,,,,,,,,,,,,,,61.0,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1064.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Alectinib,Required,Completed,NCT01801111,NP28673,PCD,2014Oct24,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf,Previously-treated,,Overall Response Rate,138.0,138.0,,,44.0,,,,11.2,,,,,,,,,,,,,,,,,,,,,,,,61.0,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1065.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Alectinib,Required,Completed,NCT01588028,NP28761,PCD,2014Oct01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf,Previously-treated,,Maximum tolerated dose/toxicity,87.0,87.0,,,38.0,,28-49,,7.5,,,,,,,,,,,,,,,,,,,,,,,,33.0,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1066.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Alectinib,Required,Completed,NCT01588028,NP28761,PCD,2014Oct01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf,Previously-treated,,Maximum tolerated dose/toxicity,87.0,87.0,,,38.0,,28-49,,7.5,,,,,,,,,,,,,,,,,,,,,,,,33.0,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1067.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Alectinib,Required,Completed,NCT01588028,NP28761,PCD,2014Oct01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf,Previously-treated,,Maximum tolerated dose/toxicity,87.0,87.0,,,38.0,,28-49,,7.5,,,,,,,,,,,,,,,,,,,,,,,,33.0,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1068.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Alectinib,Required,Completed,NCT01588028,NP28761,PCD,2014Oct01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf,Previously-treated,,Maximum tolerated dose/toxicity,87.0,87.0,,,38.0,,28-49,,7.5,,,,,,,,,,,,,,,,,,,,,,,,33.0,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1069.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Alectinib,Required,Completed,NCT01588028,NP28761,PCD,2014Oct01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf,Previously-treated,,Maximum tolerated dose/toxicity,87.0,87.0,,,38.0,,28-49,,7.5,,,,,,,,,,,,,,,,,,,,,,,,33.0,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1070.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Alectinib,Required,Completed,NCT01588028,NP28761,PCD,2014Oct01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf,Previously-treated,,Maximum tolerated dose/toxicity,87.0,87.0,,,38.0,,28-49,,7.5,,,,,,,,,,,,,,,,,,,,,,,,33.0,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1071.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Alectinib,Required,Completed,NCT01588028,NP28761,PCD,2014Oct01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf,Previously-treated,,Maximum tolerated dose/toxicity,87.0,87.0,,,38.0,,28-49,,7.5,,,,,,,,,,,,,,,,,,,,,,,,33.0,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1072.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Alectinib,Required,Completed,NCT01588028,NP28761,PCD,2014Oct01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf,Previously-treated,,Maximum tolerated dose/toxicity,87.0,87.0,,,38.0,,28-49,,7.5,,,,,,,,,,,,,,,,,,,,,,,,33.0,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1073.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Alectinib,Required,Completed,NCT01588028,NP28761,PCD,2014Oct01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf,Previously-treated,,Maximum tolerated dose/toxicity,87.0,87.0,,,38.0,,28-49,,7.5,,,,,,,,,,,,,,,,,,,,,,,,33.0,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1074.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Alectinib,Required,"Active, not recruiting",NCT02075840,ALEX,PCD,2017Feb09,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf,Untreated,,Progression free survival,303.0,152.0,151.0,Crizotinib,79.0,72,,0.1652,,,,,25.7,10.4,0.53,0.38-0.73,<0.0001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1075.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Alectinib,Required,"Active, not recruiting",NCT02075840,ALEX,PCD,2017Feb09,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf,Untreated,,Progression free survival,303.0,152.0,151.0,Crizotinib,79.0,72,,0.1652,,,,,25.7,10.4,0.53,0.38-0.73,<0.0001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1076.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Alectinib,Required,"Active, not recruiting",NCT02075840,ALEX,PCD,2017Feb09,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf,Untreated,,Progression free survival,303.0,152.0,151.0,Crizotinib,79.0,72,,0.1652,,,,,25.7,10.4,0.53,0.38-0.73,<0.0001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1077.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Alectinib,Required,"Active, not recruiting",NCT02075840,ALEX,PCD,2017Feb09,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf,Untreated,,Progression free survival,303.0,152.0,151.0,Crizotinib,79.0,72,,0.1652,,,,,25.7,10.4,0.53,0.38-0.73,<0.0001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1078.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Alectinib,Required,"Active, not recruiting",NCT02075840,ALEX,PCD,2017Feb09,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf,Untreated,,Progression free survival,303.0,152.0,151.0,Crizotinib,79.0,72,,0.1652,,,,,25.7,10.4,0.53,0.38-0.73,<0.0001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1079.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Alectinib,Required,"Active, not recruiting",NCT02075840,ALEX,PCD,2017Feb09,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf,Untreated,,Progression free survival,303.0,152.0,151.0,Crizotinib,79.0,72,,0.1652,,,,,25.7,10.4,0.53,0.38-0.73,<0.0001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1080.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Alectinib,Required,"Active, not recruiting",NCT02075840,ALEX,PCD,2017Feb09,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf,Untreated,,Progression free survival,303.0,152.0,151.0,Crizotinib,79.0,72,,0.1652,,,,,25.7,10.4,0.53,0.38-0.73,<0.0001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1081.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Alectinib,Required,"Active, not recruiting",NCT02075840,ALEX,PCD,2017Feb09,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf,Untreated,,Progression free survival,303.0,152.0,151.0,Crizotinib,79.0,72,,0.1652,,,,,25.7,10.4,0.53,0.38-0.73,<0.0001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1082.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Alectinib,Required,"Active, not recruiting",NCT02075840,ALEX,PCD,2017Feb09,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf,Untreated,,Progression free survival,303.0,152.0,151.0,Crizotinib,79.0,72,,0.1652,,,,,25.7,10.4,0.53,0.38-0.73,<0.0001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1380.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 1,Alectinib,,Terminated,NCT03131206,,PCD,2018Nov08,Yes,Yes,"Slow accrual, no benefit of treatment",4.0,NCT03131206,,,Overall Response Rate,5.0,5.0,,,20.0,,0.52-71.63,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct29,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1381.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 1,Alectinib,,Terminated,NCT03131206,,PCD,2018Nov08,Yes,Yes,"Slow accrual, no benefit of treatment",4.0,NCT03131206,,,Overall Response Rate,5.0,5.0,,,20.0,,0.52-71.63,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct29,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1382.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 1,Alectinib,,Terminated,NCT03131206,,PCD,2018Nov08,Yes,Yes,"Slow accrual, no benefit of treatment",4.0,NCT03131206,,,Overall Response Rate,5.0,5.0,,,20.0,,0.52-71.63,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct29,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1383.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 1,Alectinib,,Terminated,NCT03131206,,PCD,2018Nov08,Yes,Yes,"Slow accrual, no benefit of treatment",4.0,NCT03131206,,,Overall Response Rate,5.0,5.0,,,20.0,,0.52-71.63,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct29,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1384.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 1,Alectinib,,Terminated,NCT03131206,,PCD,2018Nov08,Yes,Yes,"Slow accrual, no benefit of treatment",4.0,NCT03131206,,,Overall Response Rate,5.0,5.0,,,20.0,,0.52-71.63,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct29,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1385.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 1,Alectinib,,Terminated,NCT03131206,,PCD,2018Nov08,Yes,Yes,"Slow accrual, no benefit of treatment",4.0,NCT03131206,,,Overall Response Rate,5.0,5.0,,,20.0,,0.52-71.63,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct29,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1386.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 1,Alectinib,,Terminated,NCT03131206,,PCD,2018Nov08,Yes,Yes,"Slow accrual, no benefit of treatment",4.0,NCT03131206,,,Overall Response Rate,5.0,5.0,,,20.0,,0.52-71.63,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct29,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1387.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 1,Alectinib,,Terminated,NCT03131206,,PCD,2018Nov08,Yes,Yes,"Slow accrual, no benefit of treatment",4.0,NCT03131206,,,Overall Response Rate,5.0,5.0,,,20.0,,0.52-71.63,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct29,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1388.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 1,Alectinib,,Terminated,NCT03131206,,PCD,2018Nov08,Yes,Yes,"Slow accrual, no benefit of treatment",4.0,NCT03131206,,,Overall Response Rate,5.0,5.0,,,20.0,,0.52-71.63,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct29,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1857.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Recruiting,NCT05015010,ALNEO,ECD,2023May28,Yes,No,,4.0,NCT05015010,,,Major pathologic response,33.0,33.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Aug25,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1858.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Recruiting,NCT05015010,ALNEO,ECD,2023May28,Yes,No,,4.0,NCT05015010,,,Major pathologic response,33.0,33.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Aug25,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1859.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Recruiting,NCT05015010,ALNEO,ECD,2023May28,Yes,No,,4.0,NCT05015010,,,Major pathologic response,33.0,33.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Aug25,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1860.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Recruiting,NCT05015010,ALNEO,ECD,2023May28,Yes,No,,4.0,NCT05015010,,,Major pathologic response,33.0,33.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Aug25,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1861.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Recruiting,NCT05015010,ALNEO,ECD,2023May28,Yes,No,,4.0,NCT05015010,,,Major pathologic response,33.0,33.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Aug25,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1862.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Recruiting,NCT05015010,ALNEO,ECD,2023May28,Yes,No,,4.0,NCT05015010,,,Major pathologic response,33.0,33.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Aug25,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1863.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Recruiting,NCT05015010,ALNEO,ECD,2023May28,Yes,No,,4.0,NCT05015010,,,Major pathologic response,33.0,33.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Aug25,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1864.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Recruiting,NCT05015010,ALNEO,ECD,2023May28,Yes,No,,4.0,NCT05015010,,,Major pathologic response,33.0,33.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Aug25,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1865.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Recruiting,NCT05015010,ALNEO,ECD,2023May28,Yes,No,,4.0,NCT05015010,,,Major pathologic response,33.0,33.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Aug25,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1866.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Completed,NCT03155009,ATALK,PCD,2019Sep26,Yes,Yes,,3.0,https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003924-22/results#endPointsSection,,,Overall Response Rate,39.0,39.0,,,51.3,,,,,,,,,,,,,,,,,,,,,,,,,,,4.0,16.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1867.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Completed,NCT03155009,ATALK,PCD,2019Sep26,Yes,Yes,,3.0,https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003924-22/results#endPointsSection,,,Overall Response Rate,39.0,39.0,,,51.3,,,,,,,,,,,,,,,,,,,,,,,,,,,4.0,16.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1868.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Completed,NCT03155009,ATALK,PCD,2019Sep26,Yes,Yes,,3.0,https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003924-22/results#endPointsSection,,,Overall Response Rate,39.0,39.0,,,51.3,,,,,,,,,,,,,,,,,,,,,,,,,,,4.0,16.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1869.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Completed,NCT03155009,ATALK,PCD,2019Sep26,Yes,Yes,,3.0,https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003924-22/results#endPointsSection,,,Overall Response Rate,39.0,39.0,,,51.3,,,,,,,,,,,,,,,,,,,,,,,,,,,4.0,16.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1870.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Completed,NCT03155009,ATALK,PCD,2019Sep26,Yes,Yes,,3.0,https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003924-22/results#endPointsSection,,,Overall Response Rate,39.0,39.0,,,51.3,,,,,,,,,,,,,,,,,,,,,,,,,,,4.0,16.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1871.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Completed,NCT03155009,ATALK,PCD,2019Sep26,Yes,Yes,,3.0,https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003924-22/results#endPointsSection,,,Overall Response Rate,39.0,39.0,,,51.3,,,,,,,,,,,,,,,,,,,,,,,,,,,4.0,16.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1872.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Completed,NCT03155009,ATALK,PCD,2019Sep26,Yes,Yes,,3.0,https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003924-22/results#endPointsSection,,,Overall Response Rate,39.0,39.0,,,51.3,,,,,,,,,,,,,,,,,,,,,,,,,,,4.0,16.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1873.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Completed,NCT03155009,ATALK,PCD,2019Sep26,Yes,Yes,,3.0,https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003924-22/results#endPointsSection,,,Overall Response Rate,39.0,39.0,,,51.3,,,,,,,,,,,,,,,,,,,,,,,,,,,4.0,16.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1874.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Completed,NCT03155009,ATALK,PCD,2019Sep26,Yes,Yes,,3.0,https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003924-22/results#endPointsSection,,,Overall Response Rate,39.0,39.0,,,51.3,,,,,,,,,,,,,,,,,,,,,,,,,,,4.0,16.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1875.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Recruiting,NCT02314481,DARWIN II,ECD,2024Nov01,Yes,No,,4.0,NCT02314481,,,Progression free survival,119.0,119.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1876.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Recruiting,NCT02314481,DARWIN II,ECD,2024Nov01,Yes,No,,4.0,NCT02314481,,,Progression free survival,119.0,119.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1877.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Recruiting,NCT02314481,DARWIN II,ECD,2024Nov01,Yes,No,,4.0,NCT02314481,,,Progression free survival,119.0,119.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1878.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Recruiting,NCT02314481,DARWIN II,ECD,2024Nov01,Yes,No,,4.0,NCT02314481,,,Progression free survival,119.0,119.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1879.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Recruiting,NCT02314481,DARWIN II,ECD,2024Nov01,Yes,No,,4.0,NCT02314481,,,Progression free survival,119.0,119.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1880.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Recruiting,NCT02314481,DARWIN II,ECD,2024Nov01,Yes,No,,4.0,NCT02314481,,,Progression free survival,119.0,119.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1881.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Recruiting,NCT02314481,DARWIN II,ECD,2024Nov01,Yes,No,,4.0,NCT02314481,,,Progression free survival,119.0,119.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1882.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Recruiting,NCT02314481,DARWIN II,ECD,2024Nov01,Yes,No,,4.0,NCT02314481,,,Progression free survival,119.0,119.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1883.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Recruiting,NCT02314481,DARWIN II,ECD,2024Nov01,Yes,No,,4.0,NCT02314481,,,Progression free survival,119.0,119.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1884.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Completed,NCT01871805,,PCD,2014Oct24,Yes,Yes,,1.0,29748847,,,Maximum tolerated dose/toxicity,134.0,134.0,,,,,,,,,,,,,,,,,,,,,,,,29.1,,,21.3-39.0,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1885.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Completed,NCT01871805,,PCD,2014Oct24,Yes,Yes,,1.0,29748847,,,Maximum tolerated dose/toxicity,134.0,134.0,,,,,,,,,,,,,,,,,,,,,,,,29.1,,,21.3-39.0,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1886.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Completed,NCT01871805,,PCD,2014Oct24,Yes,Yes,,1.0,29748847,,,Maximum tolerated dose/toxicity,134.0,134.0,,,,,,,,,,,,,,,,,,,,,,,,29.1,,,21.3-39.0,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1887.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Completed,NCT01871805,,PCD,2014Oct24,Yes,Yes,,1.0,29748847,,,Maximum tolerated dose/toxicity,134.0,134.0,,,,,,,,,,,,,,,,,,,,,,,,29.1,,,21.3-39.0,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1888.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Completed,NCT01871805,,PCD,2014Oct24,Yes,Yes,,1.0,29748847,,,Maximum tolerated dose/toxicity,134.0,134.0,,,,,,,,,,,,,,,,,,,,,,,,29.1,,,21.3-39.0,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1889.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Completed,NCT01871805,,PCD,2014Oct24,Yes,Yes,,1.0,29748847,,,Maximum tolerated dose/toxicity,134.0,134.0,,,,,,,,,,,,,,,,,,,,,,,,29.1,,,21.3-39.0,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1890.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Completed,NCT01871805,,PCD,2014Oct24,Yes,Yes,,1.0,29748847,,,Maximum tolerated dose/toxicity,134.0,134.0,,,,,,,,,,,,,,,,,,,,,,,,29.1,,,21.3-39.0,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1891.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Completed,NCT01871805,,PCD,2014Oct24,Yes,Yes,,1.0,29748847,,,Maximum tolerated dose/toxicity,134.0,134.0,,,,,,,,,,,,,,,,,,,,,,,,29.1,,,21.3-39.0,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1892.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Alectinib,,Completed,NCT01871805,,PCD,2014Oct24,Yes,Yes,,1.0,29748847,,,Maximum tolerated dose/toxicity,134.0,134.0,,,,,,,,,,,,,,,,,,,,,,,,29.1,,,21.3-39.0,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2082.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Recruiting,NCT05170204,,ECD,2029Jun17,Expression confirmed,No,,4.0,NCT05170204,Previously-treated,,Progression free survival,320.0,320.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2083.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Recruiting,NCT05170204,,ECD,2029Jun17,Expression confirmed,No,,4.0,NCT05170204,Previously-treated,,Progression free survival,320.0,320.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2084.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Recruiting,NCT05170204,,ECD,2029Jun17,Expression confirmed,No,,4.0,NCT05170204,Previously-treated,,Progression free survival,320.0,320.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2085.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Recruiting,NCT05170204,,ECD,2029Jun17,Expression confirmed,No,,4.0,NCT05170204,Previously-treated,,Progression free survival,320.0,320.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2086.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Recruiting,NCT05170204,,ECD,2029Jun17,Expression confirmed,No,,4.0,NCT05170204,Previously-treated,,Progression free survival,320.0,320.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2087.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Recruiting,NCT05170204,,ECD,2029Jun17,Expression confirmed,No,,4.0,NCT05170204,Previously-treated,,Progression free survival,320.0,320.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2088.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Recruiting,NCT05170204,,ECD,2029Jun17,Expression confirmed,No,,4.0,NCT05170204,Previously-treated,,Progression free survival,320.0,320.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2089.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Recruiting,NCT05170204,,ECD,2029Jun17,Expression confirmed,No,,4.0,NCT05170204,Previously-treated,,Progression free survival,320.0,320.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2090.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Recruiting,NCT05170204,,ECD,2029Jun17,Expression confirmed,No,,4.0,NCT05170204,Previously-treated,,Progression free survival,320.0,320.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2091.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Unknown,NCT02838420,ALESIA,PCD,2018May31,Yes,Yes,,3.0,https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Primary-results-of-ALESIA-A-randomised-phase-III-open-label-study-of-alectinib-vs-crizotinib-in-Asian-patients-with-treatment-naive-ALK-advanced-NSCLC,Untreated,,Progression free survival,187.0,125.0,62.0,Crizotinib,,,,,,,,,,11.1,0.37,0.13-0.38,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2092.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Unknown,NCT02838420,ALESIA,PCD,2018May31,Yes,Yes,,3.0,https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Primary-results-of-ALESIA-A-randomised-phase-III-open-label-study-of-alectinib-vs-crizotinib-in-Asian-patients-with-treatment-naive-ALK-advanced-NSCLC,Untreated,,Progression free survival,187.0,125.0,62.0,Crizotinib,,,,,,,,,,11.1,0.37,0.13-0.38,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2093.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Unknown,NCT02838420,ALESIA,PCD,2018May31,Yes,Yes,,3.0,https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Primary-results-of-ALESIA-A-randomised-phase-III-open-label-study-of-alectinib-vs-crizotinib-in-Asian-patients-with-treatment-naive-ALK-advanced-NSCLC,Untreated,,Progression free survival,187.0,125.0,62.0,Crizotinib,,,,,,,,,,11.1,0.37,0.13-0.38,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2094.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Unknown,NCT02838420,ALESIA,PCD,2018May31,Yes,Yes,,3.0,https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Primary-results-of-ALESIA-A-randomised-phase-III-open-label-study-of-alectinib-vs-crizotinib-in-Asian-patients-with-treatment-naive-ALK-advanced-NSCLC,Untreated,,Progression free survival,187.0,125.0,62.0,Crizotinib,,,,,,,,,,11.1,0.37,0.13-0.38,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2095.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Unknown,NCT02838420,ALESIA,PCD,2018May31,Yes,Yes,,3.0,https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Primary-results-of-ALESIA-A-randomised-phase-III-open-label-study-of-alectinib-vs-crizotinib-in-Asian-patients-with-treatment-naive-ALK-advanced-NSCLC,Untreated,,Progression free survival,187.0,125.0,62.0,Crizotinib,,,,,,,,,,11.1,0.37,0.13-0.38,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2096.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Unknown,NCT02838420,ALESIA,PCD,2018May31,Yes,Yes,,3.0,https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Primary-results-of-ALESIA-A-randomised-phase-III-open-label-study-of-alectinib-vs-crizotinib-in-Asian-patients-with-treatment-naive-ALK-advanced-NSCLC,Untreated,,Progression free survival,187.0,125.0,62.0,Crizotinib,,,,,,,,,,11.1,0.37,0.13-0.38,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2097.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Unknown,NCT02838420,ALESIA,PCD,2018May31,Yes,Yes,,3.0,https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Primary-results-of-ALESIA-A-randomised-phase-III-open-label-study-of-alectinib-vs-crizotinib-in-Asian-patients-with-treatment-naive-ALK-advanced-NSCLC,Untreated,,Progression free survival,187.0,125.0,62.0,Crizotinib,,,,,,,,,,11.1,0.37,0.13-0.38,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2098.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Unknown,NCT02838420,ALESIA,PCD,2018May31,Yes,Yes,,3.0,https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Primary-results-of-ALESIA-A-randomised-phase-III-open-label-study-of-alectinib-vs-crizotinib-in-Asian-patients-with-treatment-naive-ALK-advanced-NSCLC,Untreated,,Progression free survival,187.0,125.0,62.0,Crizotinib,,,,,,,,,,11.1,0.37,0.13-0.38,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2099.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Unknown,NCT02838420,ALESIA,PCD,2018May31,Yes,Yes,,3.0,https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Primary-results-of-ALESIA-A-randomised-phase-III-open-label-study-of-alectinib-vs-crizotinib-in-Asian-patients-with-treatment-naive-ALK-advanced-NSCLC,Untreated,,Progression free survival,187.0,125.0,62.0,Crizotinib,,,,,,,,,,11.1,0.37,0.13-0.38,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2100.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Recruiting,NCT03178552,B-FAST Cohort A,ECD,2024Apr27,Yes,Yes,PFS 12m 78.4%,2.0,10.1093/annonc/mdz394.079,,,Overall Response Rate,87.0,87.0,,,92.0,,84.1-96.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2101.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Recruiting,NCT03178552,B-FAST Cohort A,ECD,2024Apr27,Yes,Yes,PFS 12m 78.4%,2.0,10.1093/annonc/mdz394.079,,,Overall Response Rate,87.0,87.0,,,92.0,,84.1-96.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2102.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Recruiting,NCT03178552,B-FAST Cohort A,ECD,2024Apr27,Yes,Yes,PFS 12m 78.4%,2.0,10.1093/annonc/mdz394.079,,,Overall Response Rate,87.0,87.0,,,92.0,,84.1-96.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2103.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Recruiting,NCT03178552,B-FAST Cohort A,ECD,2024Apr27,Yes,Yes,PFS 12m 78.4%,2.0,10.1093/annonc/mdz394.079,,,Overall Response Rate,87.0,87.0,,,92.0,,84.1-96.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2104.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Recruiting,NCT03178552,B-FAST Cohort A,ECD,2024Apr27,Yes,Yes,PFS 12m 78.4%,2.0,10.1093/annonc/mdz394.079,,,Overall Response Rate,87.0,87.0,,,92.0,,84.1-96.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2105.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Recruiting,NCT03178552,B-FAST Cohort A,ECD,2024Apr27,Yes,Yes,PFS 12m 78.4%,2.0,10.1093/annonc/mdz394.079,,,Overall Response Rate,87.0,87.0,,,92.0,,84.1-96.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2106.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Recruiting,NCT03178552,B-FAST Cohort A,ECD,2024Apr27,Yes,Yes,PFS 12m 78.4%,2.0,10.1093/annonc/mdz394.079,,,Overall Response Rate,87.0,87.0,,,92.0,,84.1-96.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2107.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Recruiting,NCT03178552,B-FAST Cohort A,ECD,2024Apr27,Yes,Yes,PFS 12m 78.4%,2.0,10.1093/annonc/mdz394.079,,,Overall Response Rate,87.0,87.0,,,92.0,,84.1-96.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2108.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Recruiting,NCT03178552,B-FAST Cohort A,ECD,2024Apr27,Yes,Yes,PFS 12m 78.4%,2.0,10.1093/annonc/mdz394.079,,,Overall Response Rate,87.0,87.0,,,92.0,,84.1-96.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2109.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Completed,NCT02604342,ALUR,PCD,2017Jan26,Yes,Yes,,4.0,NCT02604342,Previously-treated,,Progression free survival,119.0,79.0,40.0,Chemotherapy,,,,,,,,,10.9,1.4,0.2,0.12-0.33,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2110.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Completed,NCT02604342,ALUR,PCD,2017Jan26,Yes,Yes,,4.0,NCT02604342,Previously-treated,,Progression free survival,119.0,79.0,40.0,Chemotherapy,,,,,,,,,10.9,1.4,0.2,0.12-0.33,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2111.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Completed,NCT02604342,ALUR,PCD,2017Jan26,Yes,Yes,,4.0,NCT02604342,Previously-treated,,Progression free survival,119.0,79.0,40.0,Chemotherapy,,,,,,,,,10.9,1.4,0.2,0.12-0.33,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2112.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Completed,NCT02604342,ALUR,PCD,2017Jan26,Yes,Yes,,4.0,NCT02604342,Previously-treated,,Progression free survival,119.0,79.0,40.0,Chemotherapy,,,,,,,,,10.9,1.4,0.2,0.12-0.33,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2113.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Completed,NCT02604342,ALUR,PCD,2017Jan26,Yes,Yes,,4.0,NCT02604342,Previously-treated,,Progression free survival,119.0,79.0,40.0,Chemotherapy,,,,,,,,,10.9,1.4,0.2,0.12-0.33,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2114.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Completed,NCT02604342,ALUR,PCD,2017Jan26,Yes,Yes,,4.0,NCT02604342,Previously-treated,,Progression free survival,119.0,79.0,40.0,Chemotherapy,,,,,,,,,10.9,1.4,0.2,0.12-0.33,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2115.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Completed,NCT02604342,ALUR,PCD,2017Jan26,Yes,Yes,,4.0,NCT02604342,Previously-treated,,Progression free survival,119.0,79.0,40.0,Chemotherapy,,,,,,,,,10.9,1.4,0.2,0.12-0.33,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2116.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Completed,NCT02604342,ALUR,PCD,2017Jan26,Yes,Yes,,4.0,NCT02604342,Previously-treated,,Progression free survival,119.0,79.0,40.0,Chemotherapy,,,,,,,,,10.9,1.4,0.2,0.12-0.33,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2117.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,Completed,NCT02604342,ALUR,PCD,2017Jan26,Yes,Yes,,4.0,NCT02604342,Previously-treated,,Progression free survival,119.0,79.0,40.0,Chemotherapy,,,,,,,,,10.9,1.4,0.2,0.12-0.33,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2118.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,"Active, not recruiting",NCT03456076,,ECD,2023Jun30,Yes,No,,4.0,NCT03456076,,,Progression free survival,257.0,,,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May11,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2119.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,"Active, not recruiting",NCT03456076,,ECD,2023Jun30,Yes,No,,4.0,NCT03456076,,,Progression free survival,257.0,,,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May11,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2120.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,"Active, not recruiting",NCT03456076,,ECD,2023Jun30,Yes,No,,4.0,NCT03456076,,,Progression free survival,257.0,,,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May11,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2121.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,"Active, not recruiting",NCT03456076,,ECD,2023Jun30,Yes,No,,4.0,NCT03456076,,,Progression free survival,257.0,,,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May11,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2122.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,"Active, not recruiting",NCT03456076,,ECD,2023Jun30,Yes,No,,4.0,NCT03456076,,,Progression free survival,257.0,,,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May11,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2123.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,"Active, not recruiting",NCT03456076,,ECD,2023Jun30,Yes,No,,4.0,NCT03456076,,,Progression free survival,257.0,,,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May11,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2124.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,"Active, not recruiting",NCT03456076,,ECD,2023Jun30,Yes,No,,4.0,NCT03456076,,,Progression free survival,257.0,,,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May11,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2125.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,"Active, not recruiting",NCT03456076,,ECD,2023Jun30,Yes,No,,4.0,NCT03456076,,,Progression free survival,257.0,,,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May11,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2126.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Alectinib,,"Active, not recruiting",NCT03456076,,ECD,2023Jun30,Yes,No,,4.0,NCT03456076,,,Progression free survival,257.0,,,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May11,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14871.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Out of trials human study,Alectinib,,Unknown,,,,,Yes,Yes,,1.0,27544060,,,Unknown,4.0,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,1.0,,,,,,,,,COSO29915674,2022Mar02,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14872.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Out of trials human study,Alectinib,,Unknown,,,,,Yes,Yes,,1.0,27544060,,,Unknown,4.0,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,1.0,,,,,,,,,COSO29915674,2022Mar02,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14873.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Out of trials human study,Alectinib,,Unknown,,,,,Yes,Yes,,1.0,27544060,,,Unknown,4.0,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,1.0,,,,,,,,,COSO29915674,2022Mar02,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14874.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Out of trials human study,Alectinib,,Unknown,,,,,Yes,Yes,,1.0,27544060,,,Unknown,4.0,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,1.0,,,,,,,,,COSO29915674,2022Mar02,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14875.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Out of trials human study,Alectinib,,Unknown,,,,,Yes,Yes,,1.0,27544060,,,Unknown,4.0,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,1.0,,,,,,,,,COSO29915674,2022Mar02,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14876.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Out of trials human study,Alectinib,,Unknown,,,,,Yes,Yes,,1.0,27544060,,,Unknown,4.0,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,1.0,,,,,,,,,COSO29915674,2022Mar02,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14877.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Out of trials human study,Alectinib,,Unknown,,,,,Yes,Yes,,1.0,27544060,,,Unknown,4.0,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,1.0,,,,,,,,,COSO29915674,2022Mar02,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14878.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Out of trials human study,Alectinib,,Unknown,,,,,Yes,Yes,,1.0,27544060,,,Unknown,4.0,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,1.0,,,,,,,,,COSO29915674,2022Mar02,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14879.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Out of trials human study,Alectinib,,Unknown,,,,,Yes,Yes,,1.0,27544060,,,Unknown,4.0,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,1.0,,,,,,,,,COSO29915674,2022Mar02,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14898.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 1,Alectinib,,Terminated,NCT03131206,,PCD,2018Nov08,Yes,Yes,"Slow accrual, Lack of efficacy",4.0,NCT03131206,,,Overall Response Rate,5.0,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14899.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 1,Alectinib,,Terminated,NCT03131206,,PCD,2018Nov08,Yes,Yes,"Slow accrual, Lack of efficacy",4.0,NCT03131206,,,Overall Response Rate,5.0,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14900.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 1,Alectinib,,Terminated,NCT03131206,,PCD,2018Nov08,Yes,Yes,"Slow accrual, Lack of efficacy",4.0,NCT03131206,,,Overall Response Rate,5.0,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14901.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 1,Alectinib,,Terminated,NCT03131206,,PCD,2018Nov08,Yes,Yes,"Slow accrual, Lack of efficacy",4.0,NCT03131206,,,Overall Response Rate,5.0,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14902.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 1,Alectinib,,Terminated,NCT03131206,,PCD,2018Nov08,Yes,Yes,"Slow accrual, Lack of efficacy",4.0,NCT03131206,,,Overall Response Rate,5.0,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14903.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 1,Alectinib,,Terminated,NCT03131206,,PCD,2018Nov08,Yes,Yes,"Slow accrual, Lack of efficacy",4.0,NCT03131206,,,Overall Response Rate,5.0,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14904.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 1,Alectinib,,Terminated,NCT03131206,,PCD,2018Nov08,Yes,Yes,"Slow accrual, Lack of efficacy",4.0,NCT03131206,,,Overall Response Rate,5.0,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14905.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 1,Alectinib,,Terminated,NCT03131206,,PCD,2018Nov08,Yes,Yes,"Slow accrual, Lack of efficacy",4.0,NCT03131206,,,Overall Response Rate,5.0,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14906.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 1,Alectinib,,Terminated,NCT03131206,,PCD,2018Nov08,Yes,Yes,"Slow accrual, Lack of efficacy",4.0,NCT03131206,,,Overall Response Rate,5.0,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14979.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,Terminated,NCT03445000,ALERT-lung,PCD,2021Mar31,Yes,Yes,Slow accrual,4.0,NCT03445000,,,Best overall response,14.0,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14980.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,Terminated,NCT03445000,ALERT-lung,PCD,2021Mar31,Yes,Yes,Slow accrual,4.0,NCT03445000,,,Best overall response,14.0,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14981.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,Terminated,NCT03445000,ALERT-lung,PCD,2021Mar31,Yes,Yes,Slow accrual,4.0,NCT03445000,,,Best overall response,14.0,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14982.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,Terminated,NCT03445000,ALERT-lung,PCD,2021Mar31,Yes,Yes,Slow accrual,4.0,NCT03445000,,,Best overall response,14.0,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14983.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,Terminated,NCT03445000,ALERT-lung,PCD,2021Mar31,Yes,Yes,Slow accrual,4.0,NCT03445000,,,Best overall response,14.0,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14984.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,Terminated,NCT03445000,ALERT-lung,PCD,2021Mar31,Yes,Yes,Slow accrual,4.0,NCT03445000,,,Best overall response,14.0,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14985.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,Terminated,NCT03445000,ALERT-lung,PCD,2021Mar31,Yes,Yes,Slow accrual,4.0,NCT03445000,,,Best overall response,14.0,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14986.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,Terminated,NCT03445000,ALERT-lung,PCD,2021Mar31,Yes,Yes,Slow accrual,4.0,NCT03445000,,,Best overall response,14.0,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14987.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Alectinib,,Terminated,NCT03445000,ALERT-lung,PCD,2021Mar31,Yes,Yes,Slow accrual,4.0,NCT03445000,,,Best overall response,14.0,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15024.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Alectinib,,Recruiting,NCT03178552,B-FAST Cohort B,ECD,2024Apr27,Yes,No,,4.0,NCT03178552,,,Overall Response Rate,700.0,700.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15025.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Alectinib,,Recruiting,NCT03178552,B-FAST Cohort B,ECD,2024Apr27,Yes,No,,4.0,NCT03178552,,,Overall Response Rate,700.0,700.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15026.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Alectinib,,Recruiting,NCT03178552,B-FAST Cohort B,ECD,2024Apr27,Yes,No,,4.0,NCT03178552,,,Overall Response Rate,700.0,700.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15027.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Alectinib,,Recruiting,NCT03178552,B-FAST Cohort B,ECD,2024Apr27,Yes,No,,4.0,NCT03178552,,,Overall Response Rate,700.0,700.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15028.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Alectinib,,Recruiting,NCT03178552,B-FAST Cohort B,ECD,2024Apr27,Yes,No,,4.0,NCT03178552,,,Overall Response Rate,700.0,700.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15029.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Alectinib,,Recruiting,NCT03178552,B-FAST Cohort B,ECD,2024Apr27,Yes,No,,4.0,NCT03178552,,,Overall Response Rate,700.0,700.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15030.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Alectinib,,Recruiting,NCT03178552,B-FAST Cohort B,ECD,2024Apr27,Yes,No,,4.0,NCT03178552,,,Overall Response Rate,700.0,700.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15031.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Alectinib,,Recruiting,NCT03178552,B-FAST Cohort B,ECD,2024Apr27,Yes,No,,4.0,NCT03178552,,,Overall Response Rate,700.0,700.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15032.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Alectinib,,Recruiting,NCT03178552,B-FAST Cohort B,ECD,2024Apr27,Yes,No,,4.0,NCT03178552,,,Overall Response Rate,700.0,700.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
768.0,ALK,ALK_I1171,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
769.0,ALK,ALK_I1171,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
770.0,ALK,ALK_I1171,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
771.0,ALK,ALK_I1171,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
772.0,ALK,ALK_I1171,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
773.0,ALK,ALK_I1171,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
774.0,ALK,ALK_I1171,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
775.0,ALK,ALK_I1171,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
776.0,ALK,ALK_I1171,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
795.0,ALK,ALK_L1196,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
796.0,ALK,ALK_L1196,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
797.0,ALK,ALK_L1196,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
798.0,ALK,ALK_L1196,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
799.0,ALK,ALK_L1196,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
800.0,ALK,ALK_L1196,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
801.0,ALK,ALK_L1196,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
802.0,ALK,ALK_L1196,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
803.0,ALK,ALK_L1196,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
849.0,ALK,ALK_V1180,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
850.0,ALK,ALK_V1180,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
851.0,ALK,ALK_V1180,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
852.0,ALK,ALK_V1180,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
853.0,ALK,ALK_V1180,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
854.0,ALK,ALK_V1180,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
855.0,ALK,ALK_V1180,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
856.0,ALK,ALK_V1180,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
857.0,ALK,ALK_V1180,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,"Active, not recruiting",NCT03737994,,ECD,2025Dec13,Yes,No,,4.0,NCT03737994,Previously-treated,,Overall Response Rate,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1101.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Ceritinib,Required,Completed,NCT01283516 ,ASCEND-1,PCD,2016May01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf,Previously-treated,,Maximum tolerated dose/toxicity,163.0,163.0,,,55.0,,47-62,,7.4,,5.4-10.1,,,,,,,,,,,,,,,,,,,,,2.0,86.0,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1102.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Ceritinib,Required,Completed,NCT01283516 ,ASCEND-1,PCD,2016May01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf,Previously-treated,,Maximum tolerated dose/toxicity,163.0,163.0,,,55.0,,47-62,,7.4,,5.4-10.1,,,,,,,,,,,,,,,,,,,,,2.0,86.0,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1103.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Ceritinib,Required,Completed,NCT01283516 ,ASCEND-1,PCD,2016May01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf,Previously-treated,,Maximum tolerated dose/toxicity,163.0,163.0,,,55.0,,47-62,,7.4,,5.4-10.1,,,,,,,,,,,,,,,,,,,,,2.0,86.0,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1104.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Ceritinib,Required,Completed,NCT01283516 ,ASCEND-1,PCD,2016May01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf,Previously-treated,,Maximum tolerated dose/toxicity,163.0,163.0,,,55.0,,47-62,,7.4,,5.4-10.1,,,,,,,,,,,,,,,,,,,,,2.0,86.0,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1105.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Ceritinib,Required,Completed,NCT01283516 ,ASCEND-1,PCD,2016May01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf,Previously-treated,,Maximum tolerated dose/toxicity,163.0,163.0,,,55.0,,47-62,,7.4,,5.4-10.1,,,,,,,,,,,,,,,,,,,,,2.0,86.0,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1106.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Ceritinib,Required,Completed,NCT01283516 ,ASCEND-1,PCD,2016May01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf,Previously-treated,,Maximum tolerated dose/toxicity,163.0,163.0,,,55.0,,47-62,,7.4,,5.4-10.1,,,,,,,,,,,,,,,,,,,,,2.0,86.0,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1107.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Ceritinib,Required,Completed,NCT01283516 ,ASCEND-1,PCD,2016May01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf,Previously-treated,,Maximum tolerated dose/toxicity,163.0,163.0,,,55.0,,47-62,,7.4,,5.4-10.1,,,,,,,,,,,,,,,,,,,,,2.0,86.0,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1108.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Ceritinib,Required,Completed,NCT01283516 ,ASCEND-1,PCD,2016May01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf,Previously-treated,,Maximum tolerated dose/toxicity,163.0,163.0,,,55.0,,47-62,,7.4,,5.4-10.1,,,,,,,,,,,,,,,,,,,,,2.0,86.0,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1109.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Ceritinib,Required,Completed,NCT01283516 ,ASCEND-1,PCD,2016May01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf,Previously-treated,,Maximum tolerated dose/toxicity,163.0,163.0,,,55.0,,47-62,,7.4,,5.4-10.1,,,,,,,,,,,,,,,,,,,,,2.0,86.0,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1110.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Ceritinib,Required,"Active, not recruiting",NCT01828099,ASCEND-4,PCD,2016Jun24,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf,Untreated,,Progression free survival,375.0,189.0,187.0,Chemotherapy,,,,,,,,,16.6,8.1,0.55,5.8-11.1,<0.00001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1111.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Ceritinib,Required,"Active, not recruiting",NCT01828099,ASCEND-4,PCD,2016Jun24,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf,Untreated,,Progression free survival,375.0,189.0,187.0,Chemotherapy,,,,,,,,,16.6,8.1,0.55,5.8-11.1,<0.00001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1112.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Ceritinib,Required,"Active, not recruiting",NCT01828099,ASCEND-4,PCD,2016Jun24,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf,Untreated,,Progression free survival,375.0,189.0,187.0,Chemotherapy,,,,,,,,,16.6,8.1,0.55,5.8-11.1,<0.00001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1113.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Ceritinib,Required,"Active, not recruiting",NCT01828099,ASCEND-4,PCD,2016Jun24,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf,Untreated,,Progression free survival,375.0,189.0,187.0,Chemotherapy,,,,,,,,,16.6,8.1,0.55,5.8-11.1,<0.00001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1114.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Ceritinib,Required,"Active, not recruiting",NCT01828099,ASCEND-4,PCD,2016Jun24,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf,Untreated,,Progression free survival,375.0,189.0,187.0,Chemotherapy,,,,,,,,,16.6,8.1,0.55,5.8-11.1,<0.00001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1115.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Ceritinib,Required,"Active, not recruiting",NCT01828099,ASCEND-4,PCD,2016Jun24,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf,Untreated,,Progression free survival,375.0,189.0,187.0,Chemotherapy,,,,,,,,,16.6,8.1,0.55,5.8-11.1,<0.00001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1116.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Ceritinib,Required,"Active, not recruiting",NCT01828099,ASCEND-4,PCD,2016Jun24,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf,Untreated,,Progression free survival,375.0,189.0,187.0,Chemotherapy,,,,,,,,,16.6,8.1,0.55,5.8-11.1,<0.00001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1117.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Ceritinib,Required,"Active, not recruiting",NCT01828099,ASCEND-4,PCD,2016Jun24,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf,Untreated,,Progression free survival,375.0,189.0,187.0,Chemotherapy,,,,,,,,,16.6,8.1,0.55,5.8-11.1,<0.00001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1118.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Ceritinib,Required,"Active, not recruiting",NCT01828099,ASCEND-4,PCD,2016Jun24,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf,Untreated,,Progression free survival,375.0,189.0,187.0,Chemotherapy,,,,,,,,,16.6,8.1,0.55,5.8-11.1,<0.00001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1929.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 5,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,,,Overall Response Rate,18.0,18.0,,,16.7,,3.6-41.4,,,,,,,,,,,,,,,,66.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1930.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 5,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,,,Overall Response Rate,18.0,18.0,,,16.7,,3.6-41.4,,,,,,,,,,,,,,,,66.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1931.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 5,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,,,Overall Response Rate,18.0,18.0,,,16.7,,3.6-41.4,,,,,,,,,,,,,,,,66.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1932.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 5,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,,,Overall Response Rate,18.0,18.0,,,16.7,,3.6-41.4,,,,,,,,,,,,,,,,66.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1933.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 5,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,,,Overall Response Rate,18.0,18.0,,,16.7,,3.6-41.4,,,,,,,,,,,,,,,,66.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1934.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 5,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,,,Overall Response Rate,18.0,18.0,,,16.7,,3.6-41.4,,,,,,,,,,,,,,,,66.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1935.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 5,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,,,Overall Response Rate,18.0,18.0,,,16.7,,3.6-41.4,,,,,,,,,,,,,,,,66.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1936.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 5,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,,,Overall Response Rate,18.0,18.0,,,16.7,,3.6-41.4,,,,,,,,,,,,,,,,66.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1937.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 5,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,,,Overall Response Rate,18.0,18.0,,,16.7,,3.6-41.4,,,,,,,,,,,,,,,,66.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1938.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 4,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,Untreated,,Overall Response Rate,44.0,44.0,,,59.1,,43.2-73.7,,,,,,,,,,,,,,,,70.5,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1939.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 4,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,Untreated,,Overall Response Rate,44.0,44.0,,,59.1,,43.2-73.7,,,,,,,,,,,,,,,,70.5,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1940.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 4,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,Untreated,,Overall Response Rate,44.0,44.0,,,59.1,,43.2-73.7,,,,,,,,,,,,,,,,70.5,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1941.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 4,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,Untreated,,Overall Response Rate,44.0,44.0,,,59.1,,43.2-73.7,,,,,,,,,,,,,,,,70.5,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1942.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 4,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,Untreated,,Overall Response Rate,44.0,44.0,,,59.1,,43.2-73.7,,,,,,,,,,,,,,,,70.5,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1943.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 4,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,Untreated,,Overall Response Rate,44.0,44.0,,,59.1,,43.2-73.7,,,,,,,,,,,,,,,,70.5,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1944.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 4,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,Untreated,,Overall Response Rate,44.0,44.0,,,59.1,,43.2-73.7,,,,,,,,,,,,,,,,70.5,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1945.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 4,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,Untreated,,Overall Response Rate,44.0,44.0,,,59.1,,43.2-73.7,,,,,,,,,,,,,,,,70.5,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1946.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 4,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,Untreated,,Overall Response Rate,44.0,44.0,,,59.1,,43.2-73.7,,,,,,,,,,,,,,,,70.5,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1947.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 3,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,"Previously-treated, platinum-resistant",,Overall Response Rate,12.0,12.0,,,50.0,,21.1-78.9,,,,,,,,,,,,,,,,66.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1948.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 3,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,"Previously-treated, platinum-resistant",,Overall Response Rate,12.0,12.0,,,50.0,,21.1-78.9,,,,,,,,,,,,,,,,66.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1949.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 3,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,"Previously-treated, platinum-resistant",,Overall Response Rate,12.0,12.0,,,50.0,,21.1-78.9,,,,,,,,,,,,,,,,66.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1950.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 3,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,"Previously-treated, platinum-resistant",,Overall Response Rate,12.0,12.0,,,50.0,,21.1-78.9,,,,,,,,,,,,,,,,66.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1951.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 3,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,"Previously-treated, platinum-resistant",,Overall Response Rate,12.0,12.0,,,50.0,,21.1-78.9,,,,,,,,,,,,,,,,66.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1952.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 3,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,"Previously-treated, platinum-resistant",,Overall Response Rate,12.0,12.0,,,50.0,,21.1-78.9,,,,,,,,,,,,,,,,66.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1953.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 3,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,"Previously-treated, platinum-resistant",,Overall Response Rate,12.0,12.0,,,50.0,,21.1-78.9,,,,,,,,,,,,,,,,66.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1954.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 3,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,"Previously-treated, platinum-resistant",,Overall Response Rate,12.0,12.0,,,50.0,,21.1-78.9,,,,,,,,,,,,,,,,66.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1955.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 3,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,"Previously-treated, platinum-resistant",,Overall Response Rate,12.0,12.0,,,50.0,,21.1-78.9,,,,,,,,,,,,,,,,66.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1956.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 2,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,"Previously-treated, platinum-resistant",,Overall Response Rate,40.0,40.0,,,30.0,,16.6-46.5,,,,,,,,,,,,,,,,82.5,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1957.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 2,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,"Previously-treated, platinum-resistant",,Overall Response Rate,40.0,40.0,,,30.0,,16.6-46.5,,,,,,,,,,,,,,,,82.5,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1958.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 2,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,"Previously-treated, platinum-resistant",,Overall Response Rate,40.0,40.0,,,30.0,,16.6-46.5,,,,,,,,,,,,,,,,82.5,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1959.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 2,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,"Previously-treated, platinum-resistant",,Overall Response Rate,40.0,40.0,,,30.0,,16.6-46.5,,,,,,,,,,,,,,,,82.5,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1960.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 2,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,"Previously-treated, platinum-resistant",,Overall Response Rate,40.0,40.0,,,30.0,,16.6-46.5,,,,,,,,,,,,,,,,82.5,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1961.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 2,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,"Previously-treated, platinum-resistant",,Overall Response Rate,40.0,40.0,,,30.0,,16.6-46.5,,,,,,,,,,,,,,,,82.5,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1962.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 2,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,"Previously-treated, platinum-resistant",,Overall Response Rate,40.0,40.0,,,30.0,,16.6-46.5,,,,,,,,,,,,,,,,82.5,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1963.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 2,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,"Previously-treated, platinum-resistant",,Overall Response Rate,40.0,40.0,,,30.0,,16.6-46.5,,,,,,,,,,,,,,,,82.5,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1964.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 2,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,"Previously-treated, platinum-resistant",,Overall Response Rate,40.0,40.0,,,30.0,,16.6-46.5,,,,,,,,,,,,,,,,82.5,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1965.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT01685060,ASCEND-2,PCD,2016Mar29,Yes,Yes,,2.0,10.1200/jco.2015.33.15_suppl.8059,Previously-treated,,Overall Response Rate,140.0,140.0,,,38.6,,30.5-47.2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1966.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT01685060,ASCEND-2,PCD,2016Mar29,Yes,Yes,,2.0,10.1200/jco.2015.33.15_suppl.8059,Previously-treated,,Overall Response Rate,140.0,140.0,,,38.6,,30.5-47.2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1967.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT01685060,ASCEND-2,PCD,2016Mar29,Yes,Yes,,2.0,10.1200/jco.2015.33.15_suppl.8059,Previously-treated,,Overall Response Rate,140.0,140.0,,,38.6,,30.5-47.2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1968.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT01685060,ASCEND-2,PCD,2016Mar29,Yes,Yes,,2.0,10.1200/jco.2015.33.15_suppl.8059,Previously-treated,,Overall Response Rate,140.0,140.0,,,38.6,,30.5-47.2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1969.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT01685060,ASCEND-2,PCD,2016Mar29,Yes,Yes,,2.0,10.1200/jco.2015.33.15_suppl.8059,Previously-treated,,Overall Response Rate,140.0,140.0,,,38.6,,30.5-47.2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1970.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT01685060,ASCEND-2,PCD,2016Mar29,Yes,Yes,,2.0,10.1200/jco.2015.33.15_suppl.8059,Previously-treated,,Overall Response Rate,140.0,140.0,,,38.6,,30.5-47.2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1971.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT01685060,ASCEND-2,PCD,2016Mar29,Yes,Yes,,2.0,10.1200/jco.2015.33.15_suppl.8059,Previously-treated,,Overall Response Rate,140.0,140.0,,,38.6,,30.5-47.2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1972.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT01685060,ASCEND-2,PCD,2016Mar29,Yes,Yes,,2.0,10.1200/jco.2015.33.15_suppl.8059,Previously-treated,,Overall Response Rate,140.0,140.0,,,38.6,,30.5-47.2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1973.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT01685060,ASCEND-2,PCD,2016Mar29,Yes,Yes,,2.0,10.1200/jco.2015.33.15_suppl.8059,Previously-treated,,Overall Response Rate,140.0,140.0,,,38.6,,30.5-47.2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1974.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT01685138,ASCEND-3,PCD,2018Jan22,Yes,Yes,,2.0,10.1200/jco.2015.33.15_suppl.8060,Untreated,,Overall Response Rate,124.0,124.0,,,63.7,,,,9.3,,,,11.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1975.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT01685138,ASCEND-3,PCD,2018Jan22,Yes,Yes,,2.0,10.1200/jco.2015.33.15_suppl.8060,Untreated,,Overall Response Rate,124.0,124.0,,,63.7,,,,9.3,,,,11.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1976.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT01685138,ASCEND-3,PCD,2018Jan22,Yes,Yes,,2.0,10.1200/jco.2015.33.15_suppl.8060,Untreated,,Overall Response Rate,124.0,124.0,,,63.7,,,,9.3,,,,11.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1977.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT01685138,ASCEND-3,PCD,2018Jan22,Yes,Yes,,2.0,10.1200/jco.2015.33.15_suppl.8060,Untreated,,Overall Response Rate,124.0,124.0,,,63.7,,,,9.3,,,,11.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1978.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT01685138,ASCEND-3,PCD,2018Jan22,Yes,Yes,,2.0,10.1200/jco.2015.33.15_suppl.8060,Untreated,,Overall Response Rate,124.0,124.0,,,63.7,,,,9.3,,,,11.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1979.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT01685138,ASCEND-3,PCD,2018Jan22,Yes,Yes,,2.0,10.1200/jco.2015.33.15_suppl.8060,Untreated,,Overall Response Rate,124.0,124.0,,,63.7,,,,9.3,,,,11.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1980.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT01685138,ASCEND-3,PCD,2018Jan22,Yes,Yes,,2.0,10.1200/jco.2015.33.15_suppl.8060,Untreated,,Overall Response Rate,124.0,124.0,,,63.7,,,,9.3,,,,11.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1981.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT01685138,ASCEND-3,PCD,2018Jan22,Yes,Yes,,2.0,10.1200/jco.2015.33.15_suppl.8060,Untreated,,Overall Response Rate,124.0,124.0,,,63.7,,,,9.3,,,,11.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1982.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT01685138,ASCEND-3,PCD,2018Jan22,Yes,Yes,,2.0,10.1200/jco.2015.33.15_suppl.8060,Untreated,,Overall Response Rate,124.0,124.0,,,63.7,,,,9.3,,,,11.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1983.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02040870,ASCEND-6,PCD,2017Jul27,Yes,Yes,,3.0,https://oncologypro.esmo.org/Meeting-Resources/ESMO-Asia-2016-Congress/ASCEND-6-single-arm-open-label-multicenter-phase-1-2-study-of-ceritinib-in-Chinese-pts-with-advanced-ALK-rearranged-ALK-non-small-cell-lung-cancer-NSCLC-previously-treated-with-crizotinib,Previously-treated,,Maximum tolerated dose/toxicity,103.0,103.0,,,42.0,,31.2-50.9,,,,,,5.7,,,5.4-7.5,,,,,,,80.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1984.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02040870,ASCEND-6,PCD,2017Jul27,Yes,Yes,,3.0,https://oncologypro.esmo.org/Meeting-Resources/ESMO-Asia-2016-Congress/ASCEND-6-single-arm-open-label-multicenter-phase-1-2-study-of-ceritinib-in-Chinese-pts-with-advanced-ALK-rearranged-ALK-non-small-cell-lung-cancer-NSCLC-previously-treated-with-crizotinib,Previously-treated,,Maximum tolerated dose/toxicity,103.0,103.0,,,42.0,,31.2-50.9,,,,,,5.7,,,5.4-7.5,,,,,,,80.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1985.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02040870,ASCEND-6,PCD,2017Jul27,Yes,Yes,,3.0,https://oncologypro.esmo.org/Meeting-Resources/ESMO-Asia-2016-Congress/ASCEND-6-single-arm-open-label-multicenter-phase-1-2-study-of-ceritinib-in-Chinese-pts-with-advanced-ALK-rearranged-ALK-non-small-cell-lung-cancer-NSCLC-previously-treated-with-crizotinib,Previously-treated,,Maximum tolerated dose/toxicity,103.0,103.0,,,42.0,,31.2-50.9,,,,,,5.7,,,5.4-7.5,,,,,,,80.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1986.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02040870,ASCEND-6,PCD,2017Jul27,Yes,Yes,,3.0,https://oncologypro.esmo.org/Meeting-Resources/ESMO-Asia-2016-Congress/ASCEND-6-single-arm-open-label-multicenter-phase-1-2-study-of-ceritinib-in-Chinese-pts-with-advanced-ALK-rearranged-ALK-non-small-cell-lung-cancer-NSCLC-previously-treated-with-crizotinib,Previously-treated,,Maximum tolerated dose/toxicity,103.0,103.0,,,42.0,,31.2-50.9,,,,,,5.7,,,5.4-7.5,,,,,,,80.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1987.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02040870,ASCEND-6,PCD,2017Jul27,Yes,Yes,,3.0,https://oncologypro.esmo.org/Meeting-Resources/ESMO-Asia-2016-Congress/ASCEND-6-single-arm-open-label-multicenter-phase-1-2-study-of-ceritinib-in-Chinese-pts-with-advanced-ALK-rearranged-ALK-non-small-cell-lung-cancer-NSCLC-previously-treated-with-crizotinib,Previously-treated,,Maximum tolerated dose/toxicity,103.0,103.0,,,42.0,,31.2-50.9,,,,,,5.7,,,5.4-7.5,,,,,,,80.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1988.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02040870,ASCEND-6,PCD,2017Jul27,Yes,Yes,,3.0,https://oncologypro.esmo.org/Meeting-Resources/ESMO-Asia-2016-Congress/ASCEND-6-single-arm-open-label-multicenter-phase-1-2-study-of-ceritinib-in-Chinese-pts-with-advanced-ALK-rearranged-ALK-non-small-cell-lung-cancer-NSCLC-previously-treated-with-crizotinib,Previously-treated,,Maximum tolerated dose/toxicity,103.0,103.0,,,42.0,,31.2-50.9,,,,,,5.7,,,5.4-7.5,,,,,,,80.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1989.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02040870,ASCEND-6,PCD,2017Jul27,Yes,Yes,,3.0,https://oncologypro.esmo.org/Meeting-Resources/ESMO-Asia-2016-Congress/ASCEND-6-single-arm-open-label-multicenter-phase-1-2-study-of-ceritinib-in-Chinese-pts-with-advanced-ALK-rearranged-ALK-non-small-cell-lung-cancer-NSCLC-previously-treated-with-crizotinib,Previously-treated,,Maximum tolerated dose/toxicity,103.0,103.0,,,42.0,,31.2-50.9,,,,,,5.7,,,5.4-7.5,,,,,,,80.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1990.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02040870,ASCEND-6,PCD,2017Jul27,Yes,Yes,,3.0,https://oncologypro.esmo.org/Meeting-Resources/ESMO-Asia-2016-Congress/ASCEND-6-single-arm-open-label-multicenter-phase-1-2-study-of-ceritinib-in-Chinese-pts-with-advanced-ALK-rearranged-ALK-non-small-cell-lung-cancer-NSCLC-previously-treated-with-crizotinib,Previously-treated,,Maximum tolerated dose/toxicity,103.0,103.0,,,42.0,,31.2-50.9,,,,,,5.7,,,5.4-7.5,,,,,,,80.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1991.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02040870,ASCEND-6,PCD,2017Jul27,Yes,Yes,,3.0,https://oncologypro.esmo.org/Meeting-Resources/ESMO-Asia-2016-Congress/ASCEND-6-single-arm-open-label-multicenter-phase-1-2-study-of-ceritinib-in-Chinese-pts-with-advanced-ALK-rearranged-ALK-non-small-cell-lung-cancer-NSCLC-previously-treated-with-crizotinib,Previously-treated,,Maximum tolerated dose/toxicity,103.0,103.0,,,42.0,,31.2-50.9,,,,,,5.7,,,5.4-7.5,,,,,,,80.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1992.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Terminated,NCT02513667,,PCD,2020May29,Yes,Yes,Primary outcome not met,2.0,10.1200/JCO.2020.38.15_suppl.e21571,,,Progression free survival,14.0,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1993.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Terminated,NCT02513667,,PCD,2020May29,Yes,Yes,Primary outcome not met,2.0,10.1200/JCO.2020.38.15_suppl.e21571,,,Progression free survival,14.0,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1994.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Terminated,NCT02513667,,PCD,2020May29,Yes,Yes,Primary outcome not met,2.0,10.1200/JCO.2020.38.15_suppl.e21571,,,Progression free survival,14.0,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1995.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Terminated,NCT02513667,,PCD,2020May29,Yes,Yes,Primary outcome not met,2.0,10.1200/JCO.2020.38.15_suppl.e21571,,,Progression free survival,14.0,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1996.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Terminated,NCT02513667,,PCD,2020May29,Yes,Yes,Primary outcome not met,2.0,10.1200/JCO.2020.38.15_suppl.e21571,,,Progression free survival,14.0,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1997.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Terminated,NCT02513667,,PCD,2020May29,Yes,Yes,Primary outcome not met,2.0,10.1200/JCO.2020.38.15_suppl.e21571,,,Progression free survival,14.0,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1998.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Terminated,NCT02513667,,PCD,2020May29,Yes,Yes,Primary outcome not met,2.0,10.1200/JCO.2020.38.15_suppl.e21571,,,Progression free survival,14.0,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
1999.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Terminated,NCT02513667,,PCD,2020May29,Yes,Yes,Primary outcome not met,2.0,10.1200/JCO.2020.38.15_suppl.e21571,,,Progression free survival,14.0,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2000.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Terminated,NCT02513667,,PCD,2020May29,Yes,Yes,Primary outcome not met,2.0,10.1200/JCO.2020.38.15_suppl.e21571,,,Progression free survival,14.0,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2001.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02450903,,PCD,2017Jul31,Yes,Yes,,4.0,NCT02450903,Previously-treated,,Unknown,20.0,20.0,,,25.0,,8.7-49.1,,6.3,,3.5-9.2,,3.7,,,1.9-5.3,,,,,,,70.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2002.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02450903,,PCD,2017Jul31,Yes,Yes,,4.0,NCT02450903,Previously-treated,,Unknown,20.0,20.0,,,25.0,,8.7-49.1,,6.3,,3.5-9.2,,3.7,,,1.9-5.3,,,,,,,70.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2003.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02450903,,PCD,2017Jul31,Yes,Yes,,4.0,NCT02450903,Previously-treated,,Unknown,20.0,20.0,,,25.0,,8.7-49.1,,6.3,,3.5-9.2,,3.7,,,1.9-5.3,,,,,,,70.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2004.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02450903,,PCD,2017Jul31,Yes,Yes,,4.0,NCT02450903,Previously-treated,,Unknown,20.0,20.0,,,25.0,,8.7-49.1,,6.3,,3.5-9.2,,3.7,,,1.9-5.3,,,,,,,70.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2005.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02450903,,PCD,2017Jul31,Yes,Yes,,4.0,NCT02450903,Previously-treated,,Unknown,20.0,20.0,,,25.0,,8.7-49.1,,6.3,,3.5-9.2,,3.7,,,1.9-5.3,,,,,,,70.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2006.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02450903,,PCD,2017Jul31,Yes,Yes,,4.0,NCT02450903,Previously-treated,,Unknown,20.0,20.0,,,25.0,,8.7-49.1,,6.3,,3.5-9.2,,3.7,,,1.9-5.3,,,,,,,70.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2007.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02450903,,PCD,2017Jul31,Yes,Yes,,4.0,NCT02450903,Previously-treated,,Unknown,20.0,20.0,,,25.0,,8.7-49.1,,6.3,,3.5-9.2,,3.7,,,1.9-5.3,,,,,,,70.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2008.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02450903,,PCD,2017Jul31,Yes,Yes,,4.0,NCT02450903,Previously-treated,,Unknown,20.0,20.0,,,25.0,,8.7-49.1,,6.3,,3.5-9.2,,3.7,,,1.9-5.3,,,,,,,70.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2009.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02450903,,PCD,2017Jul31,Yes,Yes,,4.0,NCT02450903,Previously-treated,,Unknown,20.0,20.0,,,25.0,,8.7-49.1,,6.3,,3.5-9.2,,3.7,,,1.9-5.3,,,,,,,70.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2010.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 1,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,"Previously-treated, platinum-resistant",,Overall Response Rate,42.0,42.0,,,35.7,,21.6-52.0,,,,,,,,,,,,,,,,66.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2011.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 1,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,"Previously-treated, platinum-resistant",,Overall Response Rate,42.0,42.0,,,35.7,,21.6-52.0,,,,,,,,,,,,,,,,66.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2012.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 1,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,"Previously-treated, platinum-resistant",,Overall Response Rate,42.0,42.0,,,35.7,,21.6-52.0,,,,,,,,,,,,,,,,66.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2013.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 1,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,"Previously-treated, platinum-resistant",,Overall Response Rate,42.0,42.0,,,35.7,,21.6-52.0,,,,,,,,,,,,,,,,66.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2014.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 1,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,"Previously-treated, platinum-resistant",,Overall Response Rate,42.0,42.0,,,35.7,,21.6-52.0,,,,,,,,,,,,,,,,66.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2015.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 1,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,"Previously-treated, platinum-resistant",,Overall Response Rate,42.0,42.0,,,35.7,,21.6-52.0,,,,,,,,,,,,,,,,66.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2016.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 1,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,"Previously-treated, platinum-resistant",,Overall Response Rate,42.0,42.0,,,35.7,,21.6-52.0,,,,,,,,,,,,,,,,66.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2017.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 1,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,"Previously-treated, platinum-resistant",,Overall Response Rate,42.0,42.0,,,35.7,,21.6-52.0,,,,,,,,,,,,,,,,66.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2018.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Completed,NCT02336451,ASCEND-7 Arm 1,PCD,2019Feb06,Yes,Yes,,4.0,NCT02336451,"Previously-treated, platinum-resistant",,Overall Response Rate,42.0,42.0,,,35.7,,21.6-52.0,,,,,,,,,,,,,,,,66.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2127.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Ceritinib,,"Active, not recruiting",NCT01828112,ASCEND-5,PCD,2016Jan26,Yes,Yes,,4.0,NCT01828112,Previously-treated,,Progression free survival,231.0,115.0,116.0,Chemotherapy,,,,,,,,,5.4,1.6,0.49,0.36-0.67,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2128.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Ceritinib,,"Active, not recruiting",NCT01828112,ASCEND-5,PCD,2016Jan26,Yes,Yes,,4.0,NCT01828112,Previously-treated,,Progression free survival,231.0,115.0,116.0,Chemotherapy,,,,,,,,,5.4,1.6,0.49,0.36-0.67,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2129.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Ceritinib,,"Active, not recruiting",NCT01828112,ASCEND-5,PCD,2016Jan26,Yes,Yes,,4.0,NCT01828112,Previously-treated,,Progression free survival,231.0,115.0,116.0,Chemotherapy,,,,,,,,,5.4,1.6,0.49,0.36-0.67,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2130.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Ceritinib,,"Active, not recruiting",NCT01828112,ASCEND-5,PCD,2016Jan26,Yes,Yes,,4.0,NCT01828112,Previously-treated,,Progression free survival,231.0,115.0,116.0,Chemotherapy,,,,,,,,,5.4,1.6,0.49,0.36-0.67,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2131.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Ceritinib,,"Active, not recruiting",NCT01828112,ASCEND-5,PCD,2016Jan26,Yes,Yes,,4.0,NCT01828112,Previously-treated,,Progression free survival,231.0,115.0,116.0,Chemotherapy,,,,,,,,,5.4,1.6,0.49,0.36-0.67,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2132.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Ceritinib,,"Active, not recruiting",NCT01828112,ASCEND-5,PCD,2016Jan26,Yes,Yes,,4.0,NCT01828112,Previously-treated,,Progression free survival,231.0,115.0,116.0,Chemotherapy,,,,,,,,,5.4,1.6,0.49,0.36-0.67,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2133.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Ceritinib,,"Active, not recruiting",NCT01828112,ASCEND-5,PCD,2016Jan26,Yes,Yes,,4.0,NCT01828112,Previously-treated,,Progression free survival,231.0,115.0,116.0,Chemotherapy,,,,,,,,,5.4,1.6,0.49,0.36-0.67,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2134.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Ceritinib,,"Active, not recruiting",NCT01828112,ASCEND-5,PCD,2016Jan26,Yes,Yes,,4.0,NCT01828112,Previously-treated,,Progression free survival,231.0,115.0,116.0,Chemotherapy,,,,,,,,,5.4,1.6,0.49,0.36-0.67,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2135.0,ALK,ALK_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Ceritinib,,"Active, not recruiting",NCT01828112,ASCEND-5,PCD,2016Jan26,Yes,Yes,,4.0,NCT01828112,Previously-treated,,Progression free survival,231.0,115.0,116.0,Chemotherapy,,,,,,,,,5.4,1.6,0.49,0.36-0.67,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2226.0,ALK,ALK_unspecified or ROS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,Completed,NCT02276027,,PCD,2019Oct15,Yes,Yes,,4.0,NCT02276027,,,Overall Response Rate,26.0,26.0,,,73.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2227.0,ALK,ALK_unspecified or ROS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,Completed,NCT02276027,,PCD,2019Oct15,Yes,Yes,,4.0,NCT02276027,,,Overall Response Rate,26.0,26.0,,,73.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2228.0,ALK,ALK_unspecified or ROS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,Completed,NCT02276027,,PCD,2019Oct15,Yes,Yes,,4.0,NCT02276027,,,Overall Response Rate,26.0,26.0,,,73.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2229.0,ALK,ALK_unspecified or ROS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,Completed,NCT02276027,,PCD,2019Oct15,Yes,Yes,,4.0,NCT02276027,,,Overall Response Rate,26.0,26.0,,,73.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2230.0,ALK,ALK_unspecified or ROS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,Completed,NCT02276027,,PCD,2019Oct15,Yes,Yes,,4.0,NCT02276027,,,Overall Response Rate,26.0,26.0,,,73.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2231.0,ALK,ALK_unspecified or ROS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,Completed,NCT02276027,,PCD,2019Oct15,Yes,Yes,,4.0,NCT02276027,,,Overall Response Rate,26.0,26.0,,,73.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2232.0,ALK,ALK_unspecified or ROS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,Completed,NCT02276027,,PCD,2019Oct15,Yes,Yes,,4.0,NCT02276027,,,Overall Response Rate,26.0,26.0,,,73.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2233.0,ALK,ALK_unspecified or ROS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,Completed,NCT02276027,,PCD,2019Oct15,Yes,Yes,,4.0,NCT02276027,,,Overall Response Rate,26.0,26.0,,,73.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2234.0,ALK,ALK_unspecified or ROS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,Completed,NCT02276027,,PCD,2019Oct15,Yes,Yes,,4.0,NCT02276027,,,Overall Response Rate,26.0,26.0,,,73.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2667.0,BRAF,BRAF_unspecified or NRAS_unspecified or KRAS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,Completed,NCT02276027,,PCD,2019Oct15,Yes,Yes,,4.0,NCT02276027,,,Overall Response Rate,22.0,22.0,,,9.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2668.0,BRAF,BRAF_unspecified or NRAS_unspecified or KRAS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,Completed,NCT02276027,,PCD,2019Oct15,Yes,Yes,,4.0,NCT02276027,,,Overall Response Rate,22.0,22.0,,,9.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2669.0,BRAF,BRAF_unspecified or NRAS_unspecified or KRAS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,Completed,NCT02276027,,PCD,2019Oct15,Yes,Yes,,4.0,NCT02276027,,,Overall Response Rate,22.0,22.0,,,9.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2670.0,BRAF,BRAF_unspecified or NRAS_unspecified or KRAS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,Completed,NCT02276027,,PCD,2019Oct15,Yes,Yes,,4.0,NCT02276027,,,Overall Response Rate,22.0,22.0,,,9.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2671.0,BRAF,BRAF_unspecified or NRAS_unspecified or KRAS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,Completed,NCT02276027,,PCD,2019Oct15,Yes,Yes,,4.0,NCT02276027,,,Overall Response Rate,22.0,22.0,,,9.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2672.0,BRAF,BRAF_unspecified or NRAS_unspecified or KRAS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,Completed,NCT02276027,,PCD,2019Oct15,Yes,Yes,,4.0,NCT02276027,,,Overall Response Rate,22.0,22.0,,,9.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2673.0,BRAF,BRAF_unspecified or NRAS_unspecified or KRAS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,Completed,NCT02276027,,PCD,2019Oct15,Yes,Yes,,4.0,NCT02276027,,,Overall Response Rate,22.0,22.0,,,9.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2674.0,BRAF,BRAF_unspecified or NRAS_unspecified or KRAS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,Completed,NCT02276027,,PCD,2019Oct15,Yes,Yes,,4.0,NCT02276027,,,Overall Response Rate,22.0,22.0,,,9.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2675.0,BRAF,BRAF_unspecified or NRAS_unspecified or KRAS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Ceritinib,,Completed,NCT02276027,,PCD,2019Oct15,Yes,Yes,,4.0,NCT02276027,,,Overall Response Rate,22.0,22.0,,,9.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14358.0,MET,MET_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Ceritinib,,Completed,NCT02276027,,PCD,2019Oct15,Yes,Yes,,4.0,NCT02276027,,,Overall Response Rate,16.0,16.0,,,18.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14359.0,MET,MET_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Ceritinib,,Completed,NCT02276027,,PCD,2019Oct15,Yes,Yes,,4.0,NCT02276027,,,Overall Response Rate,16.0,16.0,,,18.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14360.0,MET,MET_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Ceritinib,,Completed,NCT02276027,,PCD,2019Oct15,Yes,Yes,,4.0,NCT02276027,,,Overall Response Rate,16.0,16.0,,,18.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14361.0,MET,MET_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Ceritinib,,Completed,NCT02276027,,PCD,2019Oct15,Yes,Yes,,4.0,NCT02276027,,,Overall Response Rate,16.0,16.0,,,18.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14362.0,MET,MET_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Ceritinib,,Completed,NCT02276027,,PCD,2019Oct15,Yes,Yes,,4.0,NCT02276027,,,Overall Response Rate,16.0,16.0,,,18.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14363.0,MET,MET_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Ceritinib,,Completed,NCT02276027,,PCD,2019Oct15,Yes,Yes,,4.0,NCT02276027,,,Overall Response Rate,16.0,16.0,,,18.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14364.0,MET,MET_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Ceritinib,,Completed,NCT02276027,,PCD,2019Oct15,Yes,Yes,,4.0,NCT02276027,,,Overall Response Rate,16.0,16.0,,,18.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14365.0,MET,MET_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Ceritinib,,Completed,NCT02276027,,PCD,2019Oct15,Yes,Yes,,4.0,NCT02276027,,,Overall Response Rate,16.0,16.0,,,18.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14366.0,MET,MET_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Ceritinib,,Completed,NCT02276027,,PCD,2019Oct15,Yes,Yes,,4.0,NCT02276027,,,Overall Response Rate,16.0,16.0,,,18.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15663.0,ROS1,ROS1_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Terminated,NCT02186821,SIGNATURE,PCD,2017Dec13,Yes,Yes,Slow accrual,4.0,NCT02186821,,,"Disease control rate, Clinical benefit rate",47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15664.0,ROS1,ROS1_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Terminated,NCT02186821,SIGNATURE,PCD,2017Dec13,Yes,Yes,Slow accrual,4.0,NCT02186821,,,"Disease control rate, Clinical benefit rate",47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15665.0,ROS1,ROS1_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Terminated,NCT02186821,SIGNATURE,PCD,2017Dec13,Yes,Yes,Slow accrual,4.0,NCT02186821,,,"Disease control rate, Clinical benefit rate",47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15666.0,ROS1,ROS1_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Terminated,NCT02186821,SIGNATURE,PCD,2017Dec13,Yes,Yes,Slow accrual,4.0,NCT02186821,,,"Disease control rate, Clinical benefit rate",47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15667.0,ROS1,ROS1_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Terminated,NCT02186821,SIGNATURE,PCD,2017Dec13,Yes,Yes,Slow accrual,4.0,NCT02186821,,,"Disease control rate, Clinical benefit rate",47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15668.0,ROS1,ROS1_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Terminated,NCT02186821,SIGNATURE,PCD,2017Dec13,Yes,Yes,Slow accrual,4.0,NCT02186821,,,"Disease control rate, Clinical benefit rate",47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15669.0,ROS1,ROS1_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Terminated,NCT02186821,SIGNATURE,PCD,2017Dec13,Yes,Yes,Slow accrual,4.0,NCT02186821,,,"Disease control rate, Clinical benefit rate",47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15670.0,ROS1,ROS1_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Terminated,NCT02186821,SIGNATURE,PCD,2017Dec13,Yes,Yes,Slow accrual,4.0,NCT02186821,,,"Disease control rate, Clinical benefit rate",47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15671.0,ROS1,ROS1_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Terminated,NCT02186821,SIGNATURE,PCD,2017Dec13,Yes,Yes,Slow accrual,4.0,NCT02186821,,,"Disease control rate, Clinical benefit rate",47.0,47.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15672.0,ROS1,ROS1_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Unknown,NCT03399487,,ECD,2020May01,Yes,No,,4.0,NCT03399487,,,Overall Response Rate,46.0,46.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15673.0,ROS1,ROS1_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Unknown,NCT03399487,,ECD,2020May01,Yes,No,,4.0,NCT03399487,,,Overall Response Rate,46.0,46.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15674.0,ROS1,ROS1_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Unknown,NCT03399487,,ECD,2020May01,Yes,No,,4.0,NCT03399487,,,Overall Response Rate,46.0,46.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15675.0,ROS1,ROS1_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Unknown,NCT03399487,,ECD,2020May01,Yes,No,,4.0,NCT03399487,,,Overall Response Rate,46.0,46.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15676.0,ROS1,ROS1_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Unknown,NCT03399487,,ECD,2020May01,Yes,No,,4.0,NCT03399487,,,Overall Response Rate,46.0,46.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15677.0,ROS1,ROS1_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Unknown,NCT03399487,,ECD,2020May01,Yes,No,,4.0,NCT03399487,,,Overall Response Rate,46.0,46.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15678.0,ROS1,ROS1_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Unknown,NCT03399487,,ECD,2020May01,Yes,No,,4.0,NCT03399487,,,Overall Response Rate,46.0,46.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15679.0,ROS1,ROS1_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Unknown,NCT03399487,,ECD,2020May01,Yes,No,,4.0,NCT03399487,,,Overall Response Rate,46.0,46.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15680.0,ROS1,ROS1_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Unknown,NCT03399487,,ECD,2020May01,Yes,No,,4.0,NCT03399487,,,Overall Response Rate,46.0,46.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15681.0,ROS1,ROS1_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Unknown,NCT01964157,,ECD,2019Dec01,Yes,Yes,,1.0,28520527,,,Overall Response Rate,32.0,32.0,,,62.0,,45-77,,21.0,,17-25,,9.3,,,,,,,,,,81.0,,,24.0,,,5-43,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15682.0,ROS1,ROS1_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Unknown,NCT01964157,,ECD,2019Dec01,Yes,Yes,,1.0,28520527,,,Overall Response Rate,32.0,32.0,,,62.0,,45-77,,21.0,,17-25,,9.3,,,,,,,,,,81.0,,,24.0,,,5-43,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15683.0,ROS1,ROS1_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Unknown,NCT01964157,,ECD,2019Dec01,Yes,Yes,,1.0,28520527,,,Overall Response Rate,32.0,32.0,,,62.0,,45-77,,21.0,,17-25,,9.3,,,,,,,,,,81.0,,,24.0,,,5-43,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15684.0,ROS1,ROS1_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Unknown,NCT01964157,,ECD,2019Dec01,Yes,Yes,,1.0,28520527,,,Overall Response Rate,32.0,32.0,,,62.0,,45-77,,21.0,,17-25,,9.3,,,,,,,,,,81.0,,,24.0,,,5-43,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15685.0,ROS1,ROS1_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Unknown,NCT01964157,,ECD,2019Dec01,Yes,Yes,,1.0,28520527,,,Overall Response Rate,32.0,32.0,,,62.0,,45-77,,21.0,,17-25,,9.3,,,,,,,,,,81.0,,,24.0,,,5-43,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15686.0,ROS1,ROS1_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Unknown,NCT01964157,,ECD,2019Dec01,Yes,Yes,,1.0,28520527,,,Overall Response Rate,32.0,32.0,,,62.0,,45-77,,21.0,,17-25,,9.3,,,,,,,,,,81.0,,,24.0,,,5-43,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15687.0,ROS1,ROS1_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Unknown,NCT01964157,,ECD,2019Dec01,Yes,Yes,,1.0,28520527,,,Overall Response Rate,32.0,32.0,,,62.0,,45-77,,21.0,,17-25,,9.3,,,,,,,,,,81.0,,,24.0,,,5-43,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15688.0,ROS1,ROS1_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Unknown,NCT01964157,,ECD,2019Dec01,Yes,Yes,,1.0,28520527,,,Overall Response Rate,32.0,32.0,,,62.0,,45-77,,21.0,,17-25,,9.3,,,,,,,,,,81.0,,,24.0,,,5-43,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15689.0,ROS1,ROS1_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Ceritinib,,Unknown,NCT01964157,,ECD,2019Dec01,Yes,Yes,,1.0,28520527,,,Overall Response Rate,32.0,32.0,,,62.0,,45-77,,21.0,,17-25,,9.3,,,,,,,,,,81.0,,,24.0,,,5-43,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
288.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Erlotinib,,"Active, not recruiting",NCT01306045,Arm 2,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
289.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Erlotinib,,"Active, not recruiting",NCT01306045,Arm 2,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
290.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Erlotinib,,"Active, not recruiting",NCT01306045,Arm 2,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
291.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Erlotinib,,"Active, not recruiting",NCT01306045,Arm 2,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
292.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Erlotinib,,"Active, not recruiting",NCT01306045,Arm 2,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
293.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Erlotinib,,"Active, not recruiting",NCT01306045,Arm 2,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
294.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Erlotinib,,"Active, not recruiting",NCT01306045,Arm 2,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
295.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Erlotinib,,"Active, not recruiting",NCT01306045,Arm 2,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
296.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Erlotinib,,"Active, not recruiting",NCT01306045,Arm 2,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
297.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Erlotinib,,"Active, not recruiting",NCT01306045,Arm 2,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
298.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Erlotinib,,"Active, not recruiting",NCT01306045,Arm 2,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
299.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Erlotinib,,"Active, not recruiting",NCT01306045,Arm 2,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
5727.0,EGFR,EGFR_E709_T710delinsD,51779132,,p.E709_T710delinsD,lung / carcinoma / non small cell carcinoma,7.0,Case study,Erlotinib,,Unknown,,,,,Yes,Yes,No benefit of treatment,1.0,27785061,,,Unknown,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5728.0,EGFR,EGFR_E709_T710delinsD,51779132,,p.E709_T710delinsD,lung / carcinoma / non small cell carcinoma,7.0,Case study,Erlotinib,,Unknown,,,,,Yes,Yes,No benefit of treatment,1.0,27785061,,,Unknown,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5729.0,EGFR,EGFR_E709_T710delinsD,51779132,,p.E709_T710delinsD,lung / carcinoma / non small cell carcinoma,7.0,Case study,Erlotinib,,Unknown,,,,,Yes,Yes,No benefit of treatment,1.0,27785061,,,Unknown,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5730.0,EGFR,EGFR_E709_T710delinsD,51779132,,p.E709_T710delinsD,lung / carcinoma / non small cell carcinoma,7.0,Case study,Erlotinib,,Unknown,,,,,Yes,Yes,No benefit of treatment,1.0,27785061,,,Unknown,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5731.0,EGFR,EGFR_E709_T710delinsD,51779132,,p.E709_T710delinsD,lung / carcinoma / non small cell carcinoma,7.0,Case study,Erlotinib,,Unknown,,,,,Yes,Yes,No benefit of treatment,1.0,27785061,,,Unknown,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5732.0,EGFR,EGFR_E709_T710delinsD,51779132,,p.E709_T710delinsD,lung / carcinoma / non small cell carcinoma,7.0,Case study,Erlotinib,,Unknown,,,,,Yes,Yes,No benefit of treatment,1.0,27785061,,,Unknown,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5733.0,EGFR,EGFR_E709_T710delinsD,51779132,,p.E709_T710delinsD,lung / carcinoma / non small cell carcinoma,7.0,Case study,Erlotinib,,Unknown,,,,,Yes,Yes,No benefit of treatment,1.0,27785061,,,Unknown,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5734.0,EGFR,EGFR_E709_T710delinsD,51779132,,p.E709_T710delinsD,lung / carcinoma / non small cell carcinoma,7.0,Case study,Erlotinib,,Unknown,,,,,Yes,Yes,No benefit of treatment,1.0,27785061,,,Unknown,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5735.0,EGFR,EGFR_E709_T710delinsD,51779132,,p.E709_T710delinsD,lung / carcinoma / non small cell carcinoma,7.0,Case study,Erlotinib,,Unknown,,,,,Yes,Yes,No benefit of treatment,1.0,27785061,,,Unknown,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5970.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_Exon19ins,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Erlotinib,,"Active, not recruiting",NCT03382795,,ECD,2023Mar31,Yes,No,,4.0,NCT03382795,,,Overall Response Rate,63.0,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jun20,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5971.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_Exon19ins,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Erlotinib,,"Active, not recruiting",NCT03382795,,ECD,2023Mar31,Yes,No,,4.0,NCT03382795,,,Overall Response Rate,63.0,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jun20,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5972.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_Exon19ins,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Erlotinib,,"Active, not recruiting",NCT03382795,,ECD,2023Mar31,Yes,No,,4.0,NCT03382795,,,Overall Response Rate,63.0,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jun20,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5973.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_Exon19ins,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Erlotinib,,"Active, not recruiting",NCT03382795,,ECD,2023Mar31,Yes,No,,4.0,NCT03382795,,,Overall Response Rate,63.0,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jun20,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5974.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_Exon19ins,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Erlotinib,,"Active, not recruiting",NCT03382795,,ECD,2023Mar31,Yes,No,,4.0,NCT03382795,,,Overall Response Rate,63.0,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jun20,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5975.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_Exon19ins,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Erlotinib,,"Active, not recruiting",NCT03382795,,ECD,2023Mar31,Yes,No,,4.0,NCT03382795,,,Overall Response Rate,63.0,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jun20,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5976.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_Exon19ins,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Erlotinib,,"Active, not recruiting",NCT03382795,,ECD,2023Mar31,Yes,No,,4.0,NCT03382795,,,Overall Response Rate,63.0,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jun20,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5977.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_Exon19ins,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Erlotinib,,"Active, not recruiting",NCT03382795,,ECD,2023Mar31,Yes,No,,4.0,NCT03382795,,,Overall Response Rate,63.0,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jun20,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5978.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_Exon19ins,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Erlotinib,,"Active, not recruiting",NCT03382795,,ECD,2023Mar31,Yes,No,,4.0,NCT03382795,,,Overall Response Rate,63.0,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jun20,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6096.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Erlotinib,Required,Completed,NCT00036647,BR.21 (Study 4),PCD,2004Jan30,No,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf,Previously-treated,,Not defined,731.0,488.0,243.0,Placebo,8.9,0.9,,,,,,,2.3,1.8,0.59,0.5-0.7,p<0.001,,,,,,,,,6.7,4.7,0.73,0.61-0.86,<0.001,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6097.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Erlotinib,Required,Completed,NCT00036647,BR.21 (Study 4),PCD,2004Jan30,No,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf,Previously-treated,,Not defined,731.0,488.0,243.0,Placebo,8.9,0.9,,,,,,,2.3,1.8,0.59,0.5-0.7,p<0.001,,,,,,,,,6.7,4.7,0.73,0.61-0.86,<0.001,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6098.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Erlotinib,Required,Completed,NCT00036647,BR.21 (Study 4),PCD,2004Jan30,No,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf,Previously-treated,,Not defined,731.0,488.0,243.0,Placebo,8.9,0.9,,,,,,,2.3,1.8,0.59,0.5-0.7,p<0.001,,,,,,,,,6.7,4.7,0.73,0.61-0.86,<0.001,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6099.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Erlotinib,Required,Completed,NCT00036647,BR.21 (Study 4),PCD,2004Jan30,No,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf,Previously-treated,,Not defined,731.0,488.0,243.0,Placebo,8.9,0.9,,,,,,,2.3,1.8,0.59,0.5-0.7,p<0.001,,,,,,,,,6.7,4.7,0.73,0.61-0.86,<0.001,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6100.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Erlotinib,Required,Completed,NCT00036647,BR.21 (Study 4),PCD,2004Jan30,No,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf,Previously-treated,,Not defined,731.0,488.0,243.0,Placebo,8.9,0.9,,,,,,,2.3,1.8,0.59,0.5-0.7,p<0.001,,,,,,,,,6.7,4.7,0.73,0.61-0.86,<0.001,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6101.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Erlotinib,Required,Completed,NCT00036647,BR.21 (Study 4),PCD,2004Jan30,No,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf,Previously-treated,,Not defined,731.0,488.0,243.0,Placebo,8.9,0.9,,,,,,,2.3,1.8,0.59,0.5-0.7,p<0.001,,,,,,,,,6.7,4.7,0.73,0.61-0.86,<0.001,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6102.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Erlotinib,Required,Completed,NCT00036647,BR.21 (Study 4),PCD,2004Jan30,No,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf,Previously-treated,,Not defined,731.0,488.0,243.0,Placebo,8.9,0.9,,,,,,,2.3,1.8,0.59,0.5-0.7,p<0.001,,,,,,,,,6.7,4.7,0.73,0.61-0.86,<0.001,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6103.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Erlotinib,Required,Completed,NCT00036647,BR.21 (Study 4),PCD,2004Jan30,No,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf,Previously-treated,,Not defined,731.0,488.0,243.0,Placebo,8.9,0.9,,,,,,,2.3,1.8,0.59,0.5-0.7,p<0.001,,,,,,,,,6.7,4.7,0.73,0.61-0.86,<0.001,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6104.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Erlotinib,Required,Completed,NCT00036647,BR.21 (Study 4),PCD,2004Jan30,No,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf,Previously-treated,,Not defined,731.0,488.0,243.0,Placebo,8.9,0.9,,,,,,,2.3,1.8,0.59,0.5-0.7,p<0.001,,,,,,,,,6.7,4.7,0.73,0.61-0.86,<0.001,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6105.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Erlotinib,Required,Completed,NCT00556712,SATURN (Study 3),PCD,2010Nov01,No,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf,Previously-treated,,Progression free survival,889.0,438.0,451.0,Placebo,,,,,,,,,2.8,2.6,0.71,0.62-0.82,p<0.0001,,,,,,,,,12.0,11.0,0.81,0.7-0.95,0.0088,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6106.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Erlotinib,Required,Completed,NCT00556712,SATURN (Study 3),PCD,2010Nov01,No,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf,Previously-treated,,Progression free survival,889.0,438.0,451.0,Placebo,,,,,,,,,2.8,2.6,0.71,0.62-0.82,p<0.0001,,,,,,,,,12.0,11.0,0.81,0.7-0.95,0.0088,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6107.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Erlotinib,Required,Completed,NCT00556712,SATURN (Study 3),PCD,2010Nov01,No,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf,Previously-treated,,Progression free survival,889.0,438.0,451.0,Placebo,,,,,,,,,2.8,2.6,0.71,0.62-0.82,p<0.0001,,,,,,,,,12.0,11.0,0.81,0.7-0.95,0.0088,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6108.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Erlotinib,Required,Completed,NCT00556712,SATURN (Study 3),PCD,2010Nov01,No,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf,Previously-treated,,Progression free survival,889.0,438.0,451.0,Placebo,,,,,,,,,2.8,2.6,0.71,0.62-0.82,p<0.0001,,,,,,,,,12.0,11.0,0.81,0.7-0.95,0.0088,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6109.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Erlotinib,Required,Completed,NCT00556712,SATURN (Study 3),PCD,2010Nov01,No,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf,Previously-treated,,Progression free survival,889.0,438.0,451.0,Placebo,,,,,,,,,2.8,2.6,0.71,0.62-0.82,p<0.0001,,,,,,,,,12.0,11.0,0.81,0.7-0.95,0.0088,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6110.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Erlotinib,Required,Completed,NCT00556712,SATURN (Study 3),PCD,2010Nov01,No,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf,Previously-treated,,Progression free survival,889.0,438.0,451.0,Placebo,,,,,,,,,2.8,2.6,0.71,0.62-0.82,p<0.0001,,,,,,,,,12.0,11.0,0.81,0.7-0.95,0.0088,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6111.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Erlotinib,Required,Completed,NCT00556712,SATURN (Study 3),PCD,2010Nov01,No,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf,Previously-treated,,Progression free survival,889.0,438.0,451.0,Placebo,,,,,,,,,2.8,2.6,0.71,0.62-0.82,p<0.0001,,,,,,,,,12.0,11.0,0.81,0.7-0.95,0.0088,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6112.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Erlotinib,Required,Completed,NCT00556712,SATURN (Study 3),PCD,2010Nov01,No,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf,Previously-treated,,Progression free survival,889.0,438.0,451.0,Placebo,,,,,,,,,2.8,2.6,0.71,0.62-0.82,p<0.0001,,,,,,,,,12.0,11.0,0.81,0.7-0.95,0.0088,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6113.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Erlotinib,Required,Completed,NCT00556712,SATURN (Study 3),PCD,2010Nov01,No,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf,Previously-treated,,Progression free survival,889.0,438.0,451.0,Placebo,,,,,,,,,2.8,2.6,0.71,0.62-0.82,p<0.0001,,,,,,,,,12.0,11.0,0.81,0.7-0.95,0.0088,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6114.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Erlotinib,Required,Completed,NCT00446225,EURTAC (Study 1),PCD,2009Dec01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf,Untreated,,Progression free survival,175.0,86.0,88.0,Chemotherapy,65.0,16,,,,,,,10.4,5.2,0.34,0.23-0.49,p<0.001,,,,,,,,,22.9,19.5,0.93,0.64-1.35,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6115.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Erlotinib,Required,Completed,NCT00446225,EURTAC (Study 1),PCD,2009Dec01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf,Untreated,,Progression free survival,175.0,86.0,88.0,Chemotherapy,65.0,16,,,,,,,10.4,5.2,0.34,0.23-0.49,p<0.001,,,,,,,,,22.9,19.5,0.93,0.64-1.35,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6116.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Erlotinib,Required,Completed,NCT00446225,EURTAC (Study 1),PCD,2009Dec01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf,Untreated,,Progression free survival,175.0,86.0,88.0,Chemotherapy,65.0,16,,,,,,,10.4,5.2,0.34,0.23-0.49,p<0.001,,,,,,,,,22.9,19.5,0.93,0.64-1.35,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6117.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Erlotinib,Required,Completed,NCT00446225,EURTAC (Study 1),PCD,2009Dec01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf,Untreated,,Progression free survival,175.0,86.0,88.0,Chemotherapy,65.0,16,,,,,,,10.4,5.2,0.34,0.23-0.49,p<0.001,,,,,,,,,22.9,19.5,0.93,0.64-1.35,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6118.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Erlotinib,Required,Completed,NCT00446225,EURTAC (Study 1),PCD,2009Dec01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf,Untreated,,Progression free survival,175.0,86.0,88.0,Chemotherapy,65.0,16,,,,,,,10.4,5.2,0.34,0.23-0.49,p<0.001,,,,,,,,,22.9,19.5,0.93,0.64-1.35,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6119.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Erlotinib,Required,Completed,NCT00446225,EURTAC (Study 1),PCD,2009Dec01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf,Untreated,,Progression free survival,175.0,86.0,88.0,Chemotherapy,65.0,16,,,,,,,10.4,5.2,0.34,0.23-0.49,p<0.001,,,,,,,,,22.9,19.5,0.93,0.64-1.35,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6120.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Erlotinib,Required,Completed,NCT00446225,EURTAC (Study 1),PCD,2009Dec01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf,Untreated,,Progression free survival,175.0,86.0,88.0,Chemotherapy,65.0,16,,,,,,,10.4,5.2,0.34,0.23-0.49,p<0.001,,,,,,,,,22.9,19.5,0.93,0.64-1.35,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6121.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Erlotinib,Required,Completed,NCT00446225,EURTAC (Study 1),PCD,2009Dec01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf,Untreated,,Progression free survival,175.0,86.0,88.0,Chemotherapy,65.0,16,,,,,,,10.4,5.2,0.34,0.23-0.49,p<0.001,,,,,,,,,22.9,19.5,0.93,0.64-1.35,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6122.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Erlotinib,Required,Completed,NCT00446225,EURTAC (Study 1),PCD,2009Dec01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf,Untreated,,Progression free survival,175.0,86.0,88.0,Chemotherapy,65.0,16,,,,,,,10.4,5.2,0.34,0.23-0.49,p<0.001,,,,,,,,,22.9,19.5,0.93,0.64-1.35,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6123.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Erlotinib,,Unknown,,,,,Yes,Yes,,1.0,15329413,,,Unknown,7.0,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6124.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Erlotinib,,Unknown,,,,,Yes,Yes,,1.0,15329413,,,Unknown,7.0,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6125.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Erlotinib,,Unknown,,,,,Yes,Yes,,1.0,15329413,,,Unknown,7.0,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6126.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Erlotinib,,Unknown,,,,,Yes,Yes,,1.0,15329413,,,Unknown,7.0,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6127.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Erlotinib,,Unknown,,,,,Yes,Yes,,1.0,15329413,,,Unknown,7.0,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6128.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Erlotinib,,Unknown,,,,,Yes,Yes,,1.0,15329413,,,Unknown,7.0,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6129.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Erlotinib,,Unknown,,,,,Yes,Yes,,1.0,15329413,,,Unknown,7.0,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6130.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Erlotinib,,Unknown,,,,,Yes,Yes,,1.0,15329413,,,Unknown,7.0,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6131.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Erlotinib,,Unknown,,,,,Yes,Yes,,1.0,15329413,,,Unknown,7.0,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7212.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Erlotinib,,Completed,NCT00556712,SATURN,PCD,2010Nov01,Expression confirmed,Yes,,1.0,20493771,Previously-treated,,Progression free survival,618.0,307.0,311.0,Placebo,,,,,,,,,2.8,2.6,0.69,0.58-0.82,p<0.0001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7213.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Erlotinib,,Completed,NCT00556712,SATURN,PCD,2010Nov01,Expression confirmed,Yes,,1.0,20493771,Previously-treated,,Progression free survival,618.0,307.0,311.0,Placebo,,,,,,,,,2.8,2.6,0.69,0.58-0.82,p<0.0001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7214.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Erlotinib,,Completed,NCT00556712,SATURN,PCD,2010Nov01,Expression confirmed,Yes,,1.0,20493771,Previously-treated,,Progression free survival,618.0,307.0,311.0,Placebo,,,,,,,,,2.8,2.6,0.69,0.58-0.82,p<0.0001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7215.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Erlotinib,,Completed,NCT00556712,SATURN,PCD,2010Nov01,Expression confirmed,Yes,,1.0,20493771,Previously-treated,,Progression free survival,618.0,307.0,311.0,Placebo,,,,,,,,,2.8,2.6,0.69,0.58-0.82,p<0.0001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7216.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Erlotinib,,Completed,NCT00556712,SATURN,PCD,2010Nov01,Expression confirmed,Yes,,1.0,20493771,Previously-treated,,Progression free survival,618.0,307.0,311.0,Placebo,,,,,,,,,2.8,2.6,0.69,0.58-0.82,p<0.0001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7217.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Erlotinib,,Completed,NCT00556712,SATURN,PCD,2010Nov01,Expression confirmed,Yes,,1.0,20493771,Previously-treated,,Progression free survival,618.0,307.0,311.0,Placebo,,,,,,,,,2.8,2.6,0.69,0.58-0.82,p<0.0001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7218.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Erlotinib,,Completed,NCT00556712,SATURN,PCD,2010Nov01,Expression confirmed,Yes,,1.0,20493771,Previously-treated,,Progression free survival,618.0,307.0,311.0,Placebo,,,,,,,,,2.8,2.6,0.69,0.58-0.82,p<0.0001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7219.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Erlotinib,,Completed,NCT00556712,SATURN,PCD,2010Nov01,Expression confirmed,Yes,,1.0,20493771,Previously-treated,,Progression free survival,618.0,307.0,311.0,Placebo,,,,,,,,,2.8,2.6,0.69,0.58-0.82,p<0.0001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7220.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Erlotinib,,Completed,NCT00556712,SATURN,PCD,2010Nov01,Expression confirmed,Yes,,1.0,20493771,Previously-treated,,Progression free survival,618.0,307.0,311.0,Placebo,,,,,,,,,2.8,2.6,0.69,0.58-0.82,p<0.0001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7581.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Erlotinib,,Completed,NCT01024413,,PCD,2015Jun01,Yes,Yes,Primary outcome not met,1.0,28103612,,,Progression free survival,256.0,128.0,128.0,Gefitinib,,,,,,,,,13.0,10.4,,0.62-1.05,0.11,,,,,,,,,22.9,20.1,,0.63-1.13,0.25,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7582.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Erlotinib,,Completed,NCT01024413,,PCD,2015Jun01,Yes,Yes,Primary outcome not met,1.0,28103612,,,Progression free survival,256.0,128.0,128.0,Gefitinib,,,,,,,,,13.0,10.4,,0.62-1.05,0.11,,,,,,,,,22.9,20.1,,0.63-1.13,0.25,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7583.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Erlotinib,,Completed,NCT01024413,,PCD,2015Jun01,Yes,Yes,Primary outcome not met,1.0,28103612,,,Progression free survival,256.0,128.0,128.0,Gefitinib,,,,,,,,,13.0,10.4,,0.62-1.05,0.11,,,,,,,,,22.9,20.1,,0.63-1.13,0.25,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7584.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Erlotinib,,Completed,NCT01024413,,PCD,2015Jun01,Yes,Yes,Primary outcome not met,1.0,28103612,,,Progression free survival,256.0,128.0,128.0,Gefitinib,,,,,,,,,13.0,10.4,,0.62-1.05,0.11,,,,,,,,,22.9,20.1,,0.63-1.13,0.25,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7585.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Erlotinib,,Completed,NCT01024413,,PCD,2015Jun01,Yes,Yes,Primary outcome not met,1.0,28103612,,,Progression free survival,256.0,128.0,128.0,Gefitinib,,,,,,,,,13.0,10.4,,0.62-1.05,0.11,,,,,,,,,22.9,20.1,,0.63-1.13,0.25,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7586.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Erlotinib,,Completed,NCT01024413,,PCD,2015Jun01,Yes,Yes,Primary outcome not met,1.0,28103612,,,Progression free survival,256.0,128.0,128.0,Gefitinib,,,,,,,,,13.0,10.4,,0.62-1.05,0.11,,,,,,,,,22.9,20.1,,0.63-1.13,0.25,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7587.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Erlotinib,,Completed,NCT01024413,,PCD,2015Jun01,Yes,Yes,Primary outcome not met,1.0,28103612,,,Progression free survival,256.0,128.0,128.0,Gefitinib,,,,,,,,,13.0,10.4,,0.62-1.05,0.11,,,,,,,,,22.9,20.1,,0.63-1.13,0.25,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7588.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Erlotinib,,Completed,NCT01024413,,PCD,2015Jun01,Yes,Yes,Primary outcome not met,1.0,28103612,,,Progression free survival,256.0,128.0,128.0,Gefitinib,,,,,,,,,13.0,10.4,,0.62-1.05,0.11,,,,,,,,,22.9,20.1,,0.63-1.13,0.25,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7589.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Erlotinib,,Completed,NCT01024413,,PCD,2015Jun01,Yes,Yes,Primary outcome not met,1.0,28103612,,,Progression free survival,256.0,128.0,128.0,Gefitinib,,,,,,,,,13.0,10.4,,0.62-1.05,0.11,,,,,,,,,22.9,20.1,,0.63-1.13,0.25,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7725.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Erlotinib,,Unknown,,,,,Yes,Yes,,1.0,24353160,,,Unknown,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,1.0,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7726.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Erlotinib,,Unknown,,,,,Yes,Yes,,1.0,24353160,,,Unknown,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,1.0,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7727.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Erlotinib,,Unknown,,,,,Yes,Yes,,1.0,24353160,,,Unknown,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,1.0,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7728.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Erlotinib,,Unknown,,,,,Yes,Yes,,1.0,24353160,,,Unknown,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,1.0,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7729.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Erlotinib,,Unknown,,,,,Yes,Yes,,1.0,24353160,,,Unknown,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,1.0,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7730.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Erlotinib,,Unknown,,,,,Yes,Yes,,1.0,24353160,,,Unknown,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,1.0,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7731.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Erlotinib,,Unknown,,,,,Yes,Yes,,1.0,24353160,,,Unknown,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,1.0,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7732.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Erlotinib,,Unknown,,,,,Yes,Yes,,1.0,24353160,,,Unknown,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,1.0,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7733.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Erlotinib,,Unknown,,,,,Yes,Yes,,1.0,24353160,,,Unknown,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,1.0,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11172.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Erlotinib,,"Active, not recruiting",NCT01306045,Arm 1,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11173.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Erlotinib,,"Active, not recruiting",NCT01306045,Arm 1,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11174.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Erlotinib,,"Active, not recruiting",NCT01306045,Arm 1,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11175.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Erlotinib,,"Active, not recruiting",NCT01306045,Arm 1,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11176.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Erlotinib,,"Active, not recruiting",NCT01306045,Arm 1,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11177.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Erlotinib,,"Active, not recruiting",NCT01306045,Arm 1,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11178.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Erlotinib,,"Active, not recruiting",NCT01306045,Arm 1,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11179.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Erlotinib,,"Active, not recruiting",NCT01306045,Arm 1,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11180.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Erlotinib,,"Active, not recruiting",NCT01306045,Arm 1,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11181.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Erlotinib,,Completed,NCT00087412,,PCD,2007Jul01,No,No,,4.0,NCT00087412,,,Overall survival,65.0,65.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11182.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Erlotinib,,Completed,NCT00087412,,PCD,2007Jul01,No,No,,4.0,NCT00087412,,,Overall survival,65.0,65.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11183.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Erlotinib,,Completed,NCT00087412,,PCD,2007Jul01,No,No,,4.0,NCT00087412,,,Overall survival,65.0,65.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11184.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Erlotinib,,Completed,NCT00087412,,PCD,2007Jul01,No,No,,4.0,NCT00087412,,,Overall survival,65.0,65.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11185.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Erlotinib,,Completed,NCT00087412,,PCD,2007Jul01,No,No,,4.0,NCT00087412,,,Overall survival,65.0,65.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11186.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Erlotinib,,Completed,NCT00087412,,PCD,2007Jul01,No,No,,4.0,NCT00087412,,,Overall survival,65.0,65.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11187.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Erlotinib,,Completed,NCT00087412,,PCD,2007Jul01,No,No,,4.0,NCT00087412,,,Overall survival,65.0,65.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11188.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Erlotinib,,Completed,NCT00087412,,PCD,2007Jul01,No,No,,4.0,NCT00087412,,,Overall survival,65.0,65.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11189.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Erlotinib,,Completed,NCT00087412,,PCD,2007Jul01,No,No,,4.0,NCT00087412,,,Overall survival,65.0,65.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11217.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Erlotinib,,"Active, not recruiting",NCT02193282,,ECD,2026Oct10,No,No,,4.0,NCT02193282,,,Overall survival,450.0,,,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11218.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Erlotinib,,"Active, not recruiting",NCT02193282,,ECD,2026Oct10,No,No,,4.0,NCT02193282,,,Overall survival,450.0,,,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11219.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Erlotinib,,"Active, not recruiting",NCT02193282,,ECD,2026Oct10,No,No,,4.0,NCT02193282,,,Overall survival,450.0,,,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11220.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Erlotinib,,"Active, not recruiting",NCT02193282,,ECD,2026Oct10,No,No,,4.0,NCT02193282,,,Overall survival,450.0,,,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11221.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Erlotinib,,"Active, not recruiting",NCT02193282,,ECD,2026Oct10,No,No,,4.0,NCT02193282,,,Overall survival,450.0,,,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11222.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Erlotinib,,"Active, not recruiting",NCT02193282,,ECD,2026Oct10,No,No,,4.0,NCT02193282,,,Overall survival,450.0,,,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11223.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Erlotinib,,"Active, not recruiting",NCT02193282,,ECD,2026Oct10,No,No,,4.0,NCT02193282,,,Overall survival,450.0,,,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11224.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Erlotinib,,"Active, not recruiting",NCT02193282,,ECD,2026Oct10,No,No,,4.0,NCT02193282,,,Overall survival,450.0,,,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11225.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Erlotinib,,"Active, not recruiting",NCT02193282,,ECD,2026Oct10,No,No,,4.0,NCT02193282,,,Overall survival,450.0,,,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5718.0,EGFR,EGFR_E709_T710delinsD,51779132,,p.E709_T710delinsD,lung / carcinoma / non small cell carcinoma,7.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,No benefit of treatment,1.0,27785061,,,Unknown,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5719.0,EGFR,EGFR_E709_T710delinsD,51779132,,p.E709_T710delinsD,lung / carcinoma / non small cell carcinoma,7.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,No benefit of treatment,1.0,27785061,,,Unknown,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5720.0,EGFR,EGFR_E709_T710delinsD,51779132,,p.E709_T710delinsD,lung / carcinoma / non small cell carcinoma,7.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,No benefit of treatment,1.0,27785061,,,Unknown,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5721.0,EGFR,EGFR_E709_T710delinsD,51779132,,p.E709_T710delinsD,lung / carcinoma / non small cell carcinoma,7.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,No benefit of treatment,1.0,27785061,,,Unknown,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5722.0,EGFR,EGFR_E709_T710delinsD,51779132,,p.E709_T710delinsD,lung / carcinoma / non small cell carcinoma,7.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,No benefit of treatment,1.0,27785061,,,Unknown,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5723.0,EGFR,EGFR_E709_T710delinsD,51779132,,p.E709_T710delinsD,lung / carcinoma / non small cell carcinoma,7.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,No benefit of treatment,1.0,27785061,,,Unknown,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5724.0,EGFR,EGFR_E709_T710delinsD,51779132,,p.E709_T710delinsD,lung / carcinoma / non small cell carcinoma,7.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,No benefit of treatment,1.0,27785061,,,Unknown,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5725.0,EGFR,EGFR_E709_T710delinsD,51779132,,p.E709_T710delinsD,lung / carcinoma / non small cell carcinoma,7.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,No benefit of treatment,1.0,27785061,,,Unknown,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5726.0,EGFR,EGFR_E709_T710delinsD,51779132,,p.E709_T710delinsD,lung / carcinoma / non small cell carcinoma,7.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,No benefit of treatment,1.0,27785061,,,Unknown,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5808.0,EGFR,EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I ,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Gefitinib,,Terminated,NCT02025218,NVALT 16,PCD,2017Jan01,Yes,No,,4.0,NCT02025218,Previously-treated,,"Disease control rate, Clinical benefit rate",21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Aug03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5809.0,EGFR,EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I ,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Gefitinib,,Terminated,NCT02025218,NVALT 16,PCD,2017Jan01,Yes,No,,4.0,NCT02025218,Previously-treated,,"Disease control rate, Clinical benefit rate",21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Aug03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5810.0,EGFR,EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I ,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Gefitinib,,Terminated,NCT02025218,NVALT 16,PCD,2017Jan01,Yes,No,,4.0,NCT02025218,Previously-treated,,"Disease control rate, Clinical benefit rate",21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Aug03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5811.0,EGFR,EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I ,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Gefitinib,,Terminated,NCT02025218,NVALT 16,PCD,2017Jan01,Yes,No,,4.0,NCT02025218,Previously-treated,,"Disease control rate, Clinical benefit rate",21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Aug03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5812.0,EGFR,EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I ,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Gefitinib,,Terminated,NCT02025218,NVALT 16,PCD,2017Jan01,Yes,No,,4.0,NCT02025218,Previously-treated,,"Disease control rate, Clinical benefit rate",21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Aug03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5813.0,EGFR,EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I ,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Gefitinib,,Terminated,NCT02025218,NVALT 16,PCD,2017Jan01,Yes,No,,4.0,NCT02025218,Previously-treated,,"Disease control rate, Clinical benefit rate",21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Aug03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5814.0,EGFR,EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I ,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Gefitinib,,Terminated,NCT02025218,NVALT 16,PCD,2017Jan01,Yes,No,,4.0,NCT02025218,Previously-treated,,"Disease control rate, Clinical benefit rate",21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Aug03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5815.0,EGFR,EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I ,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Gefitinib,,Terminated,NCT02025218,NVALT 16,PCD,2017Jan01,Yes,No,,4.0,NCT02025218,Previously-treated,,"Disease control rate, Clinical benefit rate",21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Aug03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5816.0,EGFR,EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I ,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Gefitinib,,Terminated,NCT02025218,NVALT 16,PCD,2017Jan01,Yes,No,,4.0,NCT02025218,Previously-treated,,"Disease control rate, Clinical benefit rate",21.0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Aug03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5988.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_Exon19ins,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Gefitinib,,"Active, not recruiting",NCT03382795,,ECD,2023Mar31,Yes,No,,4.0,NCT03382795,,,Overall Response Rate,63.0,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jun20,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5989.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_Exon19ins,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Gefitinib,,"Active, not recruiting",NCT03382795,,ECD,2023Mar31,Yes,No,,4.0,NCT03382795,,,Overall Response Rate,63.0,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jun20,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5990.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_Exon19ins,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Gefitinib,,"Active, not recruiting",NCT03382795,,ECD,2023Mar31,Yes,No,,4.0,NCT03382795,,,Overall Response Rate,63.0,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jun20,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5991.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_Exon19ins,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Gefitinib,,"Active, not recruiting",NCT03382795,,ECD,2023Mar31,Yes,No,,4.0,NCT03382795,,,Overall Response Rate,63.0,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jun20,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5992.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_Exon19ins,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Gefitinib,,"Active, not recruiting",NCT03382795,,ECD,2023Mar31,Yes,No,,4.0,NCT03382795,,,Overall Response Rate,63.0,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jun20,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5993.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_Exon19ins,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Gefitinib,,"Active, not recruiting",NCT03382795,,ECD,2023Mar31,Yes,No,,4.0,NCT03382795,,,Overall Response Rate,63.0,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jun20,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5994.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_Exon19ins,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Gefitinib,,"Active, not recruiting",NCT03382795,,ECD,2023Mar31,Yes,No,,4.0,NCT03382795,,,Overall Response Rate,63.0,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jun20,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5995.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_Exon19ins,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Gefitinib,,"Active, not recruiting",NCT03382795,,ECD,2023Mar31,Yes,No,,4.0,NCT03382795,,,Overall Response Rate,63.0,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jun20,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5996.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_Exon19ins,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Gefitinib,,"Active, not recruiting",NCT03382795,,ECD,2023Mar31,Yes,No,,4.0,NCT03382795,,,Overall Response Rate,63.0,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jun20,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6078.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Gefitinib,Required,Completed,NCT00322452,IPASS (Study 2),PCD,2008Apr01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf,Untreated,,Progression free survival,186.0,88.0,89.0,Chemotherapy,67.0,41,31-51,,9.6,5.5,,,10.9,7.4,0.54,0.38-0.79,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6079.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Gefitinib,Required,Completed,NCT00322452,IPASS (Study 2),PCD,2008Apr01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf,Untreated,,Progression free survival,186.0,88.0,89.0,Chemotherapy,67.0,41,31-51,,9.6,5.5,,,10.9,7.4,0.54,0.38-0.79,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6080.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Gefitinib,Required,Completed,NCT00322452,IPASS (Study 2),PCD,2008Apr01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf,Untreated,,Progression free survival,186.0,88.0,89.0,Chemotherapy,67.0,41,31-51,,9.6,5.5,,,10.9,7.4,0.54,0.38-0.79,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6081.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Gefitinib,Required,Completed,NCT00322452,IPASS (Study 2),PCD,2008Apr01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf,Untreated,,Progression free survival,186.0,88.0,89.0,Chemotherapy,67.0,41,31-51,,9.6,5.5,,,10.9,7.4,0.54,0.38-0.79,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6082.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Gefitinib,Required,Completed,NCT00322452,IPASS (Study 2),PCD,2008Apr01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf,Untreated,,Progression free survival,186.0,88.0,89.0,Chemotherapy,67.0,41,31-51,,9.6,5.5,,,10.9,7.4,0.54,0.38-0.79,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6083.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Gefitinib,Required,Completed,NCT00322452,IPASS (Study 2),PCD,2008Apr01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf,Untreated,,Progression free survival,186.0,88.0,89.0,Chemotherapy,67.0,41,31-51,,9.6,5.5,,,10.9,7.4,0.54,0.38-0.79,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6084.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Gefitinib,Required,Completed,NCT00322452,IPASS (Study 2),PCD,2008Apr01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf,Untreated,,Progression free survival,186.0,88.0,89.0,Chemotherapy,67.0,41,31-51,,9.6,5.5,,,10.9,7.4,0.54,0.38-0.79,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6085.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Gefitinib,Required,Completed,NCT00322452,IPASS (Study 2),PCD,2008Apr01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf,Untreated,,Progression free survival,186.0,88.0,89.0,Chemotherapy,67.0,41,31-51,,9.6,5.5,,,10.9,7.4,0.54,0.38-0.79,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6086.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Gefitinib,Required,Completed,NCT00322452,IPASS (Study 2),PCD,2008Apr01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf,Untreated,,Progression free survival,186.0,88.0,89.0,Chemotherapy,67.0,41,31-51,,9.6,5.5,,,10.9,7.4,0.54,0.38-0.79,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6087.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Gefitinib,Required,Completed,NCT01203917,IFUM EURTAC (Study 1),PCD,2012Aug01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf,Untreated,,Overall Response Rate,106.0,106.0,,,50.0,41-59,,,6.0,,5.1-11.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6088.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Gefitinib,Required,Completed,NCT01203917,IFUM EURTAC (Study 1),PCD,2012Aug01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf,Untreated,,Overall Response Rate,106.0,106.0,,,50.0,41-59,,,6.0,,5.1-11.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6089.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Gefitinib,Required,Completed,NCT01203917,IFUM EURTAC (Study 1),PCD,2012Aug01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf,Untreated,,Overall Response Rate,106.0,106.0,,,50.0,41-59,,,6.0,,5.1-11.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6090.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Gefitinib,Required,Completed,NCT01203917,IFUM EURTAC (Study 1),PCD,2012Aug01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf,Untreated,,Overall Response Rate,106.0,106.0,,,50.0,41-59,,,6.0,,5.1-11.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6091.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Gefitinib,Required,Completed,NCT01203917,IFUM EURTAC (Study 1),PCD,2012Aug01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf,Untreated,,Overall Response Rate,106.0,106.0,,,50.0,41-59,,,6.0,,5.1-11.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6092.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Gefitinib,Required,Completed,NCT01203917,IFUM EURTAC (Study 1),PCD,2012Aug01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf,Untreated,,Overall Response Rate,106.0,106.0,,,50.0,41-59,,,6.0,,5.1-11.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6093.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Gefitinib,Required,Completed,NCT01203917,IFUM EURTAC (Study 1),PCD,2012Aug01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf,Untreated,,Overall Response Rate,106.0,106.0,,,50.0,41-59,,,6.0,,5.1-11.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6094.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Gefitinib,Required,Completed,NCT01203917,IFUM EURTAC (Study 1),PCD,2012Aug01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf,Untreated,,Overall Response Rate,106.0,106.0,,,50.0,41-59,,,6.0,,5.1-11.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6095.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Gefitinib,Required,Completed,NCT01203917,IFUM EURTAC (Study 1),PCD,2012Aug01,Yes,Yes,,7.0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf,Untreated,,Overall Response Rate,106.0,106.0,,,50.0,41-59,,,6.0,,5.1-11.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2023Jan17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6132.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,15329413,,,Unknown,4.0,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6133.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,15329413,,,Unknown,4.0,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6134.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,15329413,,,Unknown,4.0,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6135.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,15329413,,,Unknown,4.0,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6136.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,15329413,,,Unknown,4.0,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6137.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,15329413,,,Unknown,4.0,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6138.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,15329413,,,Unknown,4.0,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6139.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,15329413,,,Unknown,4.0,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6140.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,15329413,,,Unknown,4.0,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6141.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,15118073,,,Unknown,4.0,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6142.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,15118073,,,Unknown,4.0,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6143.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,15118073,,,Unknown,4.0,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6144.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,15118073,,,Unknown,4.0,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6145.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,15118073,,,Unknown,4.0,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6146.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,15118073,,,Unknown,4.0,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6147.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,15118073,,,Unknown,4.0,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6148.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,15118073,,,Unknown,4.0,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6149.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,15118073,,,Unknown,4.0,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7176.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Gefitinib,,Unknown,NCT03399669,,ECD,2018Jun30,Yes,No,,4.0,NCT03399669,Previously-treated,,Time to progression,100.0,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7177.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Gefitinib,,Unknown,NCT03399669,,ECD,2018Jun30,Yes,No,,4.0,NCT03399669,Previously-treated,,Time to progression,100.0,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7178.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Gefitinib,,Unknown,NCT03399669,,ECD,2018Jun30,Yes,No,,4.0,NCT03399669,Previously-treated,,Time to progression,100.0,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7179.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Gefitinib,,Unknown,NCT03399669,,ECD,2018Jun30,Yes,No,,4.0,NCT03399669,Previously-treated,,Time to progression,100.0,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7180.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Gefitinib,,Unknown,NCT03399669,,ECD,2018Jun30,Yes,No,,4.0,NCT03399669,Previously-treated,,Time to progression,100.0,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7181.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Gefitinib,,Unknown,NCT03399669,,ECD,2018Jun30,Yes,No,,4.0,NCT03399669,Previously-treated,,Time to progression,100.0,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7182.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Gefitinib,,Unknown,NCT03399669,,ECD,2018Jun30,Yes,No,,4.0,NCT03399669,Previously-treated,,Time to progression,100.0,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7183.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Gefitinib,,Unknown,NCT03399669,,ECD,2018Jun30,Yes,No,,4.0,NCT03399669,Previously-treated,,Time to progression,100.0,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7184.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Gefitinib,,Unknown,NCT03399669,,ECD,2018Jun30,Yes,No,,4.0,NCT03399669,Previously-treated,,Time to progression,100.0,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7185.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Gefitinib,,Unknown,NCT02347839,NEGOTIATE,ECD,2020Jan01,Yes,No,,4.0,NCT02347839,,,Resection rate,37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7186.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Gefitinib,,Unknown,NCT02347839,NEGOTIATE,ECD,2020Jan01,Yes,No,,4.0,NCT02347839,,,Resection rate,37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7187.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Gefitinib,,Unknown,NCT02347839,NEGOTIATE,ECD,2020Jan01,Yes,No,,4.0,NCT02347839,,,Resection rate,37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7188.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Gefitinib,,Unknown,NCT02347839,NEGOTIATE,ECD,2020Jan01,Yes,No,,4.0,NCT02347839,,,Resection rate,37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7189.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Gefitinib,,Unknown,NCT02347839,NEGOTIATE,ECD,2020Jan01,Yes,No,,4.0,NCT02347839,,,Resection rate,37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7190.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Gefitinib,,Unknown,NCT02347839,NEGOTIATE,ECD,2020Jan01,Yes,No,,4.0,NCT02347839,,,Resection rate,37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7191.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Gefitinib,,Unknown,NCT02347839,NEGOTIATE,ECD,2020Jan01,Yes,No,,4.0,NCT02347839,,,Resection rate,37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7192.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Gefitinib,,Unknown,NCT02347839,NEGOTIATE,ECD,2020Jan01,Yes,No,,4.0,NCT02347839,,,Resection rate,37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7193.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Gefitinib,,Unknown,NCT02347839,NEGOTIATE,ECD,2020Jan01,Yes,No,,4.0,NCT02347839,,,Resection rate,37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7194.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Gefitinib,,Completed,NCT01933347,CTONG1304,PCD,2017Apr10,Yes,No,,2.0,10.1200/JCO.2017.35.15_suppl.9035,Previously-treated,,"Disease control rate, Clinical benefit rate",46.0,46.0,,,4.7,,,,,,,,4.4,,,,,,,,,,69.8,,,8.0,,,,,,,,,,,,,,,,,COSO29915674,2022Jun20,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7195.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Gefitinib,,Completed,NCT01933347,CTONG1304,PCD,2017Apr10,Yes,No,,2.0,10.1200/JCO.2017.35.15_suppl.9035,Previously-treated,,"Disease control rate, Clinical benefit rate",46.0,46.0,,,4.7,,,,,,,,4.4,,,,,,,,,,69.8,,,8.0,,,,,,,,,,,,,,,,,COSO29915674,2022Jun20,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7196.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Gefitinib,,Completed,NCT01933347,CTONG1304,PCD,2017Apr10,Yes,No,,2.0,10.1200/JCO.2017.35.15_suppl.9035,Previously-treated,,"Disease control rate, Clinical benefit rate",46.0,46.0,,,4.7,,,,,,,,4.4,,,,,,,,,,69.8,,,8.0,,,,,,,,,,,,,,,,,COSO29915674,2022Jun20,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7197.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Gefitinib,,Completed,NCT01933347,CTONG1304,PCD,2017Apr10,Yes,No,,2.0,10.1200/JCO.2017.35.15_suppl.9035,Previously-treated,,"Disease control rate, Clinical benefit rate",46.0,46.0,,,4.7,,,,,,,,4.4,,,,,,,,,,69.8,,,8.0,,,,,,,,,,,,,,,,,COSO29915674,2022Jun20,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7198.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Gefitinib,,Completed,NCT01933347,CTONG1304,PCD,2017Apr10,Yes,No,,2.0,10.1200/JCO.2017.35.15_suppl.9035,Previously-treated,,"Disease control rate, Clinical benefit rate",46.0,46.0,,,4.7,,,,,,,,4.4,,,,,,,,,,69.8,,,8.0,,,,,,,,,,,,,,,,,COSO29915674,2022Jun20,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7199.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Gefitinib,,Completed,NCT01933347,CTONG1304,PCD,2017Apr10,Yes,No,,2.0,10.1200/JCO.2017.35.15_suppl.9035,Previously-treated,,"Disease control rate, Clinical benefit rate",46.0,46.0,,,4.7,,,,,,,,4.4,,,,,,,,,,69.8,,,8.0,,,,,,,,,,,,,,,,,COSO29915674,2022Jun20,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7200.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Gefitinib,,Completed,NCT01933347,CTONG1304,PCD,2017Apr10,Yes,No,,2.0,10.1200/JCO.2017.35.15_suppl.9035,Previously-treated,,"Disease control rate, Clinical benefit rate",46.0,46.0,,,4.7,,,,,,,,4.4,,,,,,,,,,69.8,,,8.0,,,,,,,,,,,,,,,,,COSO29915674,2022Jun20,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7201.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Gefitinib,,Completed,NCT01933347,CTONG1304,PCD,2017Apr10,Yes,No,,2.0,10.1200/JCO.2017.35.15_suppl.9035,Previously-treated,,"Disease control rate, Clinical benefit rate",46.0,46.0,,,4.7,,,,,,,,4.4,,,,,,,,,,69.8,,,8.0,,,,,,,,,,,,,,,,,COSO29915674,2022Jun20,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7202.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Gefitinib,,Completed,NCT01933347,CTONG1304,PCD,2017Apr10,Yes,No,,2.0,10.1200/JCO.2017.35.15_suppl.9035,Previously-treated,,"Disease control rate, Clinical benefit rate",46.0,46.0,,,4.7,,,,,,,,4.4,,,,,,,,,,69.8,,,8.0,,,,,,,,,,,,,,,,,COSO29915674,2022Jun20,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7572.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Gefitinib,,Unknown,UMIN000006252,IMPACT,,,Yes,Yes,,2.0,10.1200/JCO.21.01729,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",232.0,116.0,116.0,Cisplatin + Vinorelbine,,,,,,,,,,,,,,,,,,,,,,,,1.03,0.65-1.65,0.89,,,,,35.9,25.1,0.92,0.67-1.28,0.63,,,,COSO29915674,2022Feb14,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7573.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Gefitinib,,Unknown,UMIN000006252,IMPACT,,,Yes,Yes,,2.0,10.1200/JCO.21.01729,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",232.0,116.0,116.0,Cisplatin + Vinorelbine,,,,,,,,,,,,,,,,,,,,,,,,1.03,0.65-1.65,0.89,,,,,35.9,25.1,0.92,0.67-1.28,0.63,,,,COSO29915674,2022Feb14,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7574.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Gefitinib,,Unknown,UMIN000006252,IMPACT,,,Yes,Yes,,2.0,10.1200/JCO.21.01729,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",232.0,116.0,116.0,Cisplatin + Vinorelbine,,,,,,,,,,,,,,,,,,,,,,,,1.03,0.65-1.65,0.89,,,,,35.9,25.1,0.92,0.67-1.28,0.63,,,,COSO29915674,2022Feb14,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7575.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Gefitinib,,Unknown,UMIN000006252,IMPACT,,,Yes,Yes,,2.0,10.1200/JCO.21.01729,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",232.0,116.0,116.0,Cisplatin + Vinorelbine,,,,,,,,,,,,,,,,,,,,,,,,1.03,0.65-1.65,0.89,,,,,35.9,25.1,0.92,0.67-1.28,0.63,,,,COSO29915674,2022Feb14,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7576.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Gefitinib,,Unknown,UMIN000006252,IMPACT,,,Yes,Yes,,2.0,10.1200/JCO.21.01729,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",232.0,116.0,116.0,Cisplatin + Vinorelbine,,,,,,,,,,,,,,,,,,,,,,,,1.03,0.65-1.65,0.89,,,,,35.9,25.1,0.92,0.67-1.28,0.63,,,,COSO29915674,2022Feb14,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7577.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Gefitinib,,Unknown,UMIN000006252,IMPACT,,,Yes,Yes,,2.0,10.1200/JCO.21.01729,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",232.0,116.0,116.0,Cisplatin + Vinorelbine,,,,,,,,,,,,,,,,,,,,,,,,1.03,0.65-1.65,0.89,,,,,35.9,25.1,0.92,0.67-1.28,0.63,,,,COSO29915674,2022Feb14,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7578.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Gefitinib,,Unknown,UMIN000006252,IMPACT,,,Yes,Yes,,2.0,10.1200/JCO.21.01729,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",232.0,116.0,116.0,Cisplatin + Vinorelbine,,,,,,,,,,,,,,,,,,,,,,,,1.03,0.65-1.65,0.89,,,,,35.9,25.1,0.92,0.67-1.28,0.63,,,,COSO29915674,2022Feb14,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7579.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Gefitinib,,Unknown,UMIN000006252,IMPACT,,,Yes,Yes,,2.0,10.1200/JCO.21.01729,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",232.0,116.0,116.0,Cisplatin + Vinorelbine,,,,,,,,,,,,,,,,,,,,,,,,1.03,0.65-1.65,0.89,,,,,35.9,25.1,0.92,0.67-1.28,0.63,,,,COSO29915674,2022Feb14,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7580.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Gefitinib,,Unknown,UMIN000006252,IMPACT,,,Yes,Yes,,2.0,10.1200/JCO.21.01729,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",232.0,116.0,116.0,Cisplatin + Vinorelbine,,,,,,,,,,,,,,,,,,,,,,,,1.03,0.65-1.65,0.89,,,,,35.9,25.1,0.92,0.67-1.28,0.63,,,,COSO29915674,2022Feb14,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7698.0,EGFR,EGFR_Exon_19ins,,,,lung / carcinoma / non small cell carcinoma,4.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,29483495,,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7699.0,EGFR,EGFR_Exon_19ins,,,,lung / carcinoma / non small cell carcinoma,4.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,29483495,,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7700.0,EGFR,EGFR_Exon_19ins,,,,lung / carcinoma / non small cell carcinoma,4.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,29483495,,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7701.0,EGFR,EGFR_Exon_19ins,,,,lung / carcinoma / non small cell carcinoma,4.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,29483495,,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7702.0,EGFR,EGFR_Exon_19ins,,,,lung / carcinoma / non small cell carcinoma,4.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,29483495,,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7703.0,EGFR,EGFR_Exon_19ins,,,,lung / carcinoma / non small cell carcinoma,4.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,29483495,,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7704.0,EGFR,EGFR_Exon_19ins,,,,lung / carcinoma / non small cell carcinoma,4.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,29483495,,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7705.0,EGFR,EGFR_Exon_19ins,,,,lung / carcinoma / non small cell carcinoma,4.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,29483495,,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7706.0,EGFR,EGFR_Exon_19ins,,,,lung / carcinoma / non small cell carcinoma,4.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,29483495,,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8112.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,28184913,,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,50.0,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8113.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,28184913,,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,50.0,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8114.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,28184913,,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,50.0,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8115.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,28184913,,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,50.0,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8116.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,28184913,,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,50.0,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8117.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,28184913,,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,50.0,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8118.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,28184913,,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,50.0,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8119.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,28184913,,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,50.0,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8120.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,28184913,,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,50.0,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8121.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,15118073,,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8122.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,15118073,,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8123.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,15118073,,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8124.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,15118073,,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8125.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,15118073,,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8126.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,15118073,,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8127.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,15118073,,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8128.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,15118073,,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8129.0,EGFR,EGFR_G719,,,p.G719X,lung / carcinoma / non small cell carcinoma,1.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,15118073,,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8346.0,EGFR,EGFR_S768I or EGFR_V769L,51768106 + 51811749,,p.S768I + p.V769L,lung / carcinoma / non small cell carcinoma,4.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,17045698,,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8347.0,EGFR,EGFR_S768I or EGFR_V769L,51768106 + 51811749,,p.S768I + p.V769L,lung / carcinoma / non small cell carcinoma,4.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,17045698,,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8348.0,EGFR,EGFR_S768I or EGFR_V769L,51768106 + 51811749,,p.S768I + p.V769L,lung / carcinoma / non small cell carcinoma,4.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,17045698,,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8349.0,EGFR,EGFR_S768I or EGFR_V769L,51768106 + 51811749,,p.S768I + p.V769L,lung / carcinoma / non small cell carcinoma,4.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,17045698,,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8350.0,EGFR,EGFR_S768I or EGFR_V769L,51768106 + 51811749,,p.S768I + p.V769L,lung / carcinoma / non small cell carcinoma,4.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,17045698,,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8351.0,EGFR,EGFR_S768I or EGFR_V769L,51768106 + 51811749,,p.S768I + p.V769L,lung / carcinoma / non small cell carcinoma,4.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,17045698,,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8352.0,EGFR,EGFR_S768I or EGFR_V769L,51768106 + 51811749,,p.S768I + p.V769L,lung / carcinoma / non small cell carcinoma,4.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,17045698,,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8353.0,EGFR,EGFR_S768I or EGFR_V769L,51768106 + 51811749,,p.S768I + p.V769L,lung / carcinoma / non small cell carcinoma,4.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,17045698,,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8354.0,EGFR,EGFR_S768I or EGFR_V769L,51768106 + 51811749,,p.S768I + p.V769L,lung / carcinoma / non small cell carcinoma,4.0,Case study,Gefitinib,,Unknown,,,,,Yes,Yes,,1.0,17045698,,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11145.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Gefitinib,,Completed,NCT00344773,,PCD,2007Dec01,Yes,Yes,,4.0,NCT00344773,,,Overall Response Rate,46.0,46.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Jun17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11146.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Gefitinib,,Completed,NCT00344773,,PCD,2007Dec01,Yes,Yes,,4.0,NCT00344773,,,Overall Response Rate,46.0,46.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Jun17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11147.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Gefitinib,,Completed,NCT00344773,,PCD,2007Dec01,Yes,Yes,,4.0,NCT00344773,,,Overall Response Rate,46.0,46.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Jun17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11148.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Gefitinib,,Completed,NCT00344773,,PCD,2007Dec01,Yes,Yes,,4.0,NCT00344773,,,Overall Response Rate,46.0,46.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Jun17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11149.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Gefitinib,,Completed,NCT00344773,,PCD,2007Dec01,Yes,Yes,,4.0,NCT00344773,,,Overall Response Rate,46.0,46.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Jun17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11150.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Gefitinib,,Completed,NCT00344773,,PCD,2007Dec01,Yes,Yes,,4.0,NCT00344773,,,Overall Response Rate,46.0,46.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Jun17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11151.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Gefitinib,,Completed,NCT00344773,,PCD,2007Dec01,Yes,Yes,,4.0,NCT00344773,,,Overall Response Rate,46.0,46.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Jun17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11152.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Gefitinib,,Completed,NCT00344773,,PCD,2007Dec01,Yes,Yes,,4.0,NCT00344773,,,Overall Response Rate,46.0,46.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Jun17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11153.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Gefitinib,,Completed,NCT00344773,,PCD,2007Dec01,Yes,Yes,,4.0,NCT00344773,,,Overall Response Rate,46.0,46.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Jun17,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11154.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Gefitinib,,Completed,NCT00411047,,PCD,2007Jan01,Yes,No,,4.0,NCT00411047,Untreated,,Overall Response Rate,34.0,34.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11155.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Gefitinib,,Completed,NCT00411047,,PCD,2007Jan01,Yes,No,,4.0,NCT00411047,Untreated,,Overall Response Rate,34.0,34.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11156.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Gefitinib,,Completed,NCT00411047,,PCD,2007Jan01,Yes,No,,4.0,NCT00411047,Untreated,,Overall Response Rate,34.0,34.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11157.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Gefitinib,,Completed,NCT00411047,,PCD,2007Jan01,Yes,No,,4.0,NCT00411047,Untreated,,Overall Response Rate,34.0,34.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11158.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Gefitinib,,Completed,NCT00411047,,PCD,2007Jan01,Yes,No,,4.0,NCT00411047,Untreated,,Overall Response Rate,34.0,34.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11159.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Gefitinib,,Completed,NCT00411047,,PCD,2007Jan01,Yes,No,,4.0,NCT00411047,Untreated,,Overall Response Rate,34.0,34.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11160.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Gefitinib,,Completed,NCT00411047,,PCD,2007Jan01,Yes,No,,4.0,NCT00411047,Untreated,,Overall Response Rate,34.0,34.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11161.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Gefitinib,,Completed,NCT00411047,,PCD,2007Jan01,Yes,No,,4.0,NCT00411047,Untreated,,Overall Response Rate,34.0,34.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11162.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Gefitinib,,Completed,NCT00411047,,PCD,2007Jan01,Yes,No,,4.0,NCT00411047,Untreated,,Overall Response Rate,34.0,34.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11163.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Gefitinib,,Completed,NCT02804776,ECRU-LUNG,PCD,2018Feb21,Yes,No,,4.0,NCT02804776,,,Tumour volume,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11164.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Gefitinib,,Completed,NCT02804776,ECRU-LUNG,PCD,2018Feb21,Yes,No,,4.0,NCT02804776,,,Tumour volume,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11165.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Gefitinib,,Completed,NCT02804776,ECRU-LUNG,PCD,2018Feb21,Yes,No,,4.0,NCT02804776,,,Tumour volume,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11166.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Gefitinib,,Completed,NCT02804776,ECRU-LUNG,PCD,2018Feb21,Yes,No,,4.0,NCT02804776,,,Tumour volume,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11167.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Gefitinib,,Completed,NCT02804776,ECRU-LUNG,PCD,2018Feb21,Yes,No,,4.0,NCT02804776,,,Tumour volume,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11168.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Gefitinib,,Completed,NCT02804776,ECRU-LUNG,PCD,2018Feb21,Yes,No,,4.0,NCT02804776,,,Tumour volume,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11169.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Gefitinib,,Completed,NCT02804776,ECRU-LUNG,PCD,2018Feb21,Yes,No,,4.0,NCT02804776,,,Tumour volume,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11170.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Gefitinib,,Completed,NCT02804776,ECRU-LUNG,PCD,2018Feb21,Yes,No,,4.0,NCT02804776,,,Tumour volume,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11171.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Gefitinib,,Completed,NCT02804776,ECRU-LUNG,PCD,2018Feb21,Yes,No,,4.0,NCT02804776,,,Tumour volume,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11568.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Unknown,NCT03656393,RCTACSCNSCLC,ECD,2020Jul31,Yes,No,,4.0,NCT03656393,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",48.0,,,Carboplatin + Vinorelbine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11569.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Unknown,NCT03656393,RCTACSCNSCLC,ECD,2020Jul31,Yes,No,,4.0,NCT03656393,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",48.0,,,Carboplatin + Vinorelbine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11570.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Unknown,NCT03656393,RCTACSCNSCLC,ECD,2020Jul31,Yes,No,,4.0,NCT03656393,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",48.0,,,Carboplatin + Vinorelbine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11571.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Unknown,NCT03656393,RCTACSCNSCLC,ECD,2020Jul31,Yes,No,,4.0,NCT03656393,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",48.0,,,Carboplatin + Vinorelbine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11572.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Unknown,NCT03656393,RCTACSCNSCLC,ECD,2020Jul31,Yes,No,,4.0,NCT03656393,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",48.0,,,Carboplatin + Vinorelbine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11573.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Unknown,NCT03656393,RCTACSCNSCLC,ECD,2020Jul31,Yes,No,,4.0,NCT03656393,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",48.0,,,Carboplatin + Vinorelbine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11574.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Unknown,NCT03656393,RCTACSCNSCLC,ECD,2020Jul31,Yes,No,,4.0,NCT03656393,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",48.0,,,Carboplatin + Vinorelbine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11575.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Unknown,NCT03656393,RCTACSCNSCLC,ECD,2020Jul31,Yes,No,,4.0,NCT03656393,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",48.0,,,Carboplatin + Vinorelbine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11576.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Unknown,NCT03656393,RCTACSCNSCLC,ECD,2020Jul31,Yes,No,,4.0,NCT03656393,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",48.0,,,Carboplatin + Vinorelbine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11577.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Unknown,NCT01066195,,ECD,2010Oct01,Yes,Yes,,1.0,22674612,Previously-treated,,Progression free survival,33.0,16.0,17.0,Pemetrexed,,,,,,,,,15.7,2.9,0.3,0.13-0.72,0.005,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11578.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Unknown,NCT01066195,,ECD,2010Oct01,Yes,Yes,,1.0,22674612,Previously-treated,,Progression free survival,33.0,16.0,17.0,Pemetrexed,,,,,,,,,15.7,2.9,0.3,0.13-0.72,0.005,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11579.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Unknown,NCT01066195,,ECD,2010Oct01,Yes,Yes,,1.0,22674612,Previously-treated,,Progression free survival,33.0,16.0,17.0,Pemetrexed,,,,,,,,,15.7,2.9,0.3,0.13-0.72,0.005,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11580.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Unknown,NCT01066195,,ECD,2010Oct01,Yes,Yes,,1.0,22674612,Previously-treated,,Progression free survival,33.0,16.0,17.0,Pemetrexed,,,,,,,,,15.7,2.9,0.3,0.13-0.72,0.005,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11581.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Unknown,NCT01066195,,ECD,2010Oct01,Yes,Yes,,1.0,22674612,Previously-treated,,Progression free survival,33.0,16.0,17.0,Pemetrexed,,,,,,,,,15.7,2.9,0.3,0.13-0.72,0.005,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11582.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Unknown,NCT01066195,,ECD,2010Oct01,Yes,Yes,,1.0,22674612,Previously-treated,,Progression free survival,33.0,16.0,17.0,Pemetrexed,,,,,,,,,15.7,2.9,0.3,0.13-0.72,0.005,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11583.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Unknown,NCT01066195,,ECD,2010Oct01,Yes,Yes,,1.0,22674612,Previously-treated,,Progression free survival,33.0,16.0,17.0,Pemetrexed,,,,,,,,,15.7,2.9,0.3,0.13-0.72,0.005,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11584.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Unknown,NCT01066195,,ECD,2010Oct01,Yes,Yes,,1.0,22674612,Previously-treated,,Progression free survival,33.0,16.0,17.0,Pemetrexed,,,,,,,,,15.7,2.9,0.3,0.13-0.72,0.005,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11585.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Unknown,NCT01066195,,ECD,2010Oct01,Yes,Yes,,1.0,22674612,Previously-treated,,Progression free survival,33.0,16.0,17.0,Pemetrexed,,,,,,,,,15.7,2.9,0.3,0.13-0.72,0.005,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11586.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Completed,NCT00252707,,,,No,Yes,,1.0,18779611,Previously-treated,,Overall survival,484.0,,,Docetaxel,,,,,,,,,2.0,2.0,0.81,0.65-1.02,0.077,,,,,,,,,11.5,14.0,1.12,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11587.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Completed,NCT00252707,,,,No,Yes,,1.0,18779611,Previously-treated,,Overall survival,484.0,,,Docetaxel,,,,,,,,,2.0,2.0,0.81,0.65-1.02,0.077,,,,,,,,,11.5,14.0,1.12,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11588.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Completed,NCT00252707,,,,No,Yes,,1.0,18779611,Previously-treated,,Overall survival,484.0,,,Docetaxel,,,,,,,,,2.0,2.0,0.81,0.65-1.02,0.077,,,,,,,,,11.5,14.0,1.12,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11589.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Completed,NCT00252707,,,,No,Yes,,1.0,18779611,Previously-treated,,Overall survival,484.0,,,Docetaxel,,,,,,,,,2.0,2.0,0.81,0.65-1.02,0.077,,,,,,,,,11.5,14.0,1.12,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11590.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Completed,NCT00252707,,,,No,Yes,,1.0,18779611,Previously-treated,,Overall survival,484.0,,,Docetaxel,,,,,,,,,2.0,2.0,0.81,0.65-1.02,0.077,,,,,,,,,11.5,14.0,1.12,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11591.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Completed,NCT00252707,,,,No,Yes,,1.0,18779611,Previously-treated,,Overall survival,484.0,,,Docetaxel,,,,,,,,,2.0,2.0,0.81,0.65-1.02,0.077,,,,,,,,,11.5,14.0,1.12,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11592.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Completed,NCT00252707,,,,No,Yes,,1.0,18779611,Previously-treated,,Overall survival,484.0,,,Docetaxel,,,,,,,,,2.0,2.0,0.81,0.65-1.02,0.077,,,,,,,,,11.5,14.0,1.12,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11593.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Completed,NCT00252707,,,,No,Yes,,1.0,18779611,Previously-treated,,Overall survival,484.0,,,Docetaxel,,,,,,,,,2.0,2.0,0.81,0.65-1.02,0.077,,,,,,,,,11.5,14.0,1.12,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11594.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Completed,NCT00252707,,,,No,Yes,,1.0,18779611,Previously-treated,,Overall survival,484.0,,,Docetaxel,,,,,,,,,2.0,2.0,0.81,0.65-1.02,0.077,,,,,,,,,11.5,14.0,1.12,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11595.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Unknown,NCT01405079,ADJUVANT/CTONG1104,PCD,2017Mar01,Yes,Yes,,1.0,33332190,,,Progression free survival,222.0,111.0,111.0,Cisplatin + Vinorelbine,,,,,,,,,,,,,,,,,,,,,,75.5,62.8,0.92,0.62-1.36,0.674,,,,,28.7,18.0,0.6,0.42-0.87,0.0054,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11596.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Unknown,NCT01405079,ADJUVANT/CTONG1104,PCD,2017Mar01,Yes,Yes,,1.0,33332190,,,Progression free survival,222.0,111.0,111.0,Cisplatin + Vinorelbine,,,,,,,,,,,,,,,,,,,,,,75.5,62.8,0.92,0.62-1.36,0.674,,,,,28.7,18.0,0.6,0.42-0.87,0.0054,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11597.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Unknown,NCT01405079,ADJUVANT/CTONG1104,PCD,2017Mar01,Yes,Yes,,1.0,33332190,,,Progression free survival,222.0,111.0,111.0,Cisplatin + Vinorelbine,,,,,,,,,,,,,,,,,,,,,,75.5,62.8,0.92,0.62-1.36,0.674,,,,,28.7,18.0,0.6,0.42-0.87,0.0054,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11598.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Unknown,NCT01405079,ADJUVANT/CTONG1104,PCD,2017Mar01,Yes,Yes,,1.0,33332190,,,Progression free survival,222.0,111.0,111.0,Cisplatin + Vinorelbine,,,,,,,,,,,,,,,,,,,,,,75.5,62.8,0.92,0.62-1.36,0.674,,,,,28.7,18.0,0.6,0.42-0.87,0.0054,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11599.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Unknown,NCT01405079,ADJUVANT/CTONG1104,PCD,2017Mar01,Yes,Yes,,1.0,33332190,,,Progression free survival,222.0,111.0,111.0,Cisplatin + Vinorelbine,,,,,,,,,,,,,,,,,,,,,,75.5,62.8,0.92,0.62-1.36,0.674,,,,,28.7,18.0,0.6,0.42-0.87,0.0054,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11600.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Unknown,NCT01405079,ADJUVANT/CTONG1104,PCD,2017Mar01,Yes,Yes,,1.0,33332190,,,Progression free survival,222.0,111.0,111.0,Cisplatin + Vinorelbine,,,,,,,,,,,,,,,,,,,,,,75.5,62.8,0.92,0.62-1.36,0.674,,,,,28.7,18.0,0.6,0.42-0.87,0.0054,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11601.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Unknown,NCT01405079,ADJUVANT/CTONG1104,PCD,2017Mar01,Yes,Yes,,1.0,33332190,,,Progression free survival,222.0,111.0,111.0,Cisplatin + Vinorelbine,,,,,,,,,,,,,,,,,,,,,,75.5,62.8,0.92,0.62-1.36,0.674,,,,,28.7,18.0,0.6,0.42-0.87,0.0054,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11602.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Unknown,NCT01405079,ADJUVANT/CTONG1104,PCD,2017Mar01,Yes,Yes,,1.0,33332190,,,Progression free survival,222.0,111.0,111.0,Cisplatin + Vinorelbine,,,,,,,,,,,,,,,,,,,,,,75.5,62.8,0.92,0.62-1.36,0.674,,,,,28.7,18.0,0.6,0.42-0.87,0.0054,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11603.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 3,Gefitinib,,Unknown,NCT01405079,ADJUVANT/CTONG1104,PCD,2017Mar01,Yes,Yes,,1.0,33332190,,,Progression free survival,222.0,111.0,111.0,Cisplatin + Vinorelbine,,,,,,,,,,,,,,,,,,,,,,75.5,62.8,0.92,0.62-1.36,0.674,,,,,28.7,18.0,0.6,0.42-0.87,0.0054,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
17871.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / bronchioloalveolar adenocarcinoma,3.0,Phase 2,Gefitinib,,Completed,NCT00029003,,PCD,2004Dec01,No,No,,4.0,NCT00029003,,,Overall survival,90.0,90.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915645,2021May18,COSO29915645,lung,NS,NS,NS,carcinoma,bronchioloalveolar_adenocarcinoma,NS,NS
17872.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / bronchioloalveolar adenocarcinoma,3.0,Phase 2,Gefitinib,,Completed,NCT00029003,,PCD,2004Dec01,No,No,,4.0,NCT00029003,,,Overall survival,90.0,90.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915645,2021May18,COSO29915645,lung,NS,NS,NS,carcinoma,bronchioloalveolar_adenocarcinoma,NS,NS
17873.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / bronchioloalveolar adenocarcinoma,3.0,Phase 2,Gefitinib,,Completed,NCT00029003,,PCD,2004Dec01,No,No,,4.0,NCT00029003,,,Overall survival,90.0,90.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915645,2021May18,COSO29915645,lung,NS,NS,NS,carcinoma,bronchioloalveolar_adenocarcinoma,NS,NS
17874.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / bronchioloalveolar adenocarcinoma,3.0,Phase 2,Gefitinib,,Completed,NCT00029003,,PCD,2004Dec01,No,No,,4.0,NCT00029003,,,Overall survival,90.0,90.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915645,2021May18,COSO29915645,lung,NS,NS,NS,carcinoma,bronchioloalveolar_adenocarcinoma,NS,NS
17875.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / bronchioloalveolar adenocarcinoma,3.0,Phase 2,Gefitinib,,Completed,NCT00029003,,PCD,2004Dec01,No,No,,4.0,NCT00029003,,,Overall survival,90.0,90.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915645,2021May18,COSO29915645,lung,NS,NS,NS,carcinoma,bronchioloalveolar_adenocarcinoma,NS,NS
17876.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / bronchioloalveolar adenocarcinoma,3.0,Phase 2,Gefitinib,,Completed,NCT00029003,,PCD,2004Dec01,No,No,,4.0,NCT00029003,,,Overall survival,90.0,90.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915645,2021May18,COSO29915645,lung,NS,NS,NS,carcinoma,bronchioloalveolar_adenocarcinoma,NS,NS
17877.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / bronchioloalveolar adenocarcinoma,3.0,Phase 2,Gefitinib,,Completed,NCT00029003,,PCD,2004Dec01,No,No,,4.0,NCT00029003,,,Overall survival,90.0,90.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915645,2021May18,COSO29915645,lung,NS,NS,NS,carcinoma,bronchioloalveolar_adenocarcinoma,NS,NS
17878.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / bronchioloalveolar adenocarcinoma,3.0,Phase 2,Gefitinib,,Completed,NCT00029003,,PCD,2004Dec01,No,No,,4.0,NCT00029003,,,Overall survival,90.0,90.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915645,2021May18,COSO29915645,lung,NS,NS,NS,carcinoma,bronchioloalveolar_adenocarcinoma,NS,NS
17879.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / bronchioloalveolar adenocarcinoma,3.0,Phase 2,Gefitinib,,Completed,NCT00029003,,PCD,2004Dec01,No,No,,4.0,NCT00029003,,,Overall survival,90.0,90.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915645,2021May18,COSO29915645,lung,NS,NS,NS,carcinoma,bronchioloalveolar_adenocarcinoma,NS,NS
17880.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / bronchioloalveolar adenocarcinoma,3.0,Phase 2,Gefitinib,,Completed,NCT00029003,,PCD,2004Dec01,No,No,,4.0,NCT00029003,,,Overall survival,90.0,90.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915645,2021May18,COSO29915645,lung,NS,NS,NS,carcinoma,bronchioloalveolar_adenocarcinoma,NS,NS
17881.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / bronchioloalveolar adenocarcinoma,3.0,Phase 2,Gefitinib,,Completed,NCT00029003,,PCD,2004Dec01,No,No,,4.0,NCT00029003,,,Overall survival,90.0,90.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915645,2021May18,COSO29915645,lung,NS,NS,NS,carcinoma,bronchioloalveolar_adenocarcinoma,NS,NS
17882.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / bronchioloalveolar adenocarcinoma,3.0,Phase 2,Gefitinib,,Completed,NCT00029003,,PCD,2004Dec01,No,No,,4.0,NCT00029003,,,Overall survival,90.0,90.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915645,2021May18,COSO29915645,lung,NS,NS,NS,carcinoma,bronchioloalveolar_adenocarcinoma,NS,NS
17883.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / bronchioloalveolar adenocarcinoma,3.0,Phase 2,Gefitinib,,Completed,NCT00029003,,PCD,2004Dec01,No,No,,4.0,NCT00029003,,,Overall survival,90.0,90.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915645,2021May18,COSO29915645,lung,NS,NS,NS,carcinoma,bronchioloalveolar_adenocarcinoma,NS,NS
300.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Lapatinib,,"Active, not recruiting",NCT01306045,Arm 11,PCD,2014Feb12,Expression confirmed,Yes,,1.0,25667274,,,Response rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
301.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Lapatinib,,"Active, not recruiting",NCT01306045,Arm 11,PCD,2014Feb12,Expression confirmed,Yes,,1.0,25667274,,,Response rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
302.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Lapatinib,,"Active, not recruiting",NCT01306045,Arm 11,PCD,2014Feb12,Expression confirmed,Yes,,1.0,25667274,,,Response rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
303.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Lapatinib,,"Active, not recruiting",NCT01306045,Arm 11,PCD,2014Feb12,Expression confirmed,Yes,,1.0,25667274,,,Response rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
304.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Lapatinib,,"Active, not recruiting",NCT01306045,Arm 11,PCD,2014Feb12,Expression confirmed,Yes,,1.0,25667274,,,Response rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
305.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Lapatinib,,"Active, not recruiting",NCT01306045,Arm 11,PCD,2014Feb12,Expression confirmed,Yes,,1.0,25667274,,,Response rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
306.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Lapatinib,,"Active, not recruiting",NCT01306045,Arm 11,PCD,2014Feb12,Expression confirmed,Yes,,1.0,25667274,,,Response rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
307.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Lapatinib,,"Active, not recruiting",NCT01306045,Arm 11,PCD,2014Feb12,Expression confirmed,Yes,,1.0,25667274,,,Response rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
308.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Lapatinib,,"Active, not recruiting",NCT01306045,Arm 11,PCD,2014Feb12,Expression confirmed,Yes,,1.0,25667274,,,Response rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
309.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Lapatinib,,"Active, not recruiting",NCT01306045,Arm 11,PCD,2014Feb12,Expression confirmed,Yes,,1.0,25667274,,,Response rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
310.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Lapatinib,,"Active, not recruiting",NCT01306045,Arm 11,PCD,2014Feb12,Expression confirmed,Yes,,1.0,25667274,,,Response rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
311.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Lapatinib,,"Active, not recruiting",NCT01306045,Arm 11,PCD,2014Feb12,Expression confirmed,Yes,,1.0,25667274,,,Response rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
7014.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Lapatinib,,Terminated,NCT00073008,EGF20014,PCD,2008Jul01,Yes,Yes,No benefit of treatment,1.0,20215545,,,Overall Response Rate,131.0,131.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7015.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Lapatinib,,Terminated,NCT00073008,EGF20014,PCD,2008Jul01,Yes,Yes,No benefit of treatment,1.0,20215545,,,Overall Response Rate,131.0,131.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7016.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Lapatinib,,Terminated,NCT00073008,EGF20014,PCD,2008Jul01,Yes,Yes,No benefit of treatment,1.0,20215545,,,Overall Response Rate,131.0,131.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7017.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Lapatinib,,Terminated,NCT00073008,EGF20014,PCD,2008Jul01,Yes,Yes,No benefit of treatment,1.0,20215545,,,Overall Response Rate,131.0,131.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7018.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Lapatinib,,Terminated,NCT00073008,EGF20014,PCD,2008Jul01,Yes,Yes,No benefit of treatment,1.0,20215545,,,Overall Response Rate,131.0,131.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7019.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Lapatinib,,Terminated,NCT00073008,EGF20014,PCD,2008Jul01,Yes,Yes,No benefit of treatment,1.0,20215545,,,Overall Response Rate,131.0,131.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7020.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Lapatinib,,Terminated,NCT00073008,EGF20014,PCD,2008Jul01,Yes,Yes,No benefit of treatment,1.0,20215545,,,Overall Response Rate,131.0,131.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7021.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Lapatinib,,Terminated,NCT00073008,EGF20014,PCD,2008Jul01,Yes,Yes,No benefit of treatment,1.0,20215545,,,Overall Response Rate,131.0,131.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7022.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Lapatinib,,Terminated,NCT00073008,EGF20014,PCD,2008Jul01,Yes,Yes,No benefit of treatment,1.0,20215545,,,Overall Response Rate,131.0,131.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12495.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Lapatinib,,"Active, not recruiting",NCT01306045,Arm 10,PCD,2014Feb12,Expression confirmed,Yes,,1.0,25667274,,,Response rate,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12496.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Lapatinib,,"Active, not recruiting",NCT01306045,Arm 10,PCD,2014Feb12,Expression confirmed,Yes,,1.0,25667274,,,Response rate,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12497.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Lapatinib,,"Active, not recruiting",NCT01306045,Arm 10,PCD,2014Feb12,Expression confirmed,Yes,,1.0,25667274,,,Response rate,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12498.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Lapatinib,,"Active, not recruiting",NCT01306045,Arm 10,PCD,2014Feb12,Expression confirmed,Yes,,1.0,25667274,,,Response rate,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12499.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Lapatinib,,"Active, not recruiting",NCT01306045,Arm 10,PCD,2014Feb12,Expression confirmed,Yes,,1.0,25667274,,,Response rate,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12500.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Lapatinib,,"Active, not recruiting",NCT01306045,Arm 10,PCD,2014Feb12,Expression confirmed,Yes,,1.0,25667274,,,Response rate,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12501.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Lapatinib,,"Active, not recruiting",NCT01306045,Arm 10,PCD,2014Feb12,Expression confirmed,Yes,,1.0,25667274,,,Response rate,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12502.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Lapatinib,,"Active, not recruiting",NCT01306045,Arm 10,PCD,2014Feb12,Expression confirmed,Yes,,1.0,25667274,,,Response rate,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12503.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Lapatinib,,"Active, not recruiting",NCT01306045,Arm 10,PCD,2014Feb12,Expression confirmed,Yes,,1.0,25667274,,,Response rate,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12918.0,RET,KIF5B-RET_fusion COSF1231,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Lenvatinib,,Completed,NCT01877083,,PCD,2016Feb03,Yes,Yes,,4.0,NCT01877083,,,Overall Response Rate,25.0,25.0,,,16.0,,4.5-36.1,,,,,,7.3,,,3.6-10.2,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12919.0,RET,KIF5B-RET_fusion COSF1231,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Lenvatinib,,Completed,NCT01877083,,PCD,2016Feb03,Yes,Yes,,4.0,NCT01877083,,,Overall Response Rate,25.0,25.0,,,16.0,,4.5-36.1,,,,,,7.3,,,3.6-10.2,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12920.0,RET,KIF5B-RET_fusion COSF1231,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Lenvatinib,,Completed,NCT01877083,,PCD,2016Feb03,Yes,Yes,,4.0,NCT01877083,,,Overall Response Rate,25.0,25.0,,,16.0,,4.5-36.1,,,,,,7.3,,,3.6-10.2,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12921.0,RET,KIF5B-RET_fusion COSF1231,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Lenvatinib,,Completed,NCT01877083,,PCD,2016Feb03,Yes,Yes,,4.0,NCT01877083,,,Overall Response Rate,25.0,25.0,,,16.0,,4.5-36.1,,,,,,7.3,,,3.6-10.2,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12922.0,RET,KIF5B-RET_fusion COSF1231,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Lenvatinib,,Completed,NCT01877083,,PCD,2016Feb03,Yes,Yes,,4.0,NCT01877083,,,Overall Response Rate,25.0,25.0,,,16.0,,4.5-36.1,,,,,,7.3,,,3.6-10.2,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12923.0,RET,KIF5B-RET_fusion COSF1231,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Lenvatinib,,Completed,NCT01877083,,PCD,2016Feb03,Yes,Yes,,4.0,NCT01877083,,,Overall Response Rate,25.0,25.0,,,16.0,,4.5-36.1,,,,,,7.3,,,3.6-10.2,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12924.0,RET,KIF5B-RET_fusion COSF1231,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Lenvatinib,,Completed,NCT01877083,,PCD,2016Feb03,Yes,Yes,,4.0,NCT01877083,,,Overall Response Rate,25.0,25.0,,,16.0,,4.5-36.1,,,,,,7.3,,,3.6-10.2,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12925.0,RET,KIF5B-RET_fusion COSF1231,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Lenvatinib,,Completed,NCT01877083,,PCD,2016Feb03,Yes,Yes,,4.0,NCT01877083,,,Overall Response Rate,25.0,25.0,,,16.0,,4.5-36.1,,,,,,7.3,,,3.6-10.2,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12926.0,RET,KIF5B-RET_fusion COSF1231,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Lenvatinib,,Completed,NCT01877083,,PCD,2016Feb03,Yes,Yes,,4.0,NCT01877083,,,Overall Response Rate,25.0,25.0,,,16.0,,4.5-36.1,,,,,,7.3,,,3.6-10.2,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
36.0,ATM,ATM_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Expression confirmed,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
37.0,ATM,ATM_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Expression confirmed,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
38.0,ATM,ATM_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Expression confirmed,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
39.0,ATM,ATM_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Expression confirmed,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
40.0,ATM,ATM_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Expression confirmed,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
41.0,ATM,ATM_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Expression confirmed,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
42.0,ATM,ATM_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Expression confirmed,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
43.0,ATM,ATM_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Expression confirmed,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
44.0,ATM,ATM_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Expression confirmed,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
45.0,ATM,ATM_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Expression confirmed,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
46.0,ATM,ATM_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Expression confirmed,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
47.0,ATM,ATM_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Expression confirmed,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
120.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Yes,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
121.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Yes,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
122.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Yes,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
123.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Yes,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
124.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Yes,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
125.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Yes,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
126.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Yes,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
127.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Yes,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
128.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Yes,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
129.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Yes,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
130.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Yes,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
131.0,BRCA1,BRCA1_unspecified or BRCA2_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Yes,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
324.0,MRE11,MRE11_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Yes,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
325.0,MRE11,MRE11_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Yes,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
326.0,MRE11,MRE11_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Yes,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
327.0,MRE11,MRE11_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Yes,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
328.0,MRE11,MRE11_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Yes,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
329.0,MRE11,MRE11_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Yes,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
330.0,MRE11,MRE11_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Yes,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
331.0,MRE11,MRE11_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Yes,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
332.0,MRE11,MRE11_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Yes,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
333.0,MRE11,MRE11_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Yes,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
334.0,MRE11,MRE11_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Yes,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
335.0,MRE11,MRE11_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Olaparib,,Completed,NCT03009682,SUKSES-B,PCD,2021Jan01,Yes,Yes,Primary outcome not met,2.0,10.1200/JCO.2021.39.15_suppl.8562,,,Overall Response Rate,15.0,15.0,,,6.7,,,,,,,,1.25,,,1.18-,,,,,,,26.7,,,8.56,,,6.62-,,,,,,,,,,,,,,COSO29915333,2021Aug17,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
5772.0,EGFR,EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I ,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 1,Osimertinib,,Completed,NCT02529995,AURAChinaPK,PCD,2016Jan28,Yes,Yes,,1.0,29239002,Previously-treated,,Maximum tolerated dose/toxicity,16.0,16.0,,,75.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5773.0,EGFR,EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I ,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 1,Osimertinib,,Completed,NCT02529995,AURAChinaPK,PCD,2016Jan28,Yes,Yes,,1.0,29239002,Previously-treated,,Maximum tolerated dose/toxicity,16.0,16.0,,,75.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5774.0,EGFR,EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I ,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 1,Osimertinib,,Completed,NCT02529995,AURAChinaPK,PCD,2016Jan28,Yes,Yes,,1.0,29239002,Previously-treated,,Maximum tolerated dose/toxicity,16.0,16.0,,,75.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5775.0,EGFR,EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I ,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 1,Osimertinib,,Completed,NCT02529995,AURAChinaPK,PCD,2016Jan28,Yes,Yes,,1.0,29239002,Previously-treated,,Maximum tolerated dose/toxicity,16.0,16.0,,,75.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5776.0,EGFR,EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I ,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 1,Osimertinib,,Completed,NCT02529995,AURAChinaPK,PCD,2016Jan28,Yes,Yes,,1.0,29239002,Previously-treated,,Maximum tolerated dose/toxicity,16.0,16.0,,,75.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5777.0,EGFR,EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I ,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 1,Osimertinib,,Completed,NCT02529995,AURAChinaPK,PCD,2016Jan28,Yes,Yes,,1.0,29239002,Previously-treated,,Maximum tolerated dose/toxicity,16.0,16.0,,,75.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5778.0,EGFR,EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I ,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 1,Osimertinib,,Completed,NCT02529995,AURAChinaPK,PCD,2016Jan28,Yes,Yes,,1.0,29239002,Previously-treated,,Maximum tolerated dose/toxicity,16.0,16.0,,,75.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5779.0,EGFR,EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I ,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 1,Osimertinib,,Completed,NCT02529995,AURAChinaPK,PCD,2016Jan28,Yes,Yes,,1.0,29239002,Previously-treated,,Maximum tolerated dose/toxicity,16.0,16.0,,,75.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5780.0,EGFR,EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I ,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 1,Osimertinib,,Completed,NCT02529995,AURAChinaPK,PCD,2016Jan28,Yes,Yes,,1.0,29239002,Previously-treated,,Maximum tolerated dose/toxicity,16.0,16.0,,,75.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5979.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_Exon19ins,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,Recruiting,NCT04233021,ORBITAL,ECD,2023Apr01,Yes,No,,4.0,NCT04233021,,,Overall Response Rate,69.0,69.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5980.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_Exon19ins,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,Recruiting,NCT04233021,ORBITAL,ECD,2023Apr01,Yes,No,,4.0,NCT04233021,,,Overall Response Rate,69.0,69.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5981.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_Exon19ins,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,Recruiting,NCT04233021,ORBITAL,ECD,2023Apr01,Yes,No,,4.0,NCT04233021,,,Overall Response Rate,69.0,69.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5982.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_Exon19ins,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,Recruiting,NCT04233021,ORBITAL,ECD,2023Apr01,Yes,No,,4.0,NCT04233021,,,Overall Response Rate,69.0,69.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5983.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_Exon19ins,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,Recruiting,NCT04233021,ORBITAL,ECD,2023Apr01,Yes,No,,4.0,NCT04233021,,,Overall Response Rate,69.0,69.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5984.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_Exon19ins,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,Recruiting,NCT04233021,ORBITAL,ECD,2023Apr01,Yes,No,,4.0,NCT04233021,,,Overall Response Rate,69.0,69.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5985.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_Exon19ins,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,Recruiting,NCT04233021,ORBITAL,ECD,2023Apr01,Yes,No,,4.0,NCT04233021,,,Overall Response Rate,69.0,69.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5986.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_Exon19ins,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,Recruiting,NCT04233021,ORBITAL,ECD,2023Apr01,Yes,No,,4.0,NCT04233021,,,Overall Response Rate,69.0,69.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5987.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_Exon19ins,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,Recruiting,NCT04233021,ORBITAL,ECD,2023Apr01,Yes,No,,4.0,NCT04233021,,,Overall Response Rate,69.0,69.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6024.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_T790M,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03433469,,ECD,2022Oct31,Yes,Yes,PaR 69%,2.0,10.1016/j.jtho.2021.08.383,,,"Complete response, Pathological complete response",13.0,13.0,,,,,,,,,,,,,,,,,,,,,100.0,,,,,,,,,,6.0,7.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6025.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_T790M,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03433469,,ECD,2022Oct31,Yes,Yes,PaR 69%,2.0,10.1016/j.jtho.2021.08.383,,,"Complete response, Pathological complete response",13.0,13.0,,,,,,,,,,,,,,,,,,,,,100.0,,,,,,,,,,6.0,7.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6026.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_T790M,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03433469,,ECD,2022Oct31,Yes,Yes,PaR 69%,2.0,10.1016/j.jtho.2021.08.383,,,"Complete response, Pathological complete response",13.0,13.0,,,,,,,,,,,,,,,,,,,,,100.0,,,,,,,,,,6.0,7.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6027.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_T790M,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03433469,,ECD,2022Oct31,Yes,Yes,PaR 69%,2.0,10.1016/j.jtho.2021.08.383,,,"Complete response, Pathological complete response",13.0,13.0,,,,,,,,,,,,,,,,,,,,,100.0,,,,,,,,,,6.0,7.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6028.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_T790M,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03433469,,ECD,2022Oct31,Yes,Yes,PaR 69%,2.0,10.1016/j.jtho.2021.08.383,,,"Complete response, Pathological complete response",13.0,13.0,,,,,,,,,,,,,,,,,,,,,100.0,,,,,,,,,,6.0,7.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6029.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_T790M,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03433469,,ECD,2022Oct31,Yes,Yes,PaR 69%,2.0,10.1016/j.jtho.2021.08.383,,,"Complete response, Pathological complete response",13.0,13.0,,,,,,,,,,,,,,,,,,,,,100.0,,,,,,,,,,6.0,7.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6030.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_T790M,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03433469,,ECD,2022Oct31,Yes,Yes,PaR 69%,2.0,10.1016/j.jtho.2021.08.383,,,"Complete response, Pathological complete response",13.0,13.0,,,,,,,,,,,,,,,,,,,,,100.0,,,,,,,,,,6.0,7.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6031.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_T790M,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03433469,,ECD,2022Oct31,Yes,Yes,PaR 69%,2.0,10.1016/j.jtho.2021.08.383,,,"Complete response, Pathological complete response",13.0,13.0,,,,,,,,,,,,,,,,,,,,,100.0,,,,,,,,,,6.0,7.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6032.0,EGFR,EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_T790M,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03433469,,ECD,2022Oct31,Yes,Yes,PaR 69%,2.0,10.1016/j.jtho.2021.08.383,,,"Complete response, Pathological complete response",13.0,13.0,,,,,,,,,,,,,,,,,,,,,100.0,,,,,,,,,,6.0,7.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6051.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Osimertinib,Required,"Active, not recruiting",NCT02511106,ADAURA,PCD,2020Jan17,Yes,Yes,,2.0,10.1200/JCO.2020.38.18_suppl.LBA5,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",682.0,339.0,343.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,89.0,53.0,0.21,0.16-0.28,<0.0001,,,,COSO29915674,2021Oct28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6052.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Osimertinib,Required,"Active, not recruiting",NCT02511106,ADAURA,PCD,2020Jan17,Yes,Yes,,2.0,10.1200/JCO.2020.38.18_suppl.LBA5,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",682.0,339.0,343.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,89.0,53.0,0.21,0.16-0.28,<0.0001,,,,COSO29915674,2021Oct28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6053.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Osimertinib,Required,"Active, not recruiting",NCT02511106,ADAURA,PCD,2020Jan17,Yes,Yes,,2.0,10.1200/JCO.2020.38.18_suppl.LBA5,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",682.0,339.0,343.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,89.0,53.0,0.21,0.16-0.28,<0.0001,,,,COSO29915674,2021Oct28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6054.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Osimertinib,Required,"Active, not recruiting",NCT02511106,ADAURA,PCD,2020Jan17,Yes,Yes,,2.0,10.1200/JCO.2020.38.18_suppl.LBA5,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",682.0,339.0,343.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,89.0,53.0,0.21,0.16-0.28,<0.0001,,,,COSO29915674,2021Oct28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6055.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Osimertinib,Required,"Active, not recruiting",NCT02511106,ADAURA,PCD,2020Jan17,Yes,Yes,,2.0,10.1200/JCO.2020.38.18_suppl.LBA5,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",682.0,339.0,343.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,89.0,53.0,0.21,0.16-0.28,<0.0001,,,,COSO29915674,2021Oct28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6056.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Osimertinib,Required,"Active, not recruiting",NCT02511106,ADAURA,PCD,2020Jan17,Yes,Yes,,2.0,10.1200/JCO.2020.38.18_suppl.LBA5,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",682.0,339.0,343.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,89.0,53.0,0.21,0.16-0.28,<0.0001,,,,COSO29915674,2021Oct28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6057.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Osimertinib,Required,"Active, not recruiting",NCT02511106,ADAURA,PCD,2020Jan17,Yes,Yes,,2.0,10.1200/JCO.2020.38.18_suppl.LBA5,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",682.0,339.0,343.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,89.0,53.0,0.21,0.16-0.28,<0.0001,,,,COSO29915674,2021Oct28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6058.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Osimertinib,Required,"Active, not recruiting",NCT02511106,ADAURA,PCD,2020Jan17,Yes,Yes,,2.0,10.1200/JCO.2020.38.18_suppl.LBA5,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",682.0,339.0,343.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,89.0,53.0,0.21,0.16-0.28,<0.0001,,,,COSO29915674,2021Oct28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6059.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Osimertinib,Required,"Active, not recruiting",NCT02511106,ADAURA,PCD,2020Jan17,Yes,Yes,,2.0,10.1200/JCO.2020.38.18_suppl.LBA5,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",682.0,339.0,343.0,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,89.0,53.0,0.21,0.16-0.28,<0.0001,,,,COSO29915674,2021Oct28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6060.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Osimertinib,Required,"Active, not recruiting",NCT02296125,FLAURA,PCD,2017Jun19,Yes,Yes,,1.0,29151359,Untreated,,Progression free survival,556.0,279.0,277.0,Gefitinib,,,,,17.2,8.5,7.3-9.8,,18.9,10.2,0.46,0.37-0.57,p<0.001,,,,,,,,,83.0,71.0,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6061.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Osimertinib,Required,"Active, not recruiting",NCT02296125,FLAURA,PCD,2017Jun19,Yes,Yes,,1.0,29151359,Untreated,,Progression free survival,556.0,279.0,277.0,Gefitinib,,,,,17.2,8.5,7.3-9.8,,18.9,10.2,0.46,0.37-0.57,p<0.001,,,,,,,,,83.0,71.0,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6062.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Osimertinib,Required,"Active, not recruiting",NCT02296125,FLAURA,PCD,2017Jun19,Yes,Yes,,1.0,29151359,Untreated,,Progression free survival,556.0,279.0,277.0,Gefitinib,,,,,17.2,8.5,7.3-9.8,,18.9,10.2,0.46,0.37-0.57,p<0.001,,,,,,,,,83.0,71.0,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6063.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Osimertinib,Required,"Active, not recruiting",NCT02296125,FLAURA,PCD,2017Jun19,Yes,Yes,,1.0,29151359,Untreated,,Progression free survival,556.0,279.0,277.0,Gefitinib,,,,,17.2,8.5,7.3-9.8,,18.9,10.2,0.46,0.37-0.57,p<0.001,,,,,,,,,83.0,71.0,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6064.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Osimertinib,Required,"Active, not recruiting",NCT02296125,FLAURA,PCD,2017Jun19,Yes,Yes,,1.0,29151359,Untreated,,Progression free survival,556.0,279.0,277.0,Gefitinib,,,,,17.2,8.5,7.3-9.8,,18.9,10.2,0.46,0.37-0.57,p<0.001,,,,,,,,,83.0,71.0,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6065.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Osimertinib,Required,"Active, not recruiting",NCT02296125,FLAURA,PCD,2017Jun19,Yes,Yes,,1.0,29151359,Untreated,,Progression free survival,556.0,279.0,277.0,Gefitinib,,,,,17.2,8.5,7.3-9.8,,18.9,10.2,0.46,0.37-0.57,p<0.001,,,,,,,,,83.0,71.0,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6066.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Osimertinib,Required,"Active, not recruiting",NCT02296125,FLAURA,PCD,2017Jun19,Yes,Yes,,1.0,29151359,Untreated,,Progression free survival,556.0,279.0,277.0,Gefitinib,,,,,17.2,8.5,7.3-9.8,,18.9,10.2,0.46,0.37-0.57,p<0.001,,,,,,,,,83.0,71.0,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6067.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Osimertinib,Required,"Active, not recruiting",NCT02296125,FLAURA,PCD,2017Jun19,Yes,Yes,,1.0,29151359,Untreated,,Progression free survival,556.0,279.0,277.0,Gefitinib,,,,,17.2,8.5,7.3-9.8,,18.9,10.2,0.46,0.37-0.57,p<0.001,,,,,,,,,83.0,71.0,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6068.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Osimertinib,Required,"Active, not recruiting",NCT02296125,FLAURA,PCD,2017Jun19,Yes,Yes,,1.0,29151359,Untreated,,Progression free survival,556.0,279.0,277.0,Gefitinib,,,,,17.2,8.5,7.3-9.8,,18.9,10.2,0.46,0.37-0.57,p<0.001,,,,,,,,,83.0,71.0,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6159.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 1,Osimertinib,,Completed,NCT02228369,BLOOM,PCD,2017Aug19,Yes,Yes,,1.0,31809241,Previously-treated,,Maximum tolerated dose/toxicity,41.0,41.0,,,41.0,,26-58,,8.3,,5.6-16.5,,8.6,,,5.4-13.7,,,,,,,,,,11.0,,,8-18,,,,17.0,17.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6160.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 1,Osimertinib,,Completed,NCT02228369,BLOOM,PCD,2017Aug19,Yes,Yes,,1.0,31809241,Previously-treated,,Maximum tolerated dose/toxicity,41.0,41.0,,,41.0,,26-58,,8.3,,5.6-16.5,,8.6,,,5.4-13.7,,,,,,,,,,11.0,,,8-18,,,,17.0,17.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6161.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 1,Osimertinib,,Completed,NCT02228369,BLOOM,PCD,2017Aug19,Yes,Yes,,1.0,31809241,Previously-treated,,Maximum tolerated dose/toxicity,41.0,41.0,,,41.0,,26-58,,8.3,,5.6-16.5,,8.6,,,5.4-13.7,,,,,,,,,,11.0,,,8-18,,,,17.0,17.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6162.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 1,Osimertinib,,Completed,NCT02228369,BLOOM,PCD,2017Aug19,Yes,Yes,,1.0,31809241,Previously-treated,,Maximum tolerated dose/toxicity,41.0,41.0,,,41.0,,26-58,,8.3,,5.6-16.5,,8.6,,,5.4-13.7,,,,,,,,,,11.0,,,8-18,,,,17.0,17.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6163.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 1,Osimertinib,,Completed,NCT02228369,BLOOM,PCD,2017Aug19,Yes,Yes,,1.0,31809241,Previously-treated,,Maximum tolerated dose/toxicity,41.0,41.0,,,41.0,,26-58,,8.3,,5.6-16.5,,8.6,,,5.4-13.7,,,,,,,,,,11.0,,,8-18,,,,17.0,17.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6164.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 1,Osimertinib,,Completed,NCT02228369,BLOOM,PCD,2017Aug19,Yes,Yes,,1.0,31809241,Previously-treated,,Maximum tolerated dose/toxicity,41.0,41.0,,,41.0,,26-58,,8.3,,5.6-16.5,,8.6,,,5.4-13.7,,,,,,,,,,11.0,,,8-18,,,,17.0,17.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6165.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 1,Osimertinib,,Completed,NCT02228369,BLOOM,PCD,2017Aug19,Yes,Yes,,1.0,31809241,Previously-treated,,Maximum tolerated dose/toxicity,41.0,41.0,,,41.0,,26-58,,8.3,,5.6-16.5,,8.6,,,5.4-13.7,,,,,,,,,,11.0,,,8-18,,,,17.0,17.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6166.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 1,Osimertinib,,Completed,NCT02228369,BLOOM,PCD,2017Aug19,Yes,Yes,,1.0,31809241,Previously-treated,,Maximum tolerated dose/toxicity,41.0,41.0,,,41.0,,26-58,,8.3,,5.6-16.5,,8.6,,,5.4-13.7,,,,,,,,,,11.0,,,8-18,,,,17.0,17.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
6167.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 1,Osimertinib,,Completed,NCT02228369,BLOOM,PCD,2017Aug19,Yes,Yes,,1.0,31809241,Previously-treated,,Maximum tolerated dose/toxicity,41.0,41.0,,,41.0,,26-58,,8.3,,5.6-16.5,,8.6,,,5.4-13.7,,,,,,,,,,11.0,,,8-18,,,,17.0,17.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7104.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Suspended,NCT04591002,,ECD,2022Nov18,Yes,No,,4.0,NCT04591002,,,Clinical activity,56.0,56.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jan25,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7105.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Suspended,NCT04591002,,ECD,2022Nov18,Yes,No,,4.0,NCT04591002,,,Clinical activity,56.0,56.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jan25,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7106.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Suspended,NCT04591002,,ECD,2022Nov18,Yes,No,,4.0,NCT04591002,,,Clinical activity,56.0,56.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jan25,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7107.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Suspended,NCT04591002,,ECD,2022Nov18,Yes,No,,4.0,NCT04591002,,,Clinical activity,56.0,56.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jan25,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7108.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Suspended,NCT04591002,,ECD,2022Nov18,Yes,No,,4.0,NCT04591002,,,Clinical activity,56.0,56.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jan25,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7109.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Suspended,NCT04591002,,ECD,2022Nov18,Yes,No,,4.0,NCT04591002,,,Clinical activity,56.0,56.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jan25,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7110.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Suspended,NCT04591002,,ECD,2022Nov18,Yes,No,,4.0,NCT04591002,,,Clinical activity,56.0,56.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jan25,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7111.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Suspended,NCT04591002,,ECD,2022Nov18,Yes,No,,4.0,NCT04591002,,,Clinical activity,56.0,56.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jan25,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7112.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Suspended,NCT04591002,,ECD,2022Nov18,Yes,No,,4.0,NCT04591002,,,Clinical activity,56.0,56.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jan25,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7113.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT03769103,LUOSICNS,ECD,2025Apr01,Yes,No,,4.0,NCT03769103,,,Progression free survival,76.0,76.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7114.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT03769103,LUOSICNS,ECD,2025Apr01,Yes,No,,4.0,NCT03769103,,,Progression free survival,76.0,76.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7115.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT03769103,LUOSICNS,ECD,2025Apr01,Yes,No,,4.0,NCT03769103,,,Progression free survival,76.0,76.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7116.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT03769103,LUOSICNS,ECD,2025Apr01,Yes,No,,4.0,NCT03769103,,,Progression free survival,76.0,76.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7117.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT03769103,LUOSICNS,ECD,2025Apr01,Yes,No,,4.0,NCT03769103,,,Progression free survival,76.0,76.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7118.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT03769103,LUOSICNS,ECD,2025Apr01,Yes,No,,4.0,NCT03769103,,,Progression free survival,76.0,76.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7119.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT03769103,LUOSICNS,ECD,2025Apr01,Yes,No,,4.0,NCT03769103,,,Progression free survival,76.0,76.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7120.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT03769103,LUOSICNS,ECD,2025Apr01,Yes,No,,4.0,NCT03769103,,,Progression free survival,76.0,76.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7121.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT03769103,LUOSICNS,ECD,2025Apr01,Yes,No,,4.0,NCT03769103,,,Progression free survival,76.0,76.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7122.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT03586453,,ECD,2023Mar01,Yes,No,,4.0,NCT03586453,,,Biomarker discovery,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7123.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT03586453,,ECD,2023Mar01,Yes,No,,4.0,NCT03586453,,,Biomarker discovery,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7124.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT03586453,,ECD,2023Mar01,Yes,No,,4.0,NCT03586453,,,Biomarker discovery,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7125.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT03586453,,ECD,2023Mar01,Yes,No,,4.0,NCT03586453,,,Biomarker discovery,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7126.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT03586453,,ECD,2023Mar01,Yes,No,,4.0,NCT03586453,,,Biomarker discovery,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7127.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT03586453,,ECD,2023Mar01,Yes,No,,4.0,NCT03586453,,,Biomarker discovery,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7128.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT03586453,,ECD,2023Mar01,Yes,No,,4.0,NCT03586453,,,Biomarker discovery,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7129.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT03586453,,ECD,2023Mar01,Yes,No,,4.0,NCT03586453,,,Biomarker discovery,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7130.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT03586453,,ECD,2023Mar01,Yes,No,,4.0,NCT03586453,,,Biomarker discovery,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7527.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Recruiting,NCT05120349,ADAURA2,ECD,2027Aug02,Yes,No,,4.0,NCT05120349,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",380.0,,,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7528.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Recruiting,NCT05120349,ADAURA2,ECD,2027Aug02,Yes,No,,4.0,NCT05120349,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",380.0,,,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7529.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Recruiting,NCT05120349,ADAURA2,ECD,2027Aug02,Yes,No,,4.0,NCT05120349,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",380.0,,,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7530.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Recruiting,NCT05120349,ADAURA2,ECD,2027Aug02,Yes,No,,4.0,NCT05120349,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",380.0,,,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7531.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Recruiting,NCT05120349,ADAURA2,ECD,2027Aug02,Yes,No,,4.0,NCT05120349,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",380.0,,,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7532.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Recruiting,NCT05120349,ADAURA2,ECD,2027Aug02,Yes,No,,4.0,NCT05120349,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",380.0,,,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7533.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Recruiting,NCT05120349,ADAURA2,ECD,2027Aug02,Yes,No,,4.0,NCT05120349,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",380.0,,,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7534.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Recruiting,NCT05120349,ADAURA2,ECD,2027Aug02,Yes,No,,4.0,NCT05120349,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",380.0,,,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7535.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Recruiting,NCT05120349,ADAURA2,ECD,2027Aug02,Yes,No,,4.0,NCT05120349,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",380.0,,,Placebo,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7536.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Recruiting,NCT04351555,NeoADAURA,ECD,2024Mar26,Yes,No,,4.0,NCT04351555,,,Major pathologic response,328.0,,,Pemetrexed + Platinum-based chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jan25,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7537.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Recruiting,NCT04351555,NeoADAURA,ECD,2024Mar26,Yes,No,,4.0,NCT04351555,,,Major pathologic response,328.0,,,Pemetrexed + Platinum-based chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jan25,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7538.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Recruiting,NCT04351555,NeoADAURA,ECD,2024Mar26,Yes,No,,4.0,NCT04351555,,,Major pathologic response,328.0,,,Pemetrexed + Platinum-based chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jan25,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7539.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Recruiting,NCT04351555,NeoADAURA,ECD,2024Mar26,Yes,No,,4.0,NCT04351555,,,Major pathologic response,328.0,,,Pemetrexed + Platinum-based chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jan25,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7540.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Recruiting,NCT04351555,NeoADAURA,ECD,2024Mar26,Yes,No,,4.0,NCT04351555,,,Major pathologic response,328.0,,,Pemetrexed + Platinum-based chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jan25,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7541.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Recruiting,NCT04351555,NeoADAURA,ECD,2024Mar26,Yes,No,,4.0,NCT04351555,,,Major pathologic response,328.0,,,Pemetrexed + Platinum-based chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jan25,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7542.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Recruiting,NCT04351555,NeoADAURA,ECD,2024Mar26,Yes,No,,4.0,NCT04351555,,,Major pathologic response,328.0,,,Pemetrexed + Platinum-based chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jan25,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7543.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Recruiting,NCT04351555,NeoADAURA,ECD,2024Mar26,Yes,No,,4.0,NCT04351555,,,Major pathologic response,328.0,,,Pemetrexed + Platinum-based chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jan25,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7544.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Recruiting,NCT04351555,NeoADAURA,ECD,2024Mar26,Yes,No,,4.0,NCT04351555,,,Major pathologic response,328.0,,,Pemetrexed + Platinum-based chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Jan25,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7545.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,"Active, not recruiting",NCT04035486,FLAURA2,ECD,2023Apr03,Yes,No,,4.0,NCT04035486,,,Progression free survival,587.0,,,Carboplatin + Pemetrexed,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7546.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,"Active, not recruiting",NCT04035486,FLAURA2,ECD,2023Apr03,Yes,No,,4.0,NCT04035486,,,Progression free survival,587.0,,,Carboplatin + Pemetrexed,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7547.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,"Active, not recruiting",NCT04035486,FLAURA2,ECD,2023Apr03,Yes,No,,4.0,NCT04035486,,,Progression free survival,587.0,,,Carboplatin + Pemetrexed,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7548.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,"Active, not recruiting",NCT04035486,FLAURA2,ECD,2023Apr03,Yes,No,,4.0,NCT04035486,,,Progression free survival,587.0,,,Carboplatin + Pemetrexed,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7549.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,"Active, not recruiting",NCT04035486,FLAURA2,ECD,2023Apr03,Yes,No,,4.0,NCT04035486,,,Progression free survival,587.0,,,Carboplatin + Pemetrexed,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7550.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,"Active, not recruiting",NCT04035486,FLAURA2,ECD,2023Apr03,Yes,No,,4.0,NCT04035486,,,Progression free survival,587.0,,,Carboplatin + Pemetrexed,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7551.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,"Active, not recruiting",NCT04035486,FLAURA2,ECD,2023Apr03,Yes,No,,4.0,NCT04035486,,,Progression free survival,587.0,,,Carboplatin + Pemetrexed,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7552.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,"Active, not recruiting",NCT04035486,FLAURA2,ECD,2023Apr03,Yes,No,,4.0,NCT04035486,,,Progression free survival,587.0,,,Carboplatin + Pemetrexed,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
7553.0,EGFR,EGFR_Exon19del or EGFR_L858R,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,"Active, not recruiting",NCT04035486,FLAURA2,ECD,2023Apr03,Yes,No,,4.0,NCT04035486,,,Progression free survival,587.0,,,Carboplatin + Pemetrexed,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8004.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Suspended,NCT03191149,,ECD,2023Jul31,Yes,No,,4.0,NCT03191149,Previously-treated,,Overall Response Rate,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8005.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Suspended,NCT03191149,,ECD,2023Jul31,Yes,No,,4.0,NCT03191149,Previously-treated,,Overall Response Rate,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8006.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Suspended,NCT03191149,,ECD,2023Jul31,Yes,No,,4.0,NCT03191149,Previously-treated,,Overall Response Rate,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8007.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Suspended,NCT03191149,,ECD,2023Jul31,Yes,No,,4.0,NCT03191149,Previously-treated,,Overall Response Rate,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8008.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Suspended,NCT03191149,,ECD,2023Jul31,Yes,No,,4.0,NCT03191149,Previously-treated,,Overall Response Rate,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8009.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Suspended,NCT03191149,,ECD,2023Jul31,Yes,No,,4.0,NCT03191149,Previously-treated,,Overall Response Rate,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8010.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Suspended,NCT03191149,,ECD,2023Jul31,Yes,No,,4.0,NCT03191149,Previously-treated,,Overall Response Rate,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8011.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Suspended,NCT03191149,,ECD,2023Jul31,Yes,No,,4.0,NCT03191149,Previously-treated,,Overall Response Rate,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8012.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Suspended,NCT03191149,,ECD,2023Jul31,Yes,No,,4.0,NCT03191149,Previously-treated,,Overall Response Rate,20.0,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8013.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Completed,NCT03414814,,PCD,2021Aug03,Yes,Yes,,2.0,10.1093/annonc/mdz260.051,Previously-treated,,Overall Response Rate,3.0,3.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8014.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Completed,NCT03414814,,PCD,2021Aug03,Yes,Yes,,2.0,10.1093/annonc/mdz260.051,Previously-treated,,Overall Response Rate,3.0,3.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8015.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Completed,NCT03414814,,PCD,2021Aug03,Yes,Yes,,2.0,10.1093/annonc/mdz260.051,Previously-treated,,Overall Response Rate,3.0,3.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8016.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Completed,NCT03414814,,PCD,2021Aug03,Yes,Yes,,2.0,10.1093/annonc/mdz260.051,Previously-treated,,Overall Response Rate,3.0,3.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8017.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Completed,NCT03414814,,PCD,2021Aug03,Yes,Yes,,2.0,10.1093/annonc/mdz260.051,Previously-treated,,Overall Response Rate,3.0,3.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8018.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Completed,NCT03414814,,PCD,2021Aug03,Yes,Yes,,2.0,10.1093/annonc/mdz260.051,Previously-treated,,Overall Response Rate,3.0,3.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8019.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Completed,NCT03414814,,PCD,2021Aug03,Yes,Yes,,2.0,10.1093/annonc/mdz260.051,Previously-treated,,Overall Response Rate,3.0,3.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8020.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Completed,NCT03414814,,PCD,2021Aug03,Yes,Yes,,2.0,10.1093/annonc/mdz260.051,Previously-treated,,Overall Response Rate,3.0,3.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8021.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Completed,NCT03414814,,PCD,2021Aug03,Yes,Yes,,2.0,10.1093/annonc/mdz260.051,Previously-treated,,Overall Response Rate,3.0,3.0,,,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8085.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 4,Osimertinib,,Not yet recruiting,NCT05513664,,ECD,2023Jun01,Yes,No,,4.0,NCT05513664,,,Overall Response Rate,80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep27,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8086.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 4,Osimertinib,,Not yet recruiting,NCT05513664,,ECD,2023Jun01,Yes,No,,4.0,NCT05513664,,,Overall Response Rate,80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep27,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8087.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 4,Osimertinib,,Not yet recruiting,NCT05513664,,ECD,2023Jun01,Yes,No,,4.0,NCT05513664,,,Overall Response Rate,80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep27,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8088.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 4,Osimertinib,,Not yet recruiting,NCT05513664,,ECD,2023Jun01,Yes,No,,4.0,NCT05513664,,,Overall Response Rate,80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep27,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8089.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 4,Osimertinib,,Not yet recruiting,NCT05513664,,ECD,2023Jun01,Yes,No,,4.0,NCT05513664,,,Overall Response Rate,80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep27,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8090.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 4,Osimertinib,,Not yet recruiting,NCT05513664,,ECD,2023Jun01,Yes,No,,4.0,NCT05513664,,,Overall Response Rate,80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep27,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8091.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 4,Osimertinib,,Not yet recruiting,NCT05513664,,ECD,2023Jun01,Yes,No,,4.0,NCT05513664,,,Overall Response Rate,80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep27,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8092.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 4,Osimertinib,,Not yet recruiting,NCT05513664,,ECD,2023Jun01,Yes,No,,4.0,NCT05513664,,,Overall Response Rate,80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep27,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8093.0,EGFR,EGFR_Exon_20ins,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 4,Osimertinib,,Not yet recruiting,NCT05513664,,ECD,2023Jun01,Yes,No,,4.0,NCT05513664,,,Overall Response Rate,80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep27,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8157.0,EGFR,EGFR_G719 or EGFR_L861Q or EGFR_S768I,51766344 + 51768106,,p.G719X + p.L861Q + p.S768I,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03434418,,ECD,2023Jun30,Yes,No,,1.0,NCT03434418,Untreated,,Overall Response Rate,17.0,17.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8158.0,EGFR,EGFR_G719 or EGFR_L861Q or EGFR_S768I,51766344 + 51768106,,p.G719X + p.L861Q + p.S768I,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03434418,,ECD,2023Jun30,Yes,No,,1.0,NCT03434418,Untreated,,Overall Response Rate,17.0,17.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8159.0,EGFR,EGFR_G719 or EGFR_L861Q or EGFR_S768I,51766344 + 51768106,,p.G719X + p.L861Q + p.S768I,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03434418,,ECD,2023Jun30,Yes,No,,1.0,NCT03434418,Untreated,,Overall Response Rate,17.0,17.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8160.0,EGFR,EGFR_G719 or EGFR_L861Q or EGFR_S768I,51766344 + 51768106,,p.G719X + p.L861Q + p.S768I,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03434418,,ECD,2023Jun30,Yes,No,,1.0,NCT03434418,Untreated,,Overall Response Rate,17.0,17.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8161.0,EGFR,EGFR_G719 or EGFR_L861Q or EGFR_S768I,51766344 + 51768106,,p.G719X + p.L861Q + p.S768I,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03434418,,ECD,2023Jun30,Yes,No,,1.0,NCT03434418,Untreated,,Overall Response Rate,17.0,17.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8162.0,EGFR,EGFR_G719 or EGFR_L861Q or EGFR_S768I,51766344 + 51768106,,p.G719X + p.L861Q + p.S768I,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03434418,,ECD,2023Jun30,Yes,No,,1.0,NCT03434418,Untreated,,Overall Response Rate,17.0,17.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8163.0,EGFR,EGFR_G719 or EGFR_L861Q or EGFR_S768I,51766344 + 51768106,,p.G719X + p.L861Q + p.S768I,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03434418,,ECD,2023Jun30,Yes,No,,1.0,NCT03434418,Untreated,,Overall Response Rate,17.0,17.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8164.0,EGFR,EGFR_G719 or EGFR_L861Q or EGFR_S768I,51766344 + 51768106,,p.G719X + p.L861Q + p.S768I,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03434418,,ECD,2023Jun30,Yes,No,,1.0,NCT03434418,Untreated,,Overall Response Rate,17.0,17.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8165.0,EGFR,EGFR_G719 or EGFR_L861Q or EGFR_S768I,51766344 + 51768106,,p.G719X + p.L861Q + p.S768I,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03434418,,ECD,2023Jun30,Yes,No,,1.0,NCT03434418,Untreated,,Overall Response Rate,17.0,17.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8202.0,EGFR,EGFR_G719 or EGFR_L861Q or EGFR_S768I,51766344 + 51768106,,p.G719X + p.L861Q + p.S768I,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,Not yet recruiting,NCT05546866,,ECD,2029Jun30,Yes,No,,4.0,NCT05546866,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec16,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8203.0,EGFR,EGFR_G719 or EGFR_L861Q or EGFR_S768I,51766344 + 51768106,,p.G719X + p.L861Q + p.S768I,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,Not yet recruiting,NCT05546866,,ECD,2029Jun30,Yes,No,,4.0,NCT05546866,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec16,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8204.0,EGFR,EGFR_G719 or EGFR_L861Q or EGFR_S768I,51766344 + 51768106,,p.G719X + p.L861Q + p.S768I,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,Not yet recruiting,NCT05546866,,ECD,2029Jun30,Yes,No,,4.0,NCT05546866,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec16,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8205.0,EGFR,EGFR_G719 or EGFR_L861Q or EGFR_S768I,51766344 + 51768106,,p.G719X + p.L861Q + p.S768I,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,Not yet recruiting,NCT05546866,,ECD,2029Jun30,Yes,No,,4.0,NCT05546866,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec16,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8206.0,EGFR,EGFR_G719 or EGFR_L861Q or EGFR_S768I,51766344 + 51768106,,p.G719X + p.L861Q + p.S768I,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,Not yet recruiting,NCT05546866,,ECD,2029Jun30,Yes,No,,4.0,NCT05546866,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec16,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8207.0,EGFR,EGFR_G719 or EGFR_L861Q or EGFR_S768I,51766344 + 51768106,,p.G719X + p.L861Q + p.S768I,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,Not yet recruiting,NCT05546866,,ECD,2029Jun30,Yes,No,,4.0,NCT05546866,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec16,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8208.0,EGFR,EGFR_G719 or EGFR_L861Q or EGFR_S768I,51766344 + 51768106,,p.G719X + p.L861Q + p.S768I,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,Not yet recruiting,NCT05546866,,ECD,2029Jun30,Yes,No,,4.0,NCT05546866,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec16,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8209.0,EGFR,EGFR_G719 or EGFR_L861Q or EGFR_S768I,51766344 + 51768106,,p.G719X + p.L861Q + p.S768I,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,Not yet recruiting,NCT05546866,,ECD,2029Jun30,Yes,No,,4.0,NCT05546866,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec16,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8210.0,EGFR,EGFR_G719 or EGFR_L861Q or EGFR_S768I,51766344 + 51768106,,p.G719X + p.L861Q + p.S768I,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,Not yet recruiting,NCT05546866,,ECD,2029Jun30,Yes,No,,4.0,NCT05546866,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",50.0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec16,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8211.0,EGFR,EGFR_G719 or EGFR_L861Q or EGFR_S768I,51766344 + 51768106,,p.G719X + p.L861Q + p.S768I,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,Unknown,NCT03424759,,PCD,2017Dec31,Yes,Yes,,2.0,10.1200/JCO.2018.36.15_suppl.9050 ,,,Overall Response Rate,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8212.0,EGFR,EGFR_G719 or EGFR_L861Q or EGFR_S768I,51766344 + 51768106,,p.G719X + p.L861Q + p.S768I,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,Unknown,NCT03424759,,PCD,2017Dec31,Yes,Yes,,2.0,10.1200/JCO.2018.36.15_suppl.9050 ,,,Overall Response Rate,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8213.0,EGFR,EGFR_G719 or EGFR_L861Q or EGFR_S768I,51766344 + 51768106,,p.G719X + p.L861Q + p.S768I,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,Unknown,NCT03424759,,PCD,2017Dec31,Yes,Yes,,2.0,10.1200/JCO.2018.36.15_suppl.9050 ,,,Overall Response Rate,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8214.0,EGFR,EGFR_G719 or EGFR_L861Q or EGFR_S768I,51766344 + 51768106,,p.G719X + p.L861Q + p.S768I,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,Unknown,NCT03424759,,PCD,2017Dec31,Yes,Yes,,2.0,10.1200/JCO.2018.36.15_suppl.9050 ,,,Overall Response Rate,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8215.0,EGFR,EGFR_G719 or EGFR_L861Q or EGFR_S768I,51766344 + 51768106,,p.G719X + p.L861Q + p.S768I,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,Unknown,NCT03424759,,PCD,2017Dec31,Yes,Yes,,2.0,10.1200/JCO.2018.36.15_suppl.9050 ,,,Overall Response Rate,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8216.0,EGFR,EGFR_G719 or EGFR_L861Q or EGFR_S768I,51766344 + 51768106,,p.G719X + p.L861Q + p.S768I,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,Unknown,NCT03424759,,PCD,2017Dec31,Yes,Yes,,2.0,10.1200/JCO.2018.36.15_suppl.9050 ,,,Overall Response Rate,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8217.0,EGFR,EGFR_G719 or EGFR_L861Q or EGFR_S768I,51766344 + 51768106,,p.G719X + p.L861Q + p.S768I,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,Unknown,NCT03424759,,PCD,2017Dec31,Yes,Yes,,2.0,10.1200/JCO.2018.36.15_suppl.9050 ,,,Overall Response Rate,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8218.0,EGFR,EGFR_G719 or EGFR_L861Q or EGFR_S768I,51766344 + 51768106,,p.G719X + p.L861Q + p.S768I,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,Unknown,NCT03424759,,PCD,2017Dec31,Yes,Yes,,2.0,10.1200/JCO.2018.36.15_suppl.9050 ,,,Overall Response Rate,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8219.0,EGFR,EGFR_G719 or EGFR_L861Q or EGFR_S768I,51766344 + 51768106,,p.G719X + p.L861Q + p.S768I,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Osimertinib,,Unknown,NCT03424759,,PCD,2017Dec31,Yes,Yes,,2.0,10.1200/JCO.2018.36.15_suppl.9050 ,,,Overall Response Rate,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8301.0,EGFR,EGFR_L861Q,51766344,,p.L861Q,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT03424759,,PCD,2017Dec31,Yes,Yes,,2.0,10.1200/JCO.2018.36.15_suppl.9050 ,,,Overall Response Rate,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8302.0,EGFR,EGFR_L861Q,51766344,,p.L861Q,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT03424759,,PCD,2017Dec31,Yes,Yes,,2.0,10.1200/JCO.2018.36.15_suppl.9050 ,,,Overall Response Rate,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8303.0,EGFR,EGFR_L861Q,51766344,,p.L861Q,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT03424759,,PCD,2017Dec31,Yes,Yes,,2.0,10.1200/JCO.2018.36.15_suppl.9050 ,,,Overall Response Rate,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8304.0,EGFR,EGFR_L861Q,51766344,,p.L861Q,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT03424759,,PCD,2017Dec31,Yes,Yes,,2.0,10.1200/JCO.2018.36.15_suppl.9050 ,,,Overall Response Rate,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8305.0,EGFR,EGFR_L861Q,51766344,,p.L861Q,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT03424759,,PCD,2017Dec31,Yes,Yes,,2.0,10.1200/JCO.2018.36.15_suppl.9050 ,,,Overall Response Rate,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8306.0,EGFR,EGFR_L861Q,51766344,,p.L861Q,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT03424759,,PCD,2017Dec31,Yes,Yes,,2.0,10.1200/JCO.2018.36.15_suppl.9050 ,,,Overall Response Rate,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8307.0,EGFR,EGFR_L861Q,51766344,,p.L861Q,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT03424759,,PCD,2017Dec31,Yes,Yes,,2.0,10.1200/JCO.2018.36.15_suppl.9050 ,,,Overall Response Rate,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8308.0,EGFR,EGFR_L861Q,51766344,,p.L861Q,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT03424759,,PCD,2017Dec31,Yes,Yes,,2.0,10.1200/JCO.2018.36.15_suppl.9050 ,,,Overall Response Rate,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8309.0,EGFR,EGFR_L861Q,51766344,,p.L861Q,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT03424759,,PCD,2017Dec31,Yes,Yes,,2.0,10.1200/JCO.2018.36.15_suppl.9050 ,,,Overall Response Rate,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8328.0,EGFR,EGFR_S768I,51768106,,p.S768I,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT03424759,,PCD,2017Dec31,Yes,Yes,,2.0,10.1200/JCO.2018.36.15_suppl.9050 ,,,Overall Response Rate,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8329.0,EGFR,EGFR_S768I,51768106,,p.S768I,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT03424759,,PCD,2017Dec31,Yes,Yes,,2.0,10.1200/JCO.2018.36.15_suppl.9050 ,,,Overall Response Rate,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8330.0,EGFR,EGFR_S768I,51768106,,p.S768I,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT03424759,,PCD,2017Dec31,Yes,Yes,,2.0,10.1200/JCO.2018.36.15_suppl.9050 ,,,Overall Response Rate,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8331.0,EGFR,EGFR_S768I,51768106,,p.S768I,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT03424759,,PCD,2017Dec31,Yes,Yes,,2.0,10.1200/JCO.2018.36.15_suppl.9050 ,,,Overall Response Rate,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8332.0,EGFR,EGFR_S768I,51768106,,p.S768I,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT03424759,,PCD,2017Dec31,Yes,Yes,,2.0,10.1200/JCO.2018.36.15_suppl.9050 ,,,Overall Response Rate,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8333.0,EGFR,EGFR_S768I,51768106,,p.S768I,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT03424759,,PCD,2017Dec31,Yes,Yes,,2.0,10.1200/JCO.2018.36.15_suppl.9050 ,,,Overall Response Rate,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8334.0,EGFR,EGFR_S768I,51768106,,p.S768I,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT03424759,,PCD,2017Dec31,Yes,Yes,,2.0,10.1200/JCO.2018.36.15_suppl.9050 ,,,Overall Response Rate,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8335.0,EGFR,EGFR_S768I,51768106,,p.S768I,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT03424759,,PCD,2017Dec31,Yes,Yes,,2.0,10.1200/JCO.2018.36.15_suppl.9050 ,,,Overall Response Rate,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8336.0,EGFR,EGFR_S768I,51768106,,p.S768I,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT03424759,,PCD,2017Dec31,Yes,Yes,,2.0,10.1200/JCO.2018.36.15_suppl.9050 ,,,Overall Response Rate,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8355.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Osimertinib,Required,"Active, not recruiting",NCT02151981,AURA3,PCD,2016Apr15,Yes,Yes,,4.0,25923549,Untreated,,Progression free survival,382.0,242.0,140.0,Chemotherapy,65.0,29.0,,<0.001,11.0,4.2,,,10.1,4.4,0.3,0.23-0.41,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8356.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Osimertinib,Required,"Active, not recruiting",NCT02151981,AURA3,PCD,2016Apr15,Yes,Yes,,4.0,25923549,Untreated,,Progression free survival,382.0,242.0,140.0,Chemotherapy,65.0,29.0,,<0.001,11.0,4.2,,,10.1,4.4,0.3,0.23-0.41,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8357.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Osimertinib,Required,"Active, not recruiting",NCT02151981,AURA3,PCD,2016Apr15,Yes,Yes,,4.0,25923549,Untreated,,Progression free survival,382.0,242.0,140.0,Chemotherapy,65.0,29.0,,<0.001,11.0,4.2,,,10.1,4.4,0.3,0.23-0.41,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8358.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Osimertinib,Required,"Active, not recruiting",NCT02151981,AURA3,PCD,2016Apr15,Yes,Yes,,4.0,25923549,Untreated,,Progression free survival,382.0,242.0,140.0,Chemotherapy,65.0,29.0,,<0.001,11.0,4.2,,,10.1,4.4,0.3,0.23-0.41,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8359.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Osimertinib,Required,"Active, not recruiting",NCT02151981,AURA3,PCD,2016Apr15,Yes,Yes,,4.0,25923549,Untreated,,Progression free survival,382.0,242.0,140.0,Chemotherapy,65.0,29.0,,<0.001,11.0,4.2,,,10.1,4.4,0.3,0.23-0.41,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8360.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Osimertinib,Required,"Active, not recruiting",NCT02151981,AURA3,PCD,2016Apr15,Yes,Yes,,4.0,25923549,Untreated,,Progression free survival,382.0,242.0,140.0,Chemotherapy,65.0,29.0,,<0.001,11.0,4.2,,,10.1,4.4,0.3,0.23-0.41,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8361.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Osimertinib,Required,"Active, not recruiting",NCT02151981,AURA3,PCD,2016Apr15,Yes,Yes,,4.0,25923549,Untreated,,Progression free survival,382.0,242.0,140.0,Chemotherapy,65.0,29.0,,<0.001,11.0,4.2,,,10.1,4.4,0.3,0.23-0.41,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8362.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Osimertinib,Required,"Active, not recruiting",NCT02151981,AURA3,PCD,2016Apr15,Yes,Yes,,4.0,25923549,Untreated,,Progression free survival,382.0,242.0,140.0,Chemotherapy,65.0,29.0,,<0.001,11.0,4.2,,,10.1,4.4,0.3,0.23-0.41,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8363.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Approved FDA,Osimertinib,Required,"Active, not recruiting",NCT02151981,AURA3,PCD,2016Apr15,Yes,Yes,,4.0,25923549,Untreated,,Progression free survival,382.0,242.0,140.0,Chemotherapy,65.0,29.0,,<0.001,11.0,4.2,,,10.1,4.4,0.3,0.23-0.41,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8562.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT01802632,AURA,PCD,2015May01,Yes,Yes,,4.0,25923549,Previously-treated,,Overall Response Rate,127.0,127.0,,,61.0,21.0,,,,,,,9.6,2.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8563.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT01802632,AURA,PCD,2015May01,Yes,Yes,,4.0,25923549,Previously-treated,,Overall Response Rate,127.0,127.0,,,61.0,21.0,,,,,,,9.6,2.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8564.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT01802632,AURA,PCD,2015May01,Yes,Yes,,4.0,25923549,Previously-treated,,Overall Response Rate,127.0,127.0,,,61.0,21.0,,,,,,,9.6,2.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8565.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT01802632,AURA,PCD,2015May01,Yes,Yes,,4.0,25923549,Previously-treated,,Overall Response Rate,127.0,127.0,,,61.0,21.0,,,,,,,9.6,2.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8566.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT01802632,AURA,PCD,2015May01,Yes,Yes,,4.0,25923549,Previously-treated,,Overall Response Rate,127.0,127.0,,,61.0,21.0,,,,,,,9.6,2.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8567.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT01802632,AURA,PCD,2015May01,Yes,Yes,,4.0,25923549,Previously-treated,,Overall Response Rate,127.0,127.0,,,61.0,21.0,,,,,,,9.6,2.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8568.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT01802632,AURA,PCD,2015May01,Yes,Yes,,4.0,25923549,Previously-treated,,Overall Response Rate,127.0,127.0,,,61.0,21.0,,,,,,,9.6,2.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8569.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT01802632,AURA,PCD,2015May01,Yes,Yes,,4.0,25923549,Previously-treated,,Overall Response Rate,127.0,127.0,,,61.0,21.0,,,,,,,9.6,2.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8570.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT01802632,AURA,PCD,2015May01,Yes,Yes,,4.0,25923549,Previously-treated,,Overall Response Rate,127.0,127.0,,,61.0,21.0,,,,,,,9.6,2.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8895.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT05536505,,ECD,2025Oct01,Yes,No,,4.0,NCT05536505,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",180.0,180.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep27,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8896.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT05536505,,ECD,2025Oct01,Yes,No,,4.0,NCT05536505,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",180.0,180.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep27,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8897.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT05536505,,ECD,2025Oct01,Yes,No,,4.0,NCT05536505,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",180.0,180.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep27,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8898.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT05536505,,ECD,2025Oct01,Yes,No,,4.0,NCT05536505,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",180.0,180.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep27,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8899.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT05536505,,ECD,2025Oct01,Yes,No,,4.0,NCT05536505,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",180.0,180.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep27,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8900.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT05536505,,ECD,2025Oct01,Yes,No,,4.0,NCT05536505,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",180.0,180.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep27,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8901.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT05536505,,ECD,2025Oct01,Yes,No,,4.0,NCT05536505,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",180.0,180.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep27,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8902.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT05536505,,ECD,2025Oct01,Yes,No,,4.0,NCT05536505,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",180.0,180.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep27,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8903.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT05536505,,ECD,2025Oct01,Yes,No,,4.0,NCT05536505,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",180.0,180.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep27,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8904.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT04563871,BLOSSOM,ECD,2023Sep01,Yes,No,,4.0,NCT04563871,,,Overall survival,80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8905.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT04563871,BLOSSOM,ECD,2023Sep01,Yes,No,,4.0,NCT04563871,,,Overall survival,80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8906.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT04563871,BLOSSOM,ECD,2023Sep01,Yes,No,,4.0,NCT04563871,,,Overall survival,80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8907.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT04563871,BLOSSOM,ECD,2023Sep01,Yes,No,,4.0,NCT04563871,,,Overall survival,80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8908.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT04563871,BLOSSOM,ECD,2023Sep01,Yes,No,,4.0,NCT04563871,,,Overall survival,80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8909.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT04563871,BLOSSOM,ECD,2023Sep01,Yes,No,,4.0,NCT04563871,,,Overall survival,80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8910.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT04563871,BLOSSOM,ECD,2023Sep01,Yes,No,,4.0,NCT04563871,,,Overall survival,80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8911.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT04563871,BLOSSOM,ECD,2023Sep01,Yes,No,,4.0,NCT04563871,,,Overall survival,80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8912.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT04563871,BLOSSOM,ECD,2023Sep01,Yes,No,,4.0,NCT04563871,,,Overall survival,80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8913.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02736513,Arm B,ECD,2022Dec31,No,Yes,,1.0,35156036,Previously-treated,,Overall Response Rate,20.0,20.0,,,66.7,,,,,,,,7.6,,,5.3-,,,,,,,94.4,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep12,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8914.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02736513,Arm B,ECD,2022Dec31,No,Yes,,1.0,35156036,Previously-treated,,Overall Response Rate,20.0,20.0,,,66.7,,,,,,,,7.6,,,5.3-,,,,,,,94.4,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep12,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8915.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02736513,Arm B,ECD,2022Dec31,No,Yes,,1.0,35156036,Previously-treated,,Overall Response Rate,20.0,20.0,,,66.7,,,,,,,,7.6,,,5.3-,,,,,,,94.4,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep12,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8916.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02736513,Arm B,ECD,2022Dec31,No,Yes,,1.0,35156036,Previously-treated,,Overall Response Rate,20.0,20.0,,,66.7,,,,,,,,7.6,,,5.3-,,,,,,,94.4,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep12,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8917.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02736513,Arm B,ECD,2022Dec31,No,Yes,,1.0,35156036,Previously-treated,,Overall Response Rate,20.0,20.0,,,66.7,,,,,,,,7.6,,,5.3-,,,,,,,94.4,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep12,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8918.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02736513,Arm B,ECD,2022Dec31,No,Yes,,1.0,35156036,Previously-treated,,Overall Response Rate,20.0,20.0,,,66.7,,,,,,,,7.6,,,5.3-,,,,,,,94.4,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep12,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8919.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02736513,Arm B,ECD,2022Dec31,No,Yes,,1.0,35156036,Previously-treated,,Overall Response Rate,20.0,20.0,,,66.7,,,,,,,,7.6,,,5.3-,,,,,,,94.4,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep12,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8920.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02736513,Arm B,ECD,2022Dec31,No,Yes,,1.0,35156036,Previously-treated,,Overall Response Rate,20.0,20.0,,,66.7,,,,,,,,7.6,,,5.3-,,,,,,,94.4,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep12,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8921.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02736513,Arm B,ECD,2022Dec31,No,Yes,,1.0,35156036,Previously-treated,,Overall Response Rate,20.0,20.0,,,66.7,,,,,,,,7.6,,,5.3-,,,,,,,94.4,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep12,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8922.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT02824952,,ECD,2022Dec01,Yes,No,,4.0,NCT02824952,Untreated,,Overall Response Rate,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8923.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT02824952,,ECD,2022Dec01,Yes,No,,4.0,NCT02824952,Untreated,,Overall Response Rate,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8924.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT02824952,,ECD,2022Dec01,Yes,No,,4.0,NCT02824952,Untreated,,Overall Response Rate,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8925.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT02824952,,ECD,2022Dec01,Yes,No,,4.0,NCT02824952,Untreated,,Overall Response Rate,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8926.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT02824952,,ECD,2022Dec01,Yes,No,,4.0,NCT02824952,Untreated,,Overall Response Rate,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8927.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT02824952,,ECD,2022Dec01,Yes,No,,4.0,NCT02824952,Untreated,,Overall Response Rate,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8928.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT02824952,,ECD,2022Dec01,Yes,No,,4.0,NCT02824952,Untreated,,Overall Response Rate,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8929.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT02824952,,ECD,2022Dec01,Yes,No,,4.0,NCT02824952,Untreated,,Overall Response Rate,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8930.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT02824952,,ECD,2022Dec01,Yes,No,,4.0,NCT02824952,Untreated,,Overall Response Rate,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8931.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT02811354,PLASMA,ECD,2019Feb24,Yes,Yes,,2.0,10.1016/j.jtocrr.2020.100099,Previously-treated,,Overall Response Rate,15.0,15.0,,,53.0,,,,,,,,7.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8932.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT02811354,PLASMA,ECD,2019Feb24,Yes,Yes,,2.0,10.1016/j.jtocrr.2020.100099,Previously-treated,,Overall Response Rate,15.0,15.0,,,53.0,,,,,,,,7.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8933.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT02811354,PLASMA,ECD,2019Feb24,Yes,Yes,,2.0,10.1016/j.jtocrr.2020.100099,Previously-treated,,Overall Response Rate,15.0,15.0,,,53.0,,,,,,,,7.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8934.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT02811354,PLASMA,ECD,2019Feb24,Yes,Yes,,2.0,10.1016/j.jtocrr.2020.100099,Previously-treated,,Overall Response Rate,15.0,15.0,,,53.0,,,,,,,,7.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8935.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT02811354,PLASMA,ECD,2019Feb24,Yes,Yes,,2.0,10.1016/j.jtocrr.2020.100099,Previously-treated,,Overall Response Rate,15.0,15.0,,,53.0,,,,,,,,7.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8936.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT02811354,PLASMA,ECD,2019Feb24,Yes,Yes,,2.0,10.1016/j.jtocrr.2020.100099,Previously-treated,,Overall Response Rate,15.0,15.0,,,53.0,,,,,,,,7.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8937.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT02811354,PLASMA,ECD,2019Feb24,Yes,Yes,,2.0,10.1016/j.jtocrr.2020.100099,Previously-treated,,Overall Response Rate,15.0,15.0,,,53.0,,,,,,,,7.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8938.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT02811354,PLASMA,ECD,2019Feb24,Yes,Yes,,2.0,10.1016/j.jtocrr.2020.100099,Previously-treated,,Overall Response Rate,15.0,15.0,,,53.0,,,,,,,,7.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8939.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT02811354,PLASMA,ECD,2019Feb24,Yes,Yes,,2.0,10.1016/j.jtocrr.2020.100099,Previously-treated,,Overall Response Rate,15.0,15.0,,,53.0,,,,,,,,7.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8940.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02664935,National Lung Matrix Trial Cohort G1,ECD,2023Mar01,Yes,No,,1.0,32669708,,,"ORR, PFS, DOR",10.0,10.0,,,,,,,,,,,15.5,,,8.5-32.6,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8941.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02664935,National Lung Matrix Trial Cohort G1,ECD,2023Mar01,Yes,No,,1.0,32669708,,,"ORR, PFS, DOR",10.0,10.0,,,,,,,,,,,15.5,,,8.5-32.6,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8942.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02664935,National Lung Matrix Trial Cohort G1,ECD,2023Mar01,Yes,No,,1.0,32669708,,,"ORR, PFS, DOR",10.0,10.0,,,,,,,,,,,15.5,,,8.5-32.6,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8943.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02664935,National Lung Matrix Trial Cohort G1,ECD,2023Mar01,Yes,No,,1.0,32669708,,,"ORR, PFS, DOR",10.0,10.0,,,,,,,,,,,15.5,,,8.5-32.6,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8944.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02664935,National Lung Matrix Trial Cohort G1,ECD,2023Mar01,Yes,No,,1.0,32669708,,,"ORR, PFS, DOR",10.0,10.0,,,,,,,,,,,15.5,,,8.5-32.6,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8945.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02664935,National Lung Matrix Trial Cohort G1,ECD,2023Mar01,Yes,No,,1.0,32669708,,,"ORR, PFS, DOR",10.0,10.0,,,,,,,,,,,15.5,,,8.5-32.6,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8946.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02664935,National Lung Matrix Trial Cohort G1,ECD,2023Mar01,Yes,No,,1.0,32669708,,,"ORR, PFS, DOR",10.0,10.0,,,,,,,,,,,15.5,,,8.5-32.6,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8947.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02664935,National Lung Matrix Trial Cohort G1,ECD,2023Mar01,Yes,No,,1.0,32669708,,,"ORR, PFS, DOR",10.0,10.0,,,,,,,,,,,15.5,,,8.5-32.6,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8948.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02664935,National Lung Matrix Trial Cohort G1,ECD,2023Mar01,Yes,No,,1.0,32669708,,,"ORR, PFS, DOR",10.0,10.0,,,,,,,,,,,15.5,,,8.5-32.6,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8949.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Completed,NCT03394118,,PCD,2021Mar11,Yes,No,,4.0,NCT03394118,,,Overall Response Rate,63.0,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8950.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Completed,NCT03394118,,PCD,2021Mar11,Yes,No,,4.0,NCT03394118,,,Overall Response Rate,63.0,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8951.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Completed,NCT03394118,,PCD,2021Mar11,Yes,No,,4.0,NCT03394118,,,Overall Response Rate,63.0,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8952.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Completed,NCT03394118,,PCD,2021Mar11,Yes,No,,4.0,NCT03394118,,,Overall Response Rate,63.0,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8953.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Completed,NCT03394118,,PCD,2021Mar11,Yes,No,,4.0,NCT03394118,,,Overall Response Rate,63.0,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8954.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Completed,NCT03394118,,PCD,2021Mar11,Yes,No,,4.0,NCT03394118,,,Overall Response Rate,63.0,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8955.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Completed,NCT03394118,,PCD,2021Mar11,Yes,No,,4.0,NCT03394118,,,Overall Response Rate,63.0,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8956.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Completed,NCT03394118,,PCD,2021Mar11,Yes,No,,4.0,NCT03394118,,,Overall Response Rate,63.0,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8957.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Completed,NCT03394118,,PCD,2021Mar11,Yes,No,,4.0,NCT03394118,,,Overall Response Rate,63.0,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Nov01,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8958.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02094261,AURA2,PCD,2015May01,Yes,Yes,,4.0,NCT02094261,Previously-treated,,Overall Response Rate,199.0,199.0,,,70.9,,,,7.8,,,,8.6,,,,,,,,,,91.5,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8959.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02094261,AURA2,PCD,2015May01,Yes,Yes,,4.0,NCT02094261,Previously-treated,,Overall Response Rate,199.0,199.0,,,70.9,,,,7.8,,,,8.6,,,,,,,,,,91.5,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8960.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02094261,AURA2,PCD,2015May01,Yes,Yes,,4.0,NCT02094261,Previously-treated,,Overall Response Rate,199.0,199.0,,,70.9,,,,7.8,,,,8.6,,,,,,,,,,91.5,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8961.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02094261,AURA2,PCD,2015May01,Yes,Yes,,4.0,NCT02094261,Previously-treated,,Overall Response Rate,199.0,199.0,,,70.9,,,,7.8,,,,8.6,,,,,,,,,,91.5,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8962.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02094261,AURA2,PCD,2015May01,Yes,Yes,,4.0,NCT02094261,Previously-treated,,Overall Response Rate,199.0,199.0,,,70.9,,,,7.8,,,,8.6,,,,,,,,,,91.5,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8963.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02094261,AURA2,PCD,2015May01,Yes,Yes,,4.0,NCT02094261,Previously-treated,,Overall Response Rate,199.0,199.0,,,70.9,,,,7.8,,,,8.6,,,,,,,,,,91.5,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8964.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02094261,AURA2,PCD,2015May01,Yes,Yes,,4.0,NCT02094261,Previously-treated,,Overall Response Rate,199.0,199.0,,,70.9,,,,7.8,,,,8.6,,,,,,,,,,91.5,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8965.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02094261,AURA2,PCD,2015May01,Yes,Yes,,4.0,NCT02094261,Previously-treated,,Overall Response Rate,199.0,199.0,,,70.9,,,,7.8,,,,8.6,,,,,,,,,,91.5,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8966.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02094261,AURA2,PCD,2015May01,Yes,Yes,,4.0,NCT02094261,Previously-treated,,Overall Response Rate,199.0,199.0,,,70.9,,,,7.8,,,,8.6,,,,,,,,,,91.5,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8967.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02442349,AURA17,PCD,2016Mar04,Yes,Yes,,4.0,NCT02442349,Previously-treated,,Overall Response Rate,171.0,171.0,,,60.2,,,,,,,,,,,,,,,,,,88.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8968.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02442349,AURA17,PCD,2016Mar04,Yes,Yes,,4.0,NCT02442349,Previously-treated,,Overall Response Rate,171.0,171.0,,,60.2,,,,,,,,,,,,,,,,,,88.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8969.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02442349,AURA17,PCD,2016Mar04,Yes,Yes,,4.0,NCT02442349,Previously-treated,,Overall Response Rate,171.0,171.0,,,60.2,,,,,,,,,,,,,,,,,,88.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8970.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02442349,AURA17,PCD,2016Mar04,Yes,Yes,,4.0,NCT02442349,Previously-treated,,Overall Response Rate,171.0,171.0,,,60.2,,,,,,,,,,,,,,,,,,88.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8971.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02442349,AURA17,PCD,2016Mar04,Yes,Yes,,4.0,NCT02442349,Previously-treated,,Overall Response Rate,171.0,171.0,,,60.2,,,,,,,,,,,,,,,,,,88.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8972.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02442349,AURA17,PCD,2016Mar04,Yes,Yes,,4.0,NCT02442349,Previously-treated,,Overall Response Rate,171.0,171.0,,,60.2,,,,,,,,,,,,,,,,,,88.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8973.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02442349,AURA17,PCD,2016Mar04,Yes,Yes,,4.0,NCT02442349,Previously-treated,,Overall Response Rate,171.0,171.0,,,60.2,,,,,,,,,,,,,,,,,,88.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8974.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02442349,AURA17,PCD,2016Mar04,Yes,Yes,,4.0,NCT02442349,Previously-treated,,Overall Response Rate,171.0,171.0,,,60.2,,,,,,,,,,,,,,,,,,88.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8975.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02442349,AURA17,PCD,2016Mar04,Yes,Yes,,4.0,NCT02442349,Previously-treated,,Overall Response Rate,171.0,171.0,,,60.2,,,,,,,,,,,,,,,,,,88.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8976.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Completed,NCT02841579,AZENT,PCD,2018Dec01,Yes,Yes,,8.0,https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004828-66/results,Untreated,,Overall Response Rate,22.0,22.0,,,77.3,,,<0.025,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct29,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8977.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Completed,NCT02841579,AZENT,PCD,2018Dec01,Yes,Yes,,8.0,https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004828-66/results,Untreated,,Overall Response Rate,22.0,22.0,,,77.3,,,<0.025,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct29,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8978.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Completed,NCT02841579,AZENT,PCD,2018Dec01,Yes,Yes,,8.0,https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004828-66/results,Untreated,,Overall Response Rate,22.0,22.0,,,77.3,,,<0.025,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct29,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8979.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Completed,NCT02841579,AZENT,PCD,2018Dec01,Yes,Yes,,8.0,https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004828-66/results,Untreated,,Overall Response Rate,22.0,22.0,,,77.3,,,<0.025,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct29,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8980.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Completed,NCT02841579,AZENT,PCD,2018Dec01,Yes,Yes,,8.0,https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004828-66/results,Untreated,,Overall Response Rate,22.0,22.0,,,77.3,,,<0.025,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct29,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8981.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Completed,NCT02841579,AZENT,PCD,2018Dec01,Yes,Yes,,8.0,https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004828-66/results,Untreated,,Overall Response Rate,22.0,22.0,,,77.3,,,<0.025,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct29,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8982.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Completed,NCT02841579,AZENT,PCD,2018Dec01,Yes,Yes,,8.0,https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004828-66/results,Untreated,,Overall Response Rate,22.0,22.0,,,77.3,,,<0.025,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct29,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8983.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Completed,NCT02841579,AZENT,PCD,2018Dec01,Yes,Yes,,8.0,https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004828-66/results,Untreated,,Overall Response Rate,22.0,22.0,,,77.3,,,<0.025,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct29,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8984.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Completed,NCT02841579,AZENT,PCD,2018Dec01,Yes,Yes,,8.0,https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004828-66/results,Untreated,,Overall Response Rate,22.0,22.0,,,77.3,,,<0.025,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Oct29,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8985.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02856893,APPLE,ECD,2023Feb01,Yes,No,,4.0,NCT02856893,,,Progression free survival,156.0,156.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8986.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02856893,APPLE,ECD,2023Feb01,Yes,No,,4.0,NCT02856893,,,Progression free survival,156.0,156.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8987.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02856893,APPLE,ECD,2023Feb01,Yes,No,,4.0,NCT02856893,,,Progression free survival,156.0,156.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8988.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02856893,APPLE,ECD,2023Feb01,Yes,No,,4.0,NCT02856893,,,Progression free survival,156.0,156.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8989.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02856893,APPLE,ECD,2023Feb01,Yes,No,,4.0,NCT02856893,,,Progression free survival,156.0,156.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8990.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02856893,APPLE,ECD,2023Feb01,Yes,No,,4.0,NCT02856893,,,Progression free survival,156.0,156.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8991.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02856893,APPLE,ECD,2023Feb01,Yes,No,,4.0,NCT02856893,,,Progression free survival,156.0,156.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8992.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02856893,APPLE,ECD,2023Feb01,Yes,No,,4.0,NCT02856893,,,Progression free survival,156.0,156.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8993.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02856893,APPLE,ECD,2023Feb01,Yes,No,,4.0,NCT02856893,,,Progression free survival,156.0,156.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8994.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT02504346,TREM,ECD,2021Jan01,Comparison with wt,Yes,,1.0,32200138,Previously-treated,,Overall Response Rate,167.0,117.0,50.0,,60.0,28.0,,<0.001,11.8,10.7,,0.229,10.8,5.1,0.62,0.43-0.88,0.007,,,,,,91.0,64.0,<0.001,22.5,13.4,0.55,0.37-0.81,0.002,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8995.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT02504346,TREM,ECD,2021Jan01,Comparison with wt,Yes,,1.0,32200138,Previously-treated,,Overall Response Rate,167.0,117.0,50.0,,60.0,28.0,,<0.001,11.8,10.7,,0.229,10.8,5.1,0.62,0.43-0.88,0.007,,,,,,91.0,64.0,<0.001,22.5,13.4,0.55,0.37-0.81,0.002,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8996.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT02504346,TREM,ECD,2021Jan01,Comparison with wt,Yes,,1.0,32200138,Previously-treated,,Overall Response Rate,167.0,117.0,50.0,,60.0,28.0,,<0.001,11.8,10.7,,0.229,10.8,5.1,0.62,0.43-0.88,0.007,,,,,,91.0,64.0,<0.001,22.5,13.4,0.55,0.37-0.81,0.002,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8997.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT02504346,TREM,ECD,2021Jan01,Comparison with wt,Yes,,1.0,32200138,Previously-treated,,Overall Response Rate,167.0,117.0,50.0,,60.0,28.0,,<0.001,11.8,10.7,,0.229,10.8,5.1,0.62,0.43-0.88,0.007,,,,,,91.0,64.0,<0.001,22.5,13.4,0.55,0.37-0.81,0.002,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8998.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT02504346,TREM,ECD,2021Jan01,Comparison with wt,Yes,,1.0,32200138,Previously-treated,,Overall Response Rate,167.0,117.0,50.0,,60.0,28.0,,<0.001,11.8,10.7,,0.229,10.8,5.1,0.62,0.43-0.88,0.007,,,,,,91.0,64.0,<0.001,22.5,13.4,0.55,0.37-0.81,0.002,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
8999.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT02504346,TREM,ECD,2021Jan01,Comparison with wt,Yes,,1.0,32200138,Previously-treated,,Overall Response Rate,167.0,117.0,50.0,,60.0,28.0,,<0.001,11.8,10.7,,0.229,10.8,5.1,0.62,0.43-0.88,0.007,,,,,,91.0,64.0,<0.001,22.5,13.4,0.55,0.37-0.81,0.002,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9000.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT02504346,TREM,ECD,2021Jan01,Comparison with wt,Yes,,1.0,32200138,Previously-treated,,Overall Response Rate,167.0,117.0,50.0,,60.0,28.0,,<0.001,11.8,10.7,,0.229,10.8,5.1,0.62,0.43-0.88,0.007,,,,,,91.0,64.0,<0.001,22.5,13.4,0.55,0.37-0.81,0.002,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9001.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT02504346,TREM,ECD,2021Jan01,Comparison with wt,Yes,,1.0,32200138,Previously-treated,,Overall Response Rate,167.0,117.0,50.0,,60.0,28.0,,<0.001,11.8,10.7,,0.229,10.8,5.1,0.62,0.43-0.88,0.007,,,,,,91.0,64.0,<0.001,22.5,13.4,0.55,0.37-0.81,0.002,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9002.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Unknown,NCT02504346,TREM,ECD,2021Jan01,Comparison with wt,Yes,,1.0,32200138,Previously-treated,,Overall Response Rate,167.0,117.0,50.0,,60.0,28.0,,<0.001,11.8,10.7,,0.229,10.8,5.1,0.62,0.43-0.88,0.007,,,,,,91.0,64.0,<0.001,22.5,13.4,0.55,0.37-0.81,0.002,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9003.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,"Active, not recruiting",NCT03257124,BM cohort,PCD,2019Aug31,Yes,Yes,,1.0,32634610,Previously-treated,,Overall Response Rate,40.0,40.0,,,55.0,,,,,,,,7.6,,,5.0-16.6,,,,,,,77.5,,,16.9,,,7.9-,,,4.0,18.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9004.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,"Active, not recruiting",NCT03257124,BM cohort,PCD,2019Aug31,Yes,Yes,,1.0,32634610,Previously-treated,,Overall Response Rate,40.0,40.0,,,55.0,,,,,,,,7.6,,,5.0-16.6,,,,,,,77.5,,,16.9,,,7.9-,,,4.0,18.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9005.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,"Active, not recruiting",NCT03257124,BM cohort,PCD,2019Aug31,Yes,Yes,,1.0,32634610,Previously-treated,,Overall Response Rate,40.0,40.0,,,55.0,,,,,,,,7.6,,,5.0-16.6,,,,,,,77.5,,,16.9,,,7.9-,,,4.0,18.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9006.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,"Active, not recruiting",NCT03257124,BM cohort,PCD,2019Aug31,Yes,Yes,,1.0,32634610,Previously-treated,,Overall Response Rate,40.0,40.0,,,55.0,,,,,,,,7.6,,,5.0-16.6,,,,,,,77.5,,,16.9,,,7.9-,,,4.0,18.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9007.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,"Active, not recruiting",NCT03257124,BM cohort,PCD,2019Aug31,Yes,Yes,,1.0,32634610,Previously-treated,,Overall Response Rate,40.0,40.0,,,55.0,,,,,,,,7.6,,,5.0-16.6,,,,,,,77.5,,,16.9,,,7.9-,,,4.0,18.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9008.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,"Active, not recruiting",NCT03257124,BM cohort,PCD,2019Aug31,Yes,Yes,,1.0,32634610,Previously-treated,,Overall Response Rate,40.0,40.0,,,55.0,,,,,,,,7.6,,,5.0-16.6,,,,,,,77.5,,,16.9,,,7.9-,,,4.0,18.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9009.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,"Active, not recruiting",NCT03257124,BM cohort,PCD,2019Aug31,Yes,Yes,,1.0,32634610,Previously-treated,,Overall Response Rate,40.0,40.0,,,55.0,,,,,,,,7.6,,,5.0-16.6,,,,,,,77.5,,,16.9,,,7.9-,,,4.0,18.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9010.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,"Active, not recruiting",NCT03257124,BM cohort,PCD,2019Aug31,Yes,Yes,,1.0,32634610,Previously-treated,,Overall Response Rate,40.0,40.0,,,55.0,,,,,,,,7.6,,,5.0-16.6,,,,,,,77.5,,,16.9,,,7.9-,,,4.0,18.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9011.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,"Active, not recruiting",NCT03257124,BM cohort,PCD,2019Aug31,Yes,Yes,,1.0,32634610,Previously-treated,,Overall Response Rate,40.0,40.0,,,55.0,,,,,,,,7.6,,,5.0-16.6,,,,,,,77.5,,,16.9,,,7.9-,,,4.0,18.0,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9057.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,"Active, not recruiting",NCT03257124,LM cohort,PCD,2019Aug31,Yes,Yes,,1.0,32634610,Previously-treated,,Overall survival,40.0,40.0,,,,,,,,,,,8.0,,,7.2-,,,,,,,92.5,,,13.3,,,9.1-,,,5.0,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9058.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,"Active, not recruiting",NCT03257124,LM cohort,PCD,2019Aug31,Yes,Yes,,1.0,32634610,Previously-treated,,Overall survival,40.0,40.0,,,,,,,,,,,8.0,,,7.2-,,,,,,,92.5,,,13.3,,,9.1-,,,5.0,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9059.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,"Active, not recruiting",NCT03257124,LM cohort,PCD,2019Aug31,Yes,Yes,,1.0,32634610,Previously-treated,,Overall survival,40.0,40.0,,,,,,,,,,,8.0,,,7.2-,,,,,,,92.5,,,13.3,,,9.1-,,,5.0,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9060.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,"Active, not recruiting",NCT03257124,LM cohort,PCD,2019Aug31,Yes,Yes,,1.0,32634610,Previously-treated,,Overall survival,40.0,40.0,,,,,,,,,,,8.0,,,7.2-,,,,,,,92.5,,,13.3,,,9.1-,,,5.0,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9061.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,"Active, not recruiting",NCT03257124,LM cohort,PCD,2019Aug31,Yes,Yes,,1.0,32634610,Previously-treated,,Overall survival,40.0,40.0,,,,,,,,,,,8.0,,,7.2-,,,,,,,92.5,,,13.3,,,9.1-,,,5.0,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9062.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,"Active, not recruiting",NCT03257124,LM cohort,PCD,2019Aug31,Yes,Yes,,1.0,32634610,Previously-treated,,Overall survival,40.0,40.0,,,,,,,,,,,8.0,,,7.2-,,,,,,,92.5,,,13.3,,,9.1-,,,5.0,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9063.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,"Active, not recruiting",NCT03257124,LM cohort,PCD,2019Aug31,Yes,Yes,,1.0,32634610,Previously-treated,,Overall survival,40.0,40.0,,,,,,,,,,,8.0,,,7.2-,,,,,,,92.5,,,13.3,,,9.1-,,,5.0,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9064.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,"Active, not recruiting",NCT03257124,LM cohort,PCD,2019Aug31,Yes,Yes,,1.0,32634610,Previously-treated,,Overall survival,40.0,40.0,,,,,,,,,,,8.0,,,7.2-,,,,,,,92.5,,,13.3,,,9.1-,,,5.0,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9065.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,"Active, not recruiting",NCT03257124,LM cohort,PCD,2019Aug31,Yes,Yes,,1.0,32634610,Previously-treated,,Overall survival,40.0,40.0,,,,,,,,,,,8.0,,,7.2-,,,,,,,92.5,,,13.3,,,9.1-,,,5.0,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9066.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Completed,NCT02474355,ASTRIS,PCD,2019Apr18,Yes,Yes,,4.0,NCT02474355,,,Overall survival,3014.0,3014.0,,,,,,,,,,,11.1,,,11.0-12.0,,,,,,,,,,22.8,,,21.6-23.8,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9067.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Completed,NCT02474355,ASTRIS,PCD,2019Apr18,Yes,Yes,,4.0,NCT02474355,,,Overall survival,3014.0,3014.0,,,,,,,,,,,11.1,,,11.0-12.0,,,,,,,,,,22.8,,,21.6-23.8,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9068.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Completed,NCT02474355,ASTRIS,PCD,2019Apr18,Yes,Yes,,4.0,NCT02474355,,,Overall survival,3014.0,3014.0,,,,,,,,,,,11.1,,,11.0-12.0,,,,,,,,,,22.8,,,21.6-23.8,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9069.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Completed,NCT02474355,ASTRIS,PCD,2019Apr18,Yes,Yes,,4.0,NCT02474355,,,Overall survival,3014.0,3014.0,,,,,,,,,,,11.1,,,11.0-12.0,,,,,,,,,,22.8,,,21.6-23.8,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9070.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Completed,NCT02474355,ASTRIS,PCD,2019Apr18,Yes,Yes,,4.0,NCT02474355,,,Overall survival,3014.0,3014.0,,,,,,,,,,,11.1,,,11.0-12.0,,,,,,,,,,22.8,,,21.6-23.8,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9071.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Completed,NCT02474355,ASTRIS,PCD,2019Apr18,Yes,Yes,,4.0,NCT02474355,,,Overall survival,3014.0,3014.0,,,,,,,,,,,11.1,,,11.0-12.0,,,,,,,,,,22.8,,,21.6-23.8,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9072.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Completed,NCT02474355,ASTRIS,PCD,2019Apr18,Yes,Yes,,4.0,NCT02474355,,,Overall survival,3014.0,3014.0,,,,,,,,,,,11.1,,,11.0-12.0,,,,,,,,,,22.8,,,21.6-23.8,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9073.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Completed,NCT02474355,ASTRIS,PCD,2019Apr18,Yes,Yes,,4.0,NCT02474355,,,Overall survival,3014.0,3014.0,,,,,,,,,,,11.1,,,11.0-12.0,,,,,,,,,,22.8,,,21.6-23.8,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9074.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Completed,NCT02474355,ASTRIS,PCD,2019Apr18,Yes,Yes,,4.0,NCT02474355,,,Overall survival,3014.0,3014.0,,,,,,,,,,,11.1,,,11.0-12.0,,,,,,,,,,22.8,,,21.6-23.8,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9075.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Unknown,NCT02972333,APOLLO,ECD,2019Sep01,Yes,Yes,,1.0,32817079,Previously-treated,,Progression free survival,38.0,38.0,,,39.4,,,,,,,,8.4,,,5.8-10.9,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9076.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Unknown,NCT02972333,APOLLO,ECD,2019Sep01,Yes,Yes,,1.0,32817079,Previously-treated,,Progression free survival,38.0,38.0,,,39.4,,,,,,,,8.4,,,5.8-10.9,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9077.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Unknown,NCT02972333,APOLLO,ECD,2019Sep01,Yes,Yes,,1.0,32817079,Previously-treated,,Progression free survival,38.0,38.0,,,39.4,,,,,,,,8.4,,,5.8-10.9,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9078.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Unknown,NCT02972333,APOLLO,ECD,2019Sep01,Yes,Yes,,1.0,32817079,Previously-treated,,Progression free survival,38.0,38.0,,,39.4,,,,,,,,8.4,,,5.8-10.9,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9079.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Unknown,NCT02972333,APOLLO,ECD,2019Sep01,Yes,Yes,,1.0,32817079,Previously-treated,,Progression free survival,38.0,38.0,,,39.4,,,,,,,,8.4,,,5.8-10.9,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9080.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Unknown,NCT02972333,APOLLO,ECD,2019Sep01,Yes,Yes,,1.0,32817079,Previously-treated,,Progression free survival,38.0,38.0,,,39.4,,,,,,,,8.4,,,5.8-10.9,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9081.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Unknown,NCT02972333,APOLLO,ECD,2019Sep01,Yes,Yes,,1.0,32817079,Previously-treated,,Progression free survival,38.0,38.0,,,39.4,,,,,,,,8.4,,,5.8-10.9,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9082.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Unknown,NCT02972333,APOLLO,ECD,2019Sep01,Yes,Yes,,1.0,32817079,Previously-treated,,Progression free survival,38.0,38.0,,,39.4,,,,,,,,8.4,,,5.8-10.9,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9083.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Unknown,NCT02972333,APOLLO,ECD,2019Sep01,Yes,Yes,,1.0,32817079,Previously-treated,,Progression free survival,38.0,38.0,,,39.4,,,,,,,,8.4,,,5.8-10.9,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9084.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Completed,NCT02959749,,PCD,2017Oct01,Yes,Yes,,1.0,29858027,Previously-treated,,Progression free survival,147.0,74.0,73.0,Bevacizumab + Docetaxel,,,,,,,,,10.2,2.95,0.23,0.12-0.38,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9085.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Completed,NCT02959749,,PCD,2017Oct01,Yes,Yes,,1.0,29858027,Previously-treated,,Progression free survival,147.0,74.0,73.0,Bevacizumab + Docetaxel,,,,,,,,,10.2,2.95,0.23,0.12-0.38,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9086.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Completed,NCT02959749,,PCD,2017Oct01,Yes,Yes,,1.0,29858027,Previously-treated,,Progression free survival,147.0,74.0,73.0,Bevacizumab + Docetaxel,,,,,,,,,10.2,2.95,0.23,0.12-0.38,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9087.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Completed,NCT02959749,,PCD,2017Oct01,Yes,Yes,,1.0,29858027,Previously-treated,,Progression free survival,147.0,74.0,73.0,Bevacizumab + Docetaxel,,,,,,,,,10.2,2.95,0.23,0.12-0.38,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9088.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Completed,NCT02959749,,PCD,2017Oct01,Yes,Yes,,1.0,29858027,Previously-treated,,Progression free survival,147.0,74.0,73.0,Bevacizumab + Docetaxel,,,,,,,,,10.2,2.95,0.23,0.12-0.38,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9089.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Completed,NCT02959749,,PCD,2017Oct01,Yes,Yes,,1.0,29858027,Previously-treated,,Progression free survival,147.0,74.0,73.0,Bevacizumab + Docetaxel,,,,,,,,,10.2,2.95,0.23,0.12-0.38,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9090.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Completed,NCT02959749,,PCD,2017Oct01,Yes,Yes,,1.0,29858027,Previously-treated,,Progression free survival,147.0,74.0,73.0,Bevacizumab + Docetaxel,,,,,,,,,10.2,2.95,0.23,0.12-0.38,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9091.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Completed,NCT02959749,,PCD,2017Oct01,Yes,Yes,,1.0,29858027,Previously-treated,,Progression free survival,147.0,74.0,73.0,Bevacizumab + Docetaxel,,,,,,,,,10.2,2.95,0.23,0.12-0.38,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9092.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 3,Osimertinib,,Completed,NCT02959749,,PCD,2017Oct01,Yes,Yes,,1.0,29858027,Previously-treated,,Progression free survival,147.0,74.0,73.0,Bevacizumab + Docetaxel,,,,,,,,,10.2,2.95,0.23,0.12-0.38,<0.001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9093.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 4,Osimertinib,,Completed,NCT03853551,,PCD,2020Apr15,Yes,Yes,SAE 11.67%,4.0,NCT03853551,,,Maximum tolerated dose/toxicity,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9094.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 4,Osimertinib,,Completed,NCT03853551,,PCD,2020Apr15,Yes,Yes,SAE 11.67%,4.0,NCT03853551,,,Maximum tolerated dose/toxicity,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9095.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 4,Osimertinib,,Completed,NCT03853551,,PCD,2020Apr15,Yes,Yes,SAE 11.67%,4.0,NCT03853551,,,Maximum tolerated dose/toxicity,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9096.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 4,Osimertinib,,Completed,NCT03853551,,PCD,2020Apr15,Yes,Yes,SAE 11.67%,4.0,NCT03853551,,,Maximum tolerated dose/toxicity,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9097.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 4,Osimertinib,,Completed,NCT03853551,,PCD,2020Apr15,Yes,Yes,SAE 11.67%,4.0,NCT03853551,,,Maximum tolerated dose/toxicity,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9098.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 4,Osimertinib,,Completed,NCT03853551,,PCD,2020Apr15,Yes,Yes,SAE 11.67%,4.0,NCT03853551,,,Maximum tolerated dose/toxicity,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9099.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 4,Osimertinib,,Completed,NCT03853551,,PCD,2020Apr15,Yes,Yes,SAE 11.67%,4.0,NCT03853551,,,Maximum tolerated dose/toxicity,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9100.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 4,Osimertinib,,Completed,NCT03853551,,PCD,2020Apr15,Yes,Yes,SAE 11.67%,4.0,NCT03853551,,,Maximum tolerated dose/toxicity,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
9101.0,EGFR,EGFR_T790M,51765492,,p.T790M,lung / carcinoma / non small cell carcinoma,1.0,Phase 4,Osimertinib,,Completed,NCT03853551,,PCD,2020Apr15,Yes,Yes,SAE 11.67%,4.0,NCT03853551,,,Maximum tolerated dose/toxicity,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11055.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Not yet recruiting,NCT05526755,TARGET,ECD,2029Jun19,Yes,No,,4.0,NCT05526755,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",180.0,180.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep27,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11056.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Not yet recruiting,NCT05526755,TARGET,ECD,2029Jun19,Yes,No,,4.0,NCT05526755,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",180.0,180.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep27,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11057.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Not yet recruiting,NCT05526755,TARGET,ECD,2029Jun19,Yes,No,,4.0,NCT05526755,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",180.0,180.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep27,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11058.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Not yet recruiting,NCT05526755,TARGET,ECD,2029Jun19,Yes,No,,4.0,NCT05526755,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",180.0,180.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep27,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11059.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Not yet recruiting,NCT05526755,TARGET,ECD,2029Jun19,Yes,No,,4.0,NCT05526755,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",180.0,180.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep27,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11060.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Not yet recruiting,NCT05526755,TARGET,ECD,2029Jun19,Yes,No,,4.0,NCT05526755,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",180.0,180.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep27,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11061.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Not yet recruiting,NCT05526755,TARGET,ECD,2029Jun19,Yes,No,,4.0,NCT05526755,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",180.0,180.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep27,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11062.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Not yet recruiting,NCT05526755,TARGET,ECD,2029Jun19,Yes,No,,4.0,NCT05526755,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",180.0,180.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep27,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11063.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Not yet recruiting,NCT05526755,TARGET,ECD,2029Jun19,Yes,No,,4.0,NCT05526755,,,"Disease free survival, relapse free survival, regression free survival, recurrence free survival",180.0,180.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep27,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11064.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03804580,,ECD,2023Aug31,No,No,,4.0,NCT03804580,Untreated,,Overall Response Rate,100.0,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11065.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03804580,,ECD,2023Aug31,No,No,,4.0,NCT03804580,Untreated,,Overall Response Rate,100.0,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11066.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03804580,,ECD,2023Aug31,No,No,,4.0,NCT03804580,Untreated,,Overall Response Rate,100.0,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11067.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03804580,,ECD,2023Aug31,No,No,,4.0,NCT03804580,Untreated,,Overall Response Rate,100.0,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11068.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03804580,,ECD,2023Aug31,No,No,,4.0,NCT03804580,Untreated,,Overall Response Rate,100.0,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11069.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03804580,,ECD,2023Aug31,No,No,,4.0,NCT03804580,Untreated,,Overall Response Rate,100.0,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11070.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03804580,,ECD,2023Aug31,No,No,,4.0,NCT03804580,Untreated,,Overall Response Rate,100.0,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11071.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03804580,,ECD,2023Aug31,No,No,,4.0,NCT03804580,Untreated,,Overall Response Rate,100.0,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11072.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03804580,,ECD,2023Aug31,No,No,,4.0,NCT03804580,Untreated,,Overall Response Rate,100.0,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11073.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Recruiting,NCT03865511,MELROSE,ECD,2024Apr01,Yes,No,,4.0,NCT03865511,,,Biomarker discovery,66.0,66.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11074.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Recruiting,NCT03865511,MELROSE,ECD,2024Apr01,Yes,No,,4.0,NCT03865511,,,Biomarker discovery,66.0,66.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11075.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Recruiting,NCT03865511,MELROSE,ECD,2024Apr01,Yes,No,,4.0,NCT03865511,,,Biomarker discovery,66.0,66.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11076.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Recruiting,NCT03865511,MELROSE,ECD,2024Apr01,Yes,No,,4.0,NCT03865511,,,Biomarker discovery,66.0,66.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11077.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Recruiting,NCT03865511,MELROSE,ECD,2024Apr01,Yes,No,,4.0,NCT03865511,,,Biomarker discovery,66.0,66.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11078.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Recruiting,NCT03865511,MELROSE,ECD,2024Apr01,Yes,No,,4.0,NCT03865511,,,Biomarker discovery,66.0,66.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11079.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Recruiting,NCT03865511,MELROSE,ECD,2024Apr01,Yes,No,,4.0,NCT03865511,,,Biomarker discovery,66.0,66.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11080.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Recruiting,NCT03865511,MELROSE,ECD,2024Apr01,Yes,No,,4.0,NCT03865511,,,Biomarker discovery,66.0,66.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11081.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Recruiting,NCT03865511,MELROSE,ECD,2024Apr01,Yes,No,,4.0,NCT03865511,,,Biomarker discovery,66.0,66.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11082.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Unknown,NCT03460275,,ECD,2020Dec01,Yes,No,,4.0,NCT03460275,,,Clinical activity,100.0,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11083.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Unknown,NCT03460275,,ECD,2020Dec01,Yes,No,,4.0,NCT03460275,,,Clinical activity,100.0,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11084.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Unknown,NCT03460275,,ECD,2020Dec01,Yes,No,,4.0,NCT03460275,,,Clinical activity,100.0,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11085.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Unknown,NCT03460275,,ECD,2020Dec01,Yes,No,,4.0,NCT03460275,,,Clinical activity,100.0,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11086.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Unknown,NCT03460275,,ECD,2020Dec01,Yes,No,,4.0,NCT03460275,,,Clinical activity,100.0,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11087.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Unknown,NCT03460275,,ECD,2020Dec01,Yes,No,,4.0,NCT03460275,,,Clinical activity,100.0,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11088.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Unknown,NCT03460275,,ECD,2020Dec01,Yes,No,,4.0,NCT03460275,,,Clinical activity,100.0,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11089.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Unknown,NCT03460275,,ECD,2020Dec01,Yes,No,,4.0,NCT03460275,,,Clinical activity,100.0,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11090.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Unknown,NCT03460275,,ECD,2020Dec01,Yes,No,,4.0,NCT03460275,,,Clinical activity,100.0,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11091.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02736513,Arm A,ECD,2022Dec31,No,Yes,,1.0,35156036,Untreated,,Overall Response Rate,20.0,20.0,,,84.2,,,,,,,,11.8,,,7.7-,,,,,,,94.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep12,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11092.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02736513,Arm A,ECD,2022Dec31,No,Yes,,1.0,35156036,Untreated,,Overall Response Rate,20.0,20.0,,,84.2,,,,,,,,11.8,,,7.7-,,,,,,,94.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep12,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11093.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02736513,Arm A,ECD,2022Dec31,No,Yes,,1.0,35156036,Untreated,,Overall Response Rate,20.0,20.0,,,84.2,,,,,,,,11.8,,,7.7-,,,,,,,94.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep12,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11094.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02736513,Arm A,ECD,2022Dec31,No,Yes,,1.0,35156036,Untreated,,Overall Response Rate,20.0,20.0,,,84.2,,,,,,,,11.8,,,7.7-,,,,,,,94.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep12,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11095.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02736513,Arm A,ECD,2022Dec31,No,Yes,,1.0,35156036,Untreated,,Overall Response Rate,20.0,20.0,,,84.2,,,,,,,,11.8,,,7.7-,,,,,,,94.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep12,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11096.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02736513,Arm A,ECD,2022Dec31,No,Yes,,1.0,35156036,Untreated,,Overall Response Rate,20.0,20.0,,,84.2,,,,,,,,11.8,,,7.7-,,,,,,,94.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep12,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11097.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02736513,Arm A,ECD,2022Dec31,No,Yes,,1.0,35156036,Untreated,,Overall Response Rate,20.0,20.0,,,84.2,,,,,,,,11.8,,,7.7-,,,,,,,94.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep12,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11098.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02736513,Arm A,ECD,2022Dec31,No,Yes,,1.0,35156036,Untreated,,Overall Response Rate,20.0,20.0,,,84.2,,,,,,,,11.8,,,7.7-,,,,,,,94.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep12,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11099.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT02736513,Arm A,ECD,2022Dec31,No,Yes,,1.0,35156036,Untreated,,Overall Response Rate,20.0,20.0,,,84.2,,,,,,,,11.8,,,7.7-,,,,,,,94.7,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Sep12,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11100.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03239340,ELIOS,ECD,2024Oct31,Yes,No,,4.0,NCT03239340,Untreated,,Unknown,154.0,154.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11101.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03239340,ELIOS,ECD,2024Oct31,Yes,No,,4.0,NCT03239340,Untreated,,Unknown,154.0,154.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11102.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03239340,ELIOS,ECD,2024Oct31,Yes,No,,4.0,NCT03239340,Untreated,,Unknown,154.0,154.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11103.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03239340,ELIOS,ECD,2024Oct31,Yes,No,,4.0,NCT03239340,Untreated,,Unknown,154.0,154.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11104.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03239340,ELIOS,ECD,2024Oct31,Yes,No,,4.0,NCT03239340,Untreated,,Unknown,154.0,154.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11105.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03239340,ELIOS,ECD,2024Oct31,Yes,No,,4.0,NCT03239340,Untreated,,Unknown,154.0,154.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11106.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03239340,ELIOS,ECD,2024Oct31,Yes,No,,4.0,NCT03239340,Untreated,,Unknown,154.0,154.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11107.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03239340,ELIOS,ECD,2024Oct31,Yes,No,,4.0,NCT03239340,Untreated,,Unknown,154.0,154.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11108.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,"Active, not recruiting",NCT03239340,ELIOS,ECD,2024Oct31,Yes,No,,4.0,NCT03239340,Untreated,,Unknown,154.0,154.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Aug04,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11613.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Unknown,Osimertinib,,"Active, not recruiting",NCT03969823,,ECD,2023Sep30,Yes,No,,4.0,NCT03969823,,,Progression free survival,148.0,148.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11614.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Unknown,Osimertinib,,"Active, not recruiting",NCT03969823,,ECD,2023Sep30,Yes,No,,4.0,NCT03969823,,,Progression free survival,148.0,148.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11615.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Unknown,Osimertinib,,"Active, not recruiting",NCT03969823,,ECD,2023Sep30,Yes,No,,4.0,NCT03969823,,,Progression free survival,148.0,148.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11616.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Unknown,Osimertinib,,"Active, not recruiting",NCT03969823,,ECD,2023Sep30,Yes,No,,4.0,NCT03969823,,,Progression free survival,148.0,148.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11617.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Unknown,Osimertinib,,"Active, not recruiting",NCT03969823,,ECD,2023Sep30,Yes,No,,4.0,NCT03969823,,,Progression free survival,148.0,148.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11618.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Unknown,Osimertinib,,"Active, not recruiting",NCT03969823,,ECD,2023Sep30,Yes,No,,4.0,NCT03969823,,,Progression free survival,148.0,148.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11619.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Unknown,Osimertinib,,"Active, not recruiting",NCT03969823,,ECD,2023Sep30,Yes,No,,4.0,NCT03969823,,,Progression free survival,148.0,148.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11620.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Unknown,Osimertinib,,"Active, not recruiting",NCT03969823,,ECD,2023Sep30,Yes,No,,4.0,NCT03969823,,,Progression free survival,148.0,148.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11621.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Unknown,Osimertinib,,"Active, not recruiting",NCT03969823,,ECD,2023Sep30,Yes,No,,4.0,NCT03969823,,,Progression free survival,148.0,148.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11685.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Unknown,Osimertinib,,Recruiting,NCT04737382,OSIRIS,ECD,2023Aug22,No,No,,4.0,NCT04737382,,,Biomarker discovery,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11686.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Unknown,Osimertinib,,Recruiting,NCT04737382,OSIRIS,ECD,2023Aug22,No,No,,4.0,NCT04737382,,,Biomarker discovery,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11687.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Unknown,Osimertinib,,Recruiting,NCT04737382,OSIRIS,ECD,2023Aug22,No,No,,4.0,NCT04737382,,,Biomarker discovery,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11688.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Unknown,Osimertinib,,Recruiting,NCT04737382,OSIRIS,ECD,2023Aug22,No,No,,4.0,NCT04737382,,,Biomarker discovery,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11689.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Unknown,Osimertinib,,Recruiting,NCT04737382,OSIRIS,ECD,2023Aug22,No,No,,4.0,NCT04737382,,,Biomarker discovery,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11690.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Unknown,Osimertinib,,Recruiting,NCT04737382,OSIRIS,ECD,2023Aug22,No,No,,4.0,NCT04737382,,,Biomarker discovery,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11691.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Unknown,Osimertinib,,Recruiting,NCT04737382,OSIRIS,ECD,2023Aug22,No,No,,4.0,NCT04737382,,,Biomarker discovery,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11692.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Unknown,Osimertinib,,Recruiting,NCT04737382,OSIRIS,ECD,2023Aug22,No,No,,4.0,NCT04737382,,,Biomarker discovery,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
11693.0,EGFR,EGFR_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Unknown,Osimertinib,,Recruiting,NCT04737382,OSIRIS,ECD,2023Aug22,No,No,,4.0,NCT04737382,,,Biomarker discovery,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022May03,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12504.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT03865511,MELROSE,ECD,2024Apr01,Yes,No,,4.0,NCT03865511,,,Biomarker discovery,66.0,66.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Jun15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12505.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT03865511,MELROSE,ECD,2024Apr01,Yes,No,,4.0,NCT03865511,,,Biomarker discovery,66.0,66.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Jun15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12506.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT03865511,MELROSE,ECD,2024Apr01,Yes,No,,4.0,NCT03865511,,,Biomarker discovery,66.0,66.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Jun15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12507.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT03865511,MELROSE,ECD,2024Apr01,Yes,No,,4.0,NCT03865511,,,Biomarker discovery,66.0,66.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Jun15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12508.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT03865511,MELROSE,ECD,2024Apr01,Yes,No,,4.0,NCT03865511,,,Biomarker discovery,66.0,66.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Jun15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12509.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT03865511,MELROSE,ECD,2024Apr01,Yes,No,,4.0,NCT03865511,,,Biomarker discovery,66.0,66.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Jun15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12510.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT03865511,MELROSE,ECD,2024Apr01,Yes,No,,4.0,NCT03865511,,,Biomarker discovery,66.0,66.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Jun15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12511.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT03865511,MELROSE,ECD,2024Apr01,Yes,No,,4.0,NCT03865511,,,Biomarker discovery,66.0,66.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Jun15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12512.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Osimertinib,,Recruiting,NCT03865511,MELROSE,ECD,2024Apr01,Yes,No,,4.0,NCT03865511,,,Biomarker discovery,66.0,66.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Jun15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14124.0,MET,MET_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Recruiting,NCT03865511,MELROSE,ECD,2024Apr01,Yes,No,,4.0,NCT03865511,,,Biomarker discovery,66.0,66.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Jun15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14125.0,MET,MET_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Recruiting,NCT03865511,MELROSE,ECD,2024Apr01,Yes,No,,4.0,NCT03865511,,,Biomarker discovery,66.0,66.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Jun15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14126.0,MET,MET_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Recruiting,NCT03865511,MELROSE,ECD,2024Apr01,Yes,No,,4.0,NCT03865511,,,Biomarker discovery,66.0,66.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Jun15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14127.0,MET,MET_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Recruiting,NCT03865511,MELROSE,ECD,2024Apr01,Yes,No,,4.0,NCT03865511,,,Biomarker discovery,66.0,66.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Jun15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14128.0,MET,MET_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Recruiting,NCT03865511,MELROSE,ECD,2024Apr01,Yes,No,,4.0,NCT03865511,,,Biomarker discovery,66.0,66.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Jun15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14129.0,MET,MET_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Recruiting,NCT03865511,MELROSE,ECD,2024Apr01,Yes,No,,4.0,NCT03865511,,,Biomarker discovery,66.0,66.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Jun15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14130.0,MET,MET_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Recruiting,NCT03865511,MELROSE,ECD,2024Apr01,Yes,No,,4.0,NCT03865511,,,Biomarker discovery,66.0,66.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Jun15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14131.0,MET,MET_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Recruiting,NCT03865511,MELROSE,ECD,2024Apr01,Yes,No,,4.0,NCT03865511,,,Biomarker discovery,66.0,66.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Jun15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14132.0,MET,MET_unspecified,,,,lung / carcinoma / non small cell carcinoma,2.0,Phase 2,Osimertinib,,Recruiting,NCT03865511,MELROSE,ECD,2024Apr01,Yes,No,,4.0,NCT03865511,,,Biomarker discovery,66.0,66.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Jun15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12549.0,FGFR1,FGFR1_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 1,Regorafenib,,Terminated,NCT01187615,,PCD,2012Jun01,No,Yes,Slow accrual,1.0,26003007,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12550.0,FGFR1,FGFR1_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 1,Regorafenib,,Terminated,NCT01187615,,PCD,2012Jun01,No,Yes,Slow accrual,1.0,26003007,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12551.0,FGFR1,FGFR1_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 1,Regorafenib,,Terminated,NCT01187615,,PCD,2012Jun01,No,Yes,Slow accrual,1.0,26003007,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12552.0,FGFR1,FGFR1_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 1,Regorafenib,,Terminated,NCT01187615,,PCD,2012Jun01,No,Yes,Slow accrual,1.0,26003007,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12553.0,FGFR1,FGFR1_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 1,Regorafenib,,Terminated,NCT01187615,,PCD,2012Jun01,No,Yes,Slow accrual,1.0,26003007,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12554.0,FGFR1,FGFR1_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 1,Regorafenib,,Terminated,NCT01187615,,PCD,2012Jun01,No,Yes,Slow accrual,1.0,26003007,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12555.0,FGFR1,FGFR1_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 1,Regorafenib,,Terminated,NCT01187615,,PCD,2012Jun01,No,Yes,Slow accrual,1.0,26003007,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12556.0,FGFR1,FGFR1_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 1,Regorafenib,,Terminated,NCT01187615,,PCD,2012Jun01,No,Yes,Slow accrual,1.0,26003007,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12557.0,FGFR1,FGFR1_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 1,Regorafenib,,Terminated,NCT01187615,,PCD,2012Jun01,No,Yes,Slow accrual,1.0,26003007,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2613.0,BRAF,BRAF_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sorafenib,,Completed,NCT00098540,,PCD,2007May01,Yes,No,,4.0,NCT00098540,,,Response rate,46.0,46.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2614.0,BRAF,BRAF_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sorafenib,,Completed,NCT00098540,,PCD,2007May01,Yes,No,,4.0,NCT00098540,,,Response rate,46.0,46.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2615.0,BRAF,BRAF_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sorafenib,,Completed,NCT00098540,,PCD,2007May01,Yes,No,,4.0,NCT00098540,,,Response rate,46.0,46.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2616.0,BRAF,BRAF_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sorafenib,,Completed,NCT00098540,,PCD,2007May01,Yes,No,,4.0,NCT00098540,,,Response rate,46.0,46.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2617.0,BRAF,BRAF_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sorafenib,,Completed,NCT00098540,,PCD,2007May01,Yes,No,,4.0,NCT00098540,,,Response rate,46.0,46.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2618.0,BRAF,BRAF_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sorafenib,,Completed,NCT00098540,,PCD,2007May01,Yes,No,,4.0,NCT00098540,,,Response rate,46.0,46.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2619.0,BRAF,BRAF_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sorafenib,,Completed,NCT00098540,,PCD,2007May01,Yes,No,,4.0,NCT00098540,,,Response rate,46.0,46.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2620.0,BRAF,BRAF_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sorafenib,,Completed,NCT00098540,,PCD,2007May01,Yes,No,,4.0,NCT00098540,,,Response rate,46.0,46.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
2621.0,BRAF,BRAF_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sorafenib,,Completed,NCT00098540,,PCD,2007May01,Yes,No,,4.0,NCT00098540,,,Response rate,46.0,46.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12981.0,KRAS,KRAS_G12 or KRAS_G13 or KRAS_Q61,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Sorafenib,,Completed,NCT00411671,BATTLE,PCD,2012Nov01,Yes,Yes,,2.0,10.1200/jco.2010.28.15_suppl.7609,Previously-treated,,Unknown,18.0,18.0,,,,,,,,,,,,,,,,,,,,,61.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12982.0,KRAS,KRAS_G12 or KRAS_G13 or KRAS_Q61,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Sorafenib,,Completed,NCT00411671,BATTLE,PCD,2012Nov01,Yes,Yes,,2.0,10.1200/jco.2010.28.15_suppl.7609,Previously-treated,,Unknown,18.0,18.0,,,,,,,,,,,,,,,,,,,,,61.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12983.0,KRAS,KRAS_G12 or KRAS_G13 or KRAS_Q61,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Sorafenib,,Completed,NCT00411671,BATTLE,PCD,2012Nov01,Yes,Yes,,2.0,10.1200/jco.2010.28.15_suppl.7609,Previously-treated,,Unknown,18.0,18.0,,,,,,,,,,,,,,,,,,,,,61.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12984.0,KRAS,KRAS_G12 or KRAS_G13 or KRAS_Q61,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Sorafenib,,Completed,NCT00411671,BATTLE,PCD,2012Nov01,Yes,Yes,,2.0,10.1200/jco.2010.28.15_suppl.7609,Previously-treated,,Unknown,18.0,18.0,,,,,,,,,,,,,,,,,,,,,61.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12985.0,KRAS,KRAS_G12 or KRAS_G13 or KRAS_Q61,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Sorafenib,,Completed,NCT00411671,BATTLE,PCD,2012Nov01,Yes,Yes,,2.0,10.1200/jco.2010.28.15_suppl.7609,Previously-treated,,Unknown,18.0,18.0,,,,,,,,,,,,,,,,,,,,,61.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12986.0,KRAS,KRAS_G12 or KRAS_G13 or KRAS_Q61,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Sorafenib,,Completed,NCT00411671,BATTLE,PCD,2012Nov01,Yes,Yes,,2.0,10.1200/jco.2010.28.15_suppl.7609,Previously-treated,,Unknown,18.0,18.0,,,,,,,,,,,,,,,,,,,,,61.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12987.0,KRAS,KRAS_G12 or KRAS_G13 or KRAS_Q61,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Sorafenib,,Completed,NCT00411671,BATTLE,PCD,2012Nov01,Yes,Yes,,2.0,10.1200/jco.2010.28.15_suppl.7609,Previously-treated,,Unknown,18.0,18.0,,,,,,,,,,,,,,,,,,,,,61.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12988.0,KRAS,KRAS_G12 or KRAS_G13 or KRAS_Q61,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Sorafenib,,Completed,NCT00411671,BATTLE,PCD,2012Nov01,Yes,Yes,,2.0,10.1200/jco.2010.28.15_suppl.7609,Previously-treated,,Unknown,18.0,18.0,,,,,,,,,,,,,,,,,,,,,61.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12989.0,KRAS,KRAS_G12 or KRAS_G13 or KRAS_Q61,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Sorafenib,,Completed,NCT00411671,BATTLE,PCD,2012Nov01,Yes,Yes,,2.0,10.1200/jco.2010.28.15_suppl.7609,Previously-treated,,Unknown,18.0,18.0,,,,,,,,,,,,,,,,,,,,,61.0,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Nov28,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
13674.0,KRAS,KRAS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Sorafenib,,Unknown,,BATTLE-2,,,No,Yes,Response not correlated with mutation or expression status,1.0,27480147,Previously-treated,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
13675.0,KRAS,KRAS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Sorafenib,,Unknown,,BATTLE-2,,,No,Yes,Response not correlated with mutation or expression status,1.0,27480147,Previously-treated,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
13676.0,KRAS,KRAS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Sorafenib,,Unknown,,BATTLE-2,,,No,Yes,Response not correlated with mutation or expression status,1.0,27480147,Previously-treated,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
13677.0,KRAS,KRAS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Sorafenib,,Unknown,,BATTLE-2,,,No,Yes,Response not correlated with mutation or expression status,1.0,27480147,Previously-treated,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
13678.0,KRAS,KRAS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Sorafenib,,Unknown,,BATTLE-2,,,No,Yes,Response not correlated with mutation or expression status,1.0,27480147,Previously-treated,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
13679.0,KRAS,KRAS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Sorafenib,,Unknown,,BATTLE-2,,,No,Yes,Response not correlated with mutation or expression status,1.0,27480147,Previously-treated,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
13680.0,KRAS,KRAS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Sorafenib,,Unknown,,BATTLE-2,,,No,Yes,Response not correlated with mutation or expression status,1.0,27480147,Previously-treated,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
13681.0,KRAS,KRAS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Sorafenib,,Unknown,,BATTLE-2,,,No,Yes,Response not correlated with mutation or expression status,1.0,27480147,Previously-treated,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
13682.0,KRAS,KRAS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Sorafenib,,Unknown,,BATTLE-2,,,No,Yes,Response not correlated with mutation or expression status,1.0,27480147,Previously-treated,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
13692.0,KRAS,KRAS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Sorafenib,,Completed,NCT00863746,MISSION,PCD,2012Mar01,No,Yes,Response not correlated with mutation or expression status,1.0,26743856,Previously-treated,,Overall survival,703.0,350.0,353.0,Placebo,,,,,,,,,2.8,1.4,0.61,0.51-0.72,p<0.0001,2.9,1.4,0.54,0.45-0.65,<0.0001,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
13693.0,KRAS,KRAS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Sorafenib,,Completed,NCT00863746,MISSION,PCD,2012Mar01,No,Yes,Response not correlated with mutation or expression status,1.0,26743856,Previously-treated,,Overall survival,703.0,350.0,353.0,Placebo,,,,,,,,,2.8,1.4,0.61,0.51-0.72,p<0.0001,2.9,1.4,0.54,0.45-0.65,<0.0001,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
13694.0,KRAS,KRAS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Sorafenib,,Completed,NCT00863746,MISSION,PCD,2012Mar01,No,Yes,Response not correlated with mutation or expression status,1.0,26743856,Previously-treated,,Overall survival,703.0,350.0,353.0,Placebo,,,,,,,,,2.8,1.4,0.61,0.51-0.72,p<0.0001,2.9,1.4,0.54,0.45-0.65,<0.0001,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
13695.0,KRAS,KRAS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Sorafenib,,Completed,NCT00863746,MISSION,PCD,2012Mar01,No,Yes,Response not correlated with mutation or expression status,1.0,26743856,Previously-treated,,Overall survival,703.0,350.0,353.0,Placebo,,,,,,,,,2.8,1.4,0.61,0.51-0.72,p<0.0001,2.9,1.4,0.54,0.45-0.65,<0.0001,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
13696.0,KRAS,KRAS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Sorafenib,,Completed,NCT00863746,MISSION,PCD,2012Mar01,No,Yes,Response not correlated with mutation or expression status,1.0,26743856,Previously-treated,,Overall survival,703.0,350.0,353.0,Placebo,,,,,,,,,2.8,1.4,0.61,0.51-0.72,p<0.0001,2.9,1.4,0.54,0.45-0.65,<0.0001,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
13697.0,KRAS,KRAS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Sorafenib,,Completed,NCT00863746,MISSION,PCD,2012Mar01,No,Yes,Response not correlated with mutation or expression status,1.0,26743856,Previously-treated,,Overall survival,703.0,350.0,353.0,Placebo,,,,,,,,,2.8,1.4,0.61,0.51-0.72,p<0.0001,2.9,1.4,0.54,0.45-0.65,<0.0001,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
13698.0,KRAS,KRAS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Sorafenib,,Completed,NCT00863746,MISSION,PCD,2012Mar01,No,Yes,Response not correlated with mutation or expression status,1.0,26743856,Previously-treated,,Overall survival,703.0,350.0,353.0,Placebo,,,,,,,,,2.8,1.4,0.61,0.51-0.72,p<0.0001,2.9,1.4,0.54,0.45-0.65,<0.0001,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
13699.0,KRAS,KRAS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Sorafenib,,Completed,NCT00863746,MISSION,PCD,2012Mar01,No,Yes,Response not correlated with mutation or expression status,1.0,26743856,Previously-treated,,Overall survival,703.0,350.0,353.0,Placebo,,,,,,,,,2.8,1.4,0.61,0.51-0.72,p<0.0001,2.9,1.4,0.54,0.45-0.65,<0.0001,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
13700.0,KRAS,KRAS_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 3,Sorafenib,,Completed,NCT00863746,MISSION,PCD,2012Mar01,No,Yes,Response not correlated with mutation or expression status,1.0,26743856,Previously-treated,,Overall survival,703.0,350.0,353.0,Placebo,,,,,,,,,2.8,1.4,0.61,0.51-0.72,p<0.0001,2.9,1.4,0.54,0.45-0.65,<0.0001,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
312.0,KIT,KIT_unspecified or PDGFRA_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Sunitinib,,"Active, not recruiting",NCT01306045,Arm 14,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
313.0,KIT,KIT_unspecified or PDGFRA_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Sunitinib,,"Active, not recruiting",NCT01306045,Arm 14,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
314.0,KIT,KIT_unspecified or PDGFRA_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Sunitinib,,"Active, not recruiting",NCT01306045,Arm 14,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
315.0,KIT,KIT_unspecified or PDGFRA_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Sunitinib,,"Active, not recruiting",NCT01306045,Arm 14,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
316.0,KIT,KIT_unspecified or PDGFRA_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Sunitinib,,"Active, not recruiting",NCT01306045,Arm 14,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
317.0,KIT,KIT_unspecified or PDGFRA_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Sunitinib,,"Active, not recruiting",NCT01306045,Arm 14,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
318.0,KIT,KIT_unspecified or PDGFRA_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Sunitinib,,"Active, not recruiting",NCT01306045,Arm 14,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
319.0,KIT,KIT_unspecified or PDGFRA_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Sunitinib,,"Active, not recruiting",NCT01306045,Arm 14,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
320.0,KIT,KIT_unspecified or PDGFRA_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Sunitinib,,"Active, not recruiting",NCT01306045,Arm 14,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
321.0,KIT,KIT_unspecified or PDGFRA_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Sunitinib,,"Active, not recruiting",NCT01306045,Arm 14,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
322.0,KIT,KIT_unspecified or PDGFRA_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Sunitinib,,"Active, not recruiting",NCT01306045,Arm 14,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
323.0,KIT,KIT_unspecified or PDGFRA_unspecified,,,,lung / carcinoma / small cell carcinoma,3.0,Phase 2,Sunitinib,,"Active, not recruiting",NCT01306045,Arm 14,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915333,2022Dec15,COSO29915333,lung,NS,NS,NS,carcinoma,small_cell_carcinoma,NS,NS
5601.0,CSF1R,CSF1R_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5602.0,CSF1R,CSF1R_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5603.0,CSF1R,CSF1R_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5604.0,CSF1R,CSF1R_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5605.0,CSF1R,CSF1R_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5606.0,CSF1R,CSF1R_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5607.0,CSF1R,CSF1R_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5608.0,CSF1R,CSF1R_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
5609.0,CSF1R,CSF1R_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12531.0,FGF1,FGF1_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12532.0,FGF1,FGF1_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12533.0,FGF1,FGF1_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12534.0,FGF1,FGF1_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12535.0,FGF1,FGF1_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12536.0,FGF1,FGF1_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12537.0,FGF1,FGF1_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12538.0,FGF1,FGF1_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12539.0,FGF1,FGF1_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12765.0,FLT1,FLT1_unspecified (VEGFR1_unspecified),,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12766.0,FLT1,FLT1_unspecified (VEGFR1_unspecified),,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12767.0,FLT1,FLT1_unspecified (VEGFR1_unspecified),,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12768.0,FLT1,FLT1_unspecified (VEGFR1_unspecified),,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12769.0,FLT1,FLT1_unspecified (VEGFR1_unspecified),,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12770.0,FLT1,FLT1_unspecified (VEGFR1_unspecified),,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12771.0,FLT1,FLT1_unspecified (VEGFR1_unspecified),,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12772.0,FLT1,FLT1_unspecified (VEGFR1_unspecified),,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12773.0,FLT1,FLT1_unspecified (VEGFR1_unspecified),,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12792.0,FLT3,FLT3_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12793.0,FLT3,FLT3_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12794.0,FLT3,FLT3_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12795.0,FLT3,FLT3_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12796.0,FLT3,FLT3_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12797.0,FLT3,FLT3_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12798.0,FLT3,FLT3_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12799.0,FLT3,FLT3_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12800.0,FLT3,FLT3_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12810.0,FLT4,FLT4_unspecified (VEGFR3_unspecified),,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12811.0,FLT4,FLT4_unspecified (VEGFR3_unspecified),,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12812.0,FLT4,FLT4_unspecified (VEGFR3_unspecified),,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12813.0,FLT4,FLT4_unspecified (VEGFR3_unspecified),,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12814.0,FLT4,FLT4_unspecified (VEGFR3_unspecified),,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12815.0,FLT4,FLT4_unspecified (VEGFR3_unspecified),,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12816.0,FLT4,FLT4_unspecified (VEGFR3_unspecified),,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12817.0,FLT4,FLT4_unspecified (VEGFR3_unspecified),,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12818.0,FLT4,FLT4_unspecified (VEGFR3_unspecified),,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12837.0,KDR,KDR_unspecified (VEGFR2_unspecified),,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12838.0,KDR,KDR_unspecified (VEGFR2_unspecified),,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12839.0,KDR,KDR_unspecified (VEGFR2_unspecified),,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12840.0,KDR,KDR_unspecified (VEGFR2_unspecified),,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12841.0,KDR,KDR_unspecified (VEGFR2_unspecified),,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12842.0,KDR,KDR_unspecified (VEGFR2_unspecified),,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12843.0,KDR,KDR_unspecified (VEGFR2_unspecified),,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12844.0,KDR,KDR_unspecified (VEGFR2_unspecified),,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12845.0,KDR,KDR_unspecified (VEGFR2_unspecified),,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12927.0,KIT,KIT_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12928.0,KIT,KIT_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12929.0,KIT,KIT_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12930.0,KIT,KIT_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12931.0,KIT,KIT_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12932.0,KIT,KIT_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12933.0,KIT,KIT_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12934.0,KIT,KIT_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12935.0,KIT,KIT_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12945.0,KIT,KIT_unspecified or PDGFRA_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,"Active, not recruiting",NCT01306045,Arm 13,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12946.0,KIT,KIT_unspecified or PDGFRA_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,"Active, not recruiting",NCT01306045,Arm 13,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12947.0,KIT,KIT_unspecified or PDGFRA_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,"Active, not recruiting",NCT01306045,Arm 13,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12948.0,KIT,KIT_unspecified or PDGFRA_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,"Active, not recruiting",NCT01306045,Arm 13,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12949.0,KIT,KIT_unspecified or PDGFRA_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,"Active, not recruiting",NCT01306045,Arm 13,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12950.0,KIT,KIT_unspecified or PDGFRA_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,"Active, not recruiting",NCT01306045,Arm 13,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12951.0,KIT,KIT_unspecified or PDGFRA_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,"Active, not recruiting",NCT01306045,Arm 13,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12952.0,KIT,KIT_unspecified or PDGFRA_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,"Active, not recruiting",NCT01306045,Arm 13,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12953.0,KIT,KIT_unspecified or PDGFRA_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,"Active, not recruiting",NCT01306045,Arm 13,PCD,2014Feb12,Yes,Yes,,1.0,25667274,,,Response rate,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2022Dec15,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14655.0,PDGFRA,PDGFRA_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14656.0,PDGFRA,PDGFRA_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14657.0,PDGFRA,PDGFRA_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14658.0,PDGFRA,PDGFRA_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14659.0,PDGFRA,PDGFRA_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14660.0,PDGFRA,PDGFRA_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14661.0,PDGFRA,PDGFRA_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14662.0,PDGFRA,PDGFRA_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14663.0,PDGFRA,PDGFRA_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14682.0,PDGFRB,PDGFRB_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14683.0,PDGFRB,PDGFRB_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14684.0,PDGFRB,PDGFRB_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14685.0,PDGFRB,PDGFRB_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14686.0,PDGFRB,PDGFRB_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14687.0,PDGFRB,PDGFRB_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14688.0,PDGFRB,PDGFRB_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14689.0,PDGFRB,PDGFRB_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14690.0,PDGFRB,PDGFRB_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14988.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14989.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14990.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14991.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14992.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14993.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14994.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14995.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
14996.0,RET,RET_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15978.0,VEGFA,VEGFA_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15979.0,VEGFA,VEGFA_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15980.0,VEGFA,VEGFA_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15981.0,VEGFA,VEGFA_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15982.0,VEGFA,VEGFA_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15983.0,VEGFA,VEGFA_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15984.0,VEGFA,VEGFA_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15985.0,VEGFA,VEGFA_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
15986.0,VEGFA,VEGFA_unspecified,,,,lung / carcinoma / non small cell carcinoma,3.0,Phase 2,Sunitinib,,Completed,NCT00372775,,PCD,2009Dec01,No,Yes,,4.0,NCT00372775,,,Progression free survival,66.0,66.0,,,,,,,,,,,2.17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021May18,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12459.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Trastuzumab,,Completed,NCT00004883,,PCD,2005Aug01,Overexpression,No,,4.0,NCT00004883,,,Response rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Dec08,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12460.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Trastuzumab,,Completed,NCT00004883,,PCD,2005Aug01,Overexpression,No,,4.0,NCT00004883,,,Response rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Dec08,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12461.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Trastuzumab,,Completed,NCT00004883,,PCD,2005Aug01,Overexpression,No,,4.0,NCT00004883,,,Response rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Dec08,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12462.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Trastuzumab,,Completed,NCT00004883,,PCD,2005Aug01,Overexpression,No,,4.0,NCT00004883,,,Response rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Dec08,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12463.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Trastuzumab,,Completed,NCT00004883,,PCD,2005Aug01,Overexpression,No,,4.0,NCT00004883,,,Response rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Dec08,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12464.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Trastuzumab,,Completed,NCT00004883,,PCD,2005Aug01,Overexpression,No,,4.0,NCT00004883,,,Response rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Dec08,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12465.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Trastuzumab,,Completed,NCT00004883,,PCD,2005Aug01,Overexpression,No,,4.0,NCT00004883,,,Response rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Dec08,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12466.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Trastuzumab,,Completed,NCT00004883,,PCD,2005Aug01,Overexpression,No,,4.0,NCT00004883,,,Response rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Dec08,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12467.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Trastuzumab,,Completed,NCT00004883,,PCD,2005Aug01,Overexpression,No,,4.0,NCT00004883,,,Response rate,84.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Dec08,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12468.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Trastuzumab,,Terminated,NCT00758134,,PCD,2010Jun01,Expression confirmed,Yes,Slow accrual,4.0,NCT00758134,,,Response rate,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Dec08,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12469.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Trastuzumab,,Terminated,NCT00758134,,PCD,2010Jun01,Expression confirmed,Yes,Slow accrual,4.0,NCT00758134,,,Response rate,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Dec08,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12470.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Trastuzumab,,Terminated,NCT00758134,,PCD,2010Jun01,Expression confirmed,Yes,Slow accrual,4.0,NCT00758134,,,Response rate,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Dec08,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12471.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Trastuzumab,,Terminated,NCT00758134,,PCD,2010Jun01,Expression confirmed,Yes,Slow accrual,4.0,NCT00758134,,,Response rate,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Dec08,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12472.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Trastuzumab,,Terminated,NCT00758134,,PCD,2010Jun01,Expression confirmed,Yes,Slow accrual,4.0,NCT00758134,,,Response rate,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Dec08,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12473.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Trastuzumab,,Terminated,NCT00758134,,PCD,2010Jun01,Expression confirmed,Yes,Slow accrual,4.0,NCT00758134,,,Response rate,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Dec08,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12474.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Trastuzumab,,Terminated,NCT00758134,,PCD,2010Jun01,Expression confirmed,Yes,Slow accrual,4.0,NCT00758134,,,Response rate,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Dec08,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12475.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Trastuzumab,,Terminated,NCT00758134,,PCD,2010Jun01,Expression confirmed,Yes,Slow accrual,4.0,NCT00758134,,,Response rate,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Dec08,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12476.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Trastuzumab,,Terminated,NCT00758134,,PCD,2010Jun01,Expression confirmed,Yes,Slow accrual,4.0,NCT00758134,,,Response rate,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Dec08,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12477.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Trastuzumab,,Terminated,NCT00758134,,PCD,2010Jun01,Yes,Yes,Slow accrual,4.0,NCT00758134,,,Response rate,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Dec08,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12478.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Trastuzumab,,Terminated,NCT00758134,,PCD,2010Jun01,Yes,Yes,Slow accrual,4.0,NCT00758134,,,Response rate,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Dec08,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12479.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Trastuzumab,,Terminated,NCT00758134,,PCD,2010Jun01,Yes,Yes,Slow accrual,4.0,NCT00758134,,,Response rate,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Dec08,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12480.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Trastuzumab,,Terminated,NCT00758134,,PCD,2010Jun01,Yes,Yes,Slow accrual,4.0,NCT00758134,,,Response rate,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Dec08,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12481.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Trastuzumab,,Terminated,NCT00758134,,PCD,2010Jun01,Yes,Yes,Slow accrual,4.0,NCT00758134,,,Response rate,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Dec08,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12482.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Trastuzumab,,Terminated,NCT00758134,,PCD,2010Jun01,Yes,Yes,Slow accrual,4.0,NCT00758134,,,Response rate,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Dec08,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12483.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Trastuzumab,,Terminated,NCT00758134,,PCD,2010Jun01,Yes,Yes,Slow accrual,4.0,NCT00758134,,,Response rate,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Dec08,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12484.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Trastuzumab,,Terminated,NCT00758134,,PCD,2010Jun01,Yes,Yes,Slow accrual,4.0,NCT00758134,,,Response rate,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Dec08,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
12485.0,ERBB2,ERBB2_unspecified,,,,lung / carcinoma / non small cell carcinoma,1.0,Phase 2,Trastuzumab,,Terminated,NCT00758134,,PCD,2010Jun01,Yes,Yes,Slow accrual,4.0,NCT00758134,,,Response rate,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO29915674,2021Dec08,COSO29915674,lung,NS,NS,NS,carcinoma,non_small_cell_carcinoma,NS,NS
